EMT, cancer stem cells and drug resistance: an emergin

Oncogene

29, 4741-4751

DOI: 10.1038/onc.2010.215

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2013, 7, 320.	0.6	23
2	Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resistance Updates, 2010, 13, 109-118.	6.5	313
3	EMT in NSCLC and malignant pleural mesothelioma. Memo - Magazine of European Medical Oncology, 2010, 3, 180-184.	0.3	0
4	The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. Journal of Molecular Signaling, 2010, 5, 14.	0.5	177
5	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	0.8	159
6	Cancer Stem Cells in Pancreatic Cancer. Cancers, 2010, 2, 1629-1641.	1.7	21
7	Chemotherapy and signaling. Cancer Biology and Therapy, 2010, 10, 839-853.	1.5	88
8	Metformin against TGFÎ²-induced epithelial-to-mesenchymal transition (EMT): From cancer stem cells to aging-associated fibrosis. Cell Cycle, 2010, 9, 4461-4468.	1.3	202
9	Epithelial-Mesenchymal Transition in Pancreatic Carcinoma. Cancers, 2010, 2, 2058-2083.	1.7	59
10	Do predictive signatures really predict response to cancer chemotherapy?Â. Cell Cycle, 2010, 9, 4836-4840.	1.3	58
11	p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death and Differentiation, 2011, 18, 1487-1499.	5.0	195
12	Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis, 2011, 32, 650-658.	1.3	120
13	Epigenetic-based companion diagnostics. Personalized Medicine, 2011, 8, 623-631.	0.8	1
14	Cancer Stem Cells in Tumor Heterogeneity. Advances in Cancer Research, 2011, 112, 255-281.	1.9	71
15	Jumping the barrier: VEâ€cadherin, VEGF and other angiogenic modifiers in cancer. Biology of the Cell, 2011, 103, 593-605.	0.7	65
16	Genetic Determinants of Uveal Melanoma. Developments in Ophthalmology, 2012, 49, 150-165.	0.1	9
17	Tailoring Tyrosine Kinase Inhibitors to Fit the Lung Cancer Genome. Translational Oncology, 2011, 4, 59-70.	1.7	11
18	Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Therapy, 2011, 18, 897-905.	2.2	63

#	Article	IF	Citations
19	Diosgenin Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelialâ€“Mesenchymal Transition by Down-regulation of Mdm2 and Vimentin. Journal of Agricultural and Food Chemistry, 2011, 59, 5357-5363.	2.4	41
20	Metastatic Progression of Prostate Cancer and E-Cadherin. American Journal of Pathology, 2011, 179, 400-410.	1.9	133
21	Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast. Cell, 2011, 145, 926-940.	13.5	788
23	Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells. Cancer Letters, 2011, 310, 1-8.	3.2	86
24	Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resistance Updates, 2011, 14, 212-223.	6.5	58
25	Dual role of NO donors in the reversal of tumor cell resistance and EMT: Downregulation of the NF-Î²B/Snail/YY1/RKIP circuitry. Nitric Oxide - Biology and Chemistry, 2011, 24, 1-7.	1.2	121
26	Transcription factors that mediate epithelialâ€“mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death and Disease, 2011, 2, e179-e179.	2.7	305
27	Chemopreventive effects of tea in prostate cancer: Green tea versus black tea. Molecular Nutrition and Food Research, 2011, 55, 905-920.	1.5	63
28	E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiotherapy and Oncology, 2011, 99, 392-397.	0.3	210
29	Overexpression of TWIST2 correlates with poor prognosis in Head and Neck Squamous Cell Carcinomas. Oncotarget, 2011, 2, 1165-1175.	0.8	54
30	Slug-based epithelial-mesenchymal transition gene signature is associated with prolonged time to recurrence in glioblastoma. Nature Precedings, 0, , .	0.1	3
31	Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.	0.8	263
32	Uveal Melanoma Cell Lines Contain Stem-Like Cells That Self-Renew, Produce Differentiated Progeny, and Survive Chemotherapy. , 2011, 52, 8458.		47
33	Integrin Signaling, Cell Survival, and Anoikis: Distinctions, Differences, and Differentiation. Journal of Signal Transduction, 2011, 2011, 1-18.	2.0	113
34	Cancer Stem Cells: Repair Gone Awry?. Journal of Oncology, 2011, 2011, 1-11.	0.6	17
35	Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chinese Journal of Cancer, 2011, 30, 603-611.	4.9	174
36	Resveratrol Inhibits Pancreatic Cancer Stem Cell Characteristics in Human and KrasG12D Transgenic Mice by Inhibiting Pluripotency Maintaining Factors and Epithelial-Mesenchymal Transition. PLoS ONE, 2011, 6, e16530.	1.1	257
37	Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors. PLoS ONE, 2011, 6, e21099.	1.1	43

#	Article	IF	Citations
38	Prdm14 initiates lymphoblastic leukemia after expanding a population of cells resembling common lymphoid progenitors. Oncogene, 2011, 30, 2859-2873.	2.6	52
39	Twist2 contributes to breast cancer progression by promoting an epithelialâ€“mesenchymal transition and cancer stem-like cell self-renewal. Oncogene, 2011, 30, 4707-4720.	2.6	175
40	On the intrinsic inevitability of cancer: From foetal to fatal attraction. Seminars in Cancer Biology, 2011, 21, 183-199.	4.3	73
41	NUMB-ing down cancer by more than just a NOTCH. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 26-43.	3.3	108
42	Hallmarks of Cancer: The Next Generation. Cell, 2011, 144, 646-674.	13.5	52,242
43	Cancer cells in epithelial-to-mesenchymal transition and tumor-propagatingâ€“cancer stem cells: distinct, overlapping or same populations. Oncogene, 2011, 30, 4609-4621.	2.6	173
44	Noncanonical TGF-Î² Signaling During Mammary Tumorigenesis. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 127-146.	1.0	103
45	Side population rather than CD133+ cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. Molecular Cancer, 2011, 10, 112.	7.9	29
46	Ribosomal Protein S6 Kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein. Molecular Cancer, 2011, 10, 66.	7.9	41
47	Cancer stem cells: problems for therapy?. Journal of Pathology, 2011, 223, 148-162.	2.1	259
48	Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transplantation, 2011, 17, 943-954.	1.3	84
49	Phenotypic plasticity and epithelialâ€mesenchymal transitions in cancer and normal stem cells?. International Journal of Cancer, 2011, 129, 2310-2314.	2.3	191
50	The cancer stem cell nicheâ€"there goes the neighborhood?. International Journal of Cancer, 2011, 129, 2315-2327.	2.3	220
51	Stem cell property epithelialâ€toâ€mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbituxâ„¢) efficacy in KRAS wildâ€type tumor cells. Journal of Cellular Biochemistry, 2011, 112, 10-29.	1.2	41
52	BMI1 as a novel target for drug discovery in cancer. Journal of Cellular Biochemistry, 2011, 112, 2729-2741.	1.2	127
53	The two faces of FBW7 in cancer drug resistance. BioEssays, 2011, 33, 851-859.	1.2	39
54	Tumor-Targeted Drug Delivery with Aptamers. Current Medicinal Chemistry, 2011, 18, 4185-4194.	1.2	104
55	Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy. Mini-Reviews in Medicinal Chemistry, 2011, 11, 611-624.	1.1	15

#	Article	IF	Citations
56	Autophagy positively regulates the CD44⁺CD24^{-/low}breast cancer stem-like phenotype. Cell Cycle, 2011, 10, 3871-3885.	1.3	172
57	Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opinion on Therapeutic Targets, 2011, 15, 439-456.	1.5	77
58	New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opinion on Investigational Drugs, 2011, 20, 507-518.	1.9	52
59	Pancreatic cancer: understanding and overcoming chemoresistance. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 27-33.	8.2	303
60	A Pathway for the Control of Anoikis Sensitivity by E-Cadherin and Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 2011, 31, 4036-4051.	1.1	110
61	Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins?. Cancers, 2011, 3, 716-729.	1.7	299
62	pIgR: Frenemy of Inflammation, EMT, and HCC Progression. Journal of the National Cancer Institute, 2011, 103, 1644-1645.	3.0	13
63	The EMT regulator slug and lung carcinogenesis. Carcinogenesis, 2011, 32, 1299-1304.	1.3	274
64	Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis, 2011, 32, 1324-1332.	1.3	38
65	Mutant p53 Disrupts MCF-10A Cell Polarity in Three-dimensional Culture via Epithelial-to-mesenchymal Transitions. Journal of Biological Chemistry, 2011, 286, 16218-16228.	1.6	73
66	Slug (SNAI2) expression in oral SCC cells results in altered cell-cell adhesion and increased motility. Cell Adhesion and Migration, 2011, 5, 315-322.	1.1	42
67	Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle, 2011, 10, 2008-2016.	1.3	51
68	Signaling Network State Predicts Twist-Mediated Effects on Breast Cell Migration Across Diverse Growth Factor Contexts. Molecular and Cellular Proteomics, 2011, 10, M111.008433.	2.5	27
69	Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFÎ²-induced oncomiR miRNA-181a. Cell Cycle, 2011, 10, 1144-1151.	1.3	108
70	Metastatic Dormancy and Progression in Thyroid Cancer: Targeting Cells in the Metastatic Frontier. Thyroid, 2011, 21, 487-492.	2.4	38
71	Canine Mammary Cancer Stem Cells are Radio- and Chemo- Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype. Cancers, 2011, 3, 1744-1762.	1.7	43
72	Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer. Cancers, 2011, 3, 897-912.	1.7	18
73	Androgen regulation of epithelialâ€“mesenchymal transition in prostate tumorigenesis. Expert Review of Endocrinology and Metabolism, 2011, 6, 469-482.	1.2	44

#	Article	IF	Citations
74	PTTG1 Oncogene Promotes Tumor Malignancy via Epithelial to Mesenchymal Transition and Expansion of Cancer Stem Cell Population. Journal of Biological Chemistry, 2012, 287, 19516-19527.	1.6	86
75	The Implications of Cancer Stem Cells for Cancer Therapy. International Journal of Molecular Sciences, 2012, 13, 16636-16657.	1.8	57
76	Targeting Signal Transducer and Activator of Transcription 3 Pathway by Cucurbitacin I Diminishes Self-Renewing and Radiochemoresistant Abilities in Thyroid Cancer-Derived CD133⁺ Cells. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 410-423.	1.3	53
77	Epithelialâ€“mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 2012, 33, 1639-1646.	1.3	24
78	Oncostatin M Modulates the Mesenchymalâ€“Epithelial Transition of Lung Adenocarcinoma Cells by a Mesenchymal Stem Cell-Mediated Paracrine Effect. Cancer Research, 2012, 72, 6051-6064.	0.4	48
79	Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2760-2765.	3.3	79
80	A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem Cells. Journal of Biomolecular Screening, 2012, 17, 1231-1242.	2.6	35
81	Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biology, 2012, 2, 120066.	1.5	169
82	Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT). Journal of Biological Chemistry, 2012, 287, 42180-42194.	1.6	86
83	Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis, 2012, 33, 1149-1157.	1.3	47
84	RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer. Cancer Research, 2012, 72, 5025-5034.	0.4	120
85	Cancer Stem Cells and Novel Targets for Antitumor Strategies. Current Pharmaceutical Design, 2012, 18, 2838-2849.	0.9	121
86	Diverse Roles for the Paxillin Family of Proteins in Cancer. Genes and Cancer, 2012, 3, 362-370.	0.6	68
87	Stem-Like Cells and Therapy Resistance in Squamous Cell Carcinomas. Advances in Pharmacology, 2012, 65, 235-265.	1.2	34
88	NADPH Oxidase 1 Overexpression Enhances Invasion via Matrix Metalloproteinase-2 and Epithelialâ€“Mesenchymal Transition in Melanoma Cells. Journal of Investigative Dermatology, 2012, 132, 2033-2041.	0.3	76
89	Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle, 2012, 11, 4020-4032.	1.3	119
90	Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Laboratory Investigation, 2012, 92, 952-966.	1.7	65
91	The malignant social network. Cell Adhesion and Migration, 2012, 6, 346-355.	1.1	43

#	Article	IF	Citations
92	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. Cell Cycle, 2012, 11, 1966-1976.	1.3	43
93	Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model. Artificial Cells, Blood Substitutes, and Biotechnology, 2012, 40, 239-244.	0.9	8
94	Brachyury, a Driver of the Epithelialâ€“Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer. Clinical Cancer Research, 2012, 18, 3868-3879.	3.2	112
95	Androgen Deprivation Causes Epithelialâ€“Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy. Cancer Research, 2012, 72, 527-536.	0.4	319
96	MUC1 regulates PDGFA expression during pancreatic cancer progression. Oncogene, 2012, 31, 4935-4945.	2.6	75
97	Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence. Oncogene, 2012, 31, 2545-2554.	2.6	18
98	Mammary Epithelial Cell Polarity Is Regulated Differentially by p73 Isoforms via Epithelial-to-mesenchymal Transition. Journal of Biological Chemistry, 2012, 287, 17746-17753.	1.6	27
99	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle, 2012, 11, 1235-1246.	1.3	56
100	Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-Cell Killing. Cancer Biotherapy and Radiopharmaceuticals, 2012, 27, 23-35.	0.7	36
101	Transforming growth factor Î² signaling regulates the invasiveness of normal mammary epithelial cells and the metastasis formation of tumor cells. Hormone Molecular Biology and Clinical Investigation, 2012, 10, 227-39.	0.3	2
102	Epithelialâ€“Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines. Molecular Cancer Therapeutics, 2012, 11, 503-513.	1.9	55
103	Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition. Journal of Biological Chemistry, 2012, 287, 44508-44517.	1.6	145
104	Snail1 is involved in <italic>de novo</italic> cardiac fibrosis after myocardial infarction in mice. Acta Biochimica Et Biophysica Sinica, 2012, 44, 902-910.	0.9	16
105	Comparison of Spheroids Formed by Rat Glioma Stem Cells and Neural Stem Cells Reveals Differences in Glucose Metabolism and Promising Therapeutic Applications. Journal of Biological Chemistry, 2012, 287, 33664-33674.	1.6	55
106	Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches. Current Signal Transduction Therapy, 2012, 7, 254-264.	0.3	0
107	Exploring Protein Kinase Inhibitors. Pancreas, 2012, 41, 496-498.	0.5	5
108	Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage IIâ€“III colon cancer patients. Experimental and Therapeutic Medicine, 2012, 3, 973-982.	0.8	27
109	Association of stem cell marker expression pattern and survival in human biliary tract cancer. International Journal of Oncology, 2012, 41, 511-522.	1.4	12

#	Article	IF	Citations
110	Loss of E-cadherin promotes prostate cancer metastasis via upregulation of metastasis-associated gene 1 expression. Oncology Letters, 2012, 4, 1225-1233.	0.8	42
111	A CD44high/EGFRlow Subpopulation within Head and Neck Cancer Cell Lines Shows an Epithelial-Mesenchymal Transition Phenotype and Resistance to Treatment. PLoS ONE, 2012, 7, e44071.	1.1	60
112	Prospero Homeobox 1 Promotes Epithelialâ€“Mesenchymal Transition in Colon Cancer Cells by Inhibiting E-cadherin via miR-9. Clinical Cancer Research, 2012, 18, 6416-6425.	3.2	97
113	Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer. Clinical Cancer Research, 2012, 18, 869-881.	3.2	325
114	Inhibition of Telomerase with Imetelstat Causes Depletion of Cancer Stem Cells. , 2012, , 13-24.		0
115	Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205. American Journal of Pathology, 2012, 181, 2188-2201.	1.9	225
116	Cancer cells and adaptive explanations. Biology and Philosophy, 2012, 27, 785-810.	0.7	28
117	Strigolactones: a novel class of phytohormones that inhibit the growth and survival of breast cancer cells and breast cancer stem-like enriched mammosphere cells. Breast Cancer Research and Treatment, 2012, 134, 1041-1055.	1.1	50
118	Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene, 2012, 31, 764-775.	2.6	128
119	Analysis of cell adhesion during early stages of colon cancer based on an extended multi-valued logic approach. Molecular BioSystems, 2012, 8, 1230.	2.9	17
120	Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab on A Chip, 2012, 12, 4388.	3.1	170
121	ERÎ±, microRNAs, and the epithelialâ€“mesenchymal transition in breast cancer. Trends in Endocrinology and Metabolism, 2012, 23, 73-82.	3.1	103
122	DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2012, 18, 2360-2373.	3.2	81
123	MicroRNAs involved in regulating epithelialâ€“mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Therapy, 2012, 19, 723-730.	2.2	77
124	DEDD Interacts with PI3KC3 to Activate Autophagy and Attenuate Epithelialâ€“Mesenchymal Transition in Human Breast Cancer. Cancer Research, 2012, 72, 3238-3250.	0.4	145
125	Autism spectrum disorders. Nature Reviews Drug Discovery, 2012, 11, 745-746.	21.5	29
126	Targeting the TGFÎ² signalling pathway in disease. Nature Reviews Drug Discovery, 2012, 11, 790-811.	21.5	1,207
127	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599

#	Article	IF	Citations
128	Loss of Akt1 evokes epithelial-mesenchymal transition by autocrine regulation of transforming growth factor-Î²1. Advances in Biological Regulation, 2012, 52, 88-96.	1.4	2
129	Contribution of Epithelial-to-Mesenchymal Transition and Cancer Stem Cells to Pancreatic Cancer Progression. Journal of Surgical Research, 2012, 173, 105-112.	0.8	80
130	Cancer invasion and resistance: interconnected processes of disease progression and therapy failure. Trends in Molecular Medicine, 2012, 18, 13-26.	3.5	139
131	Chemoresistance to 5-fluorouracil induces epithelialâ€“mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells. Biochemical and Biophysical Research Communications, 2012, 417, 679-685.	1.0	108
132	CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Letters, 2012, 319, 49-55.	3.2	48
133	Acquisition of an enhanced aggressive phenotype in human lung cancer cells selected by suboptimal doses of cisplatin following cell deattachment and reattachment. Cancer Letters, 2012, 321, 36-44.	3.2	16
134	Drug resistance in the mouse cancer clinic. Drug Resistance Updates, 2012, 15, 81-89.	6.5	33
135	EGCG Inhibits Transforming Growth Factor-Î²-Mediated Epithelial-to-Mesenchymal Transition via the Inhibition of Smad2 and Erk1/2 Signaling Pathways in Nonsmall Cell Lung Cancer Cells. Journal of Agricultural and Food Chemistry, 2012, 60, 9863-9873.	2.4	62
136	Phenolic Secoiridoids in Extra Virgin Olive Oil Impede Fibrogenic and Oncogenic Epithelial-to-Mesenchymal Transition: Extra Virgin Olive Oil As a Source of Novel Antiaging Phytochemicals. Rejuvenation Research, 2012, 15, 3-21.	0.9	36
137	Defining new criteria for selection of cell-based intestinal models using publicly available databases. BMC Genomics, 2012, 13, 274.	1.2	49
138	The T-box transcription factor Brachyury regulates epithelialâ€“mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells. BMC Cancer, 2012, 12, 377.	1.1	47
139	Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt. BMC Cancer, 2012, 12, 556.	1.1	66
140	EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Molecular Cancer, 2012, 11, 73.	7.9	206
141	Wnt/Snail Signaling Regulates CytochromecOxidase and Glucose Metabolism. Cancer Research, 2012, 72, 3607-3617.	0.4	163
142	Highly sensitive profiling of CD44+/CD24â˜’ breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathway. Cancer Letters, 2012, 325, 165-174.	3.2	53
143	Response of cancer stem-like cells and non-stem cancer cells to proton and Î³-ray irradiation. Nuclear Instruments & Methods in Physics Research B, 2012, 286, 346-350.	0.6	17
144	Inflammation linking EMT and cancer stem cells. Oral Oncology, 2012, 48, 1068-1075.	0.8	55
145	Tumor progression: Chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution. Progress in Biophysics and Molecular Biology, 2012, 110, 69-86.	1.4	61

#	Article	IF	Citations
146	The bed and the bugs: Interactions between the tumor microenvironment and cancer stem cells. Seminars in Cancer Biology, 2012, 22, 462-470.	4.3	45
147	Clinical Implication of Targeting of Cancer Stem Cells. European Surgical Research, 2012, 49, 8-15.	0.6	4
148	Mechanisms of acquired resistance to targeted cancer therapies. Future Oncology, 2012, 8, 999-1014.	1.1	150
149	A Novel Small Molecule FL118 That Selectively Inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-Independent Manner, Shows Superior Antitumor Activity. PLoS ONE, 2012, 7, e45571.	1.1	97
150	Targeting pancreatic cancer stem cells for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 385-399.	3.3	19
151	The relationship between Bmi-1 and the epithelialâ€“mesenchymal transition in lung squamous cell carcinoma. Medical Oncology, 2012, 29, 1606-1613.	1.2	17
152	The metastatic niche and stromal progression. Cancer and Metastasis Reviews, 2012, 31, 429-440.	2.7	179
154	Antitumor Agents. 293. Nontoxic Dimethyl-4,4â€²-dimethoxy-5,6,5â€²,6â€²-dimethylenedioxybiphenyl-2,2â€²-dicarboxylate (DDB) Analogues Chemosensitize Multidrug-Resistant Cancer Cells to Clinical Anticancer Drugs. Journal of Medicinal Chemistry, 2012, 55, 5413-5424.	2.9	29
155	The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene, 2012, 31, 2164-2174.	2.6	109
156	1-(3,4,5-Trimethoxyphenyl)ethane-1,2-diyl esters, a novel compound class with potent chemoreversal activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7726-7729.	1.0	1
157	Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells. PLoS ONE, 2012, 7, e33214.	1.1	38
158	Down-Regulation of HtrA1 Activates the Epithelial-Mesenchymal Transition and ATM DNA Damage Response Pathways. PLoS ONE, 2012, 7, e39446.	1.1	30
159	Akt Mediates Metastasis-Associated Gene 1 (MTA1) Regulating the Expression of E-cadherin and Promoting the Invasiveness of Prostate Cancer Cells. PLoS ONE, 2012, 7, e46888.	1.1	35
160	Py2T Murine Breast Cancer Cells, a Versatile Model of TGFÎ²-Induced EMT In Vitro and In Vivo. PLoS ONE, 2012, 7, e48651.	1.1	65
161	Metformin: An Emerging New Therapeutic Option for Targeting Cancer Stem Cells and Metastasis. Journal of Oncology, 2012, 2012, 1-12.	0.6	100
162	The role of cancer stem cells in relapse of solid tumors. Frontiers in Bioscience - Elite, 2012, E4, 1528.	0.9	75
163	The Amazing Power of Cancer Cells to Recapitulate Extraembryonic Functions: The Cuckoo's Tricks. Journal of Oncology, 2012, 2012, 1-20.	0.6	7
164	EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Frontiers in Bioscience - Scholar, 2012, S4, 671-684.	0.8	75

#	Article	IF	Citations
165	Targeting Tumor Microenvironments for Cancer Prevention and Therapy. , 2012, , .		4
166	The role of cancer stem cells in relapse of solid tumors. Frontiers in Bioscience - Elite, 2012, E4, 1528-1541.	0.9	117
167	Transformation of Epithelial Ovarian Cancer Stemlike Cells into Mesenchymal Lineage via EMT Results in Cellular Heterogeneity and Supports Tumor Engraftment. Molecular Medicine, 2012, 18, 1197-1208.	1.9	36
168	Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: Utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment. Oncotarget, 2012, 3, 1600-1614.	0.8	73
169	8.4 Targeting protein-glycan interactions at cell surface during EMT and hematogenous metastasis: consequences on tumor invasion and metastasis. , 2012, , 763-784.		0
170	TGF-beta antiproliferative effects in tumor suppression. Frontiers in Bioscience - Scholar, 2012, S4, 749-766.	0.8	11
171	Colorectal Cancer Stem Cells. Stem Cells, 2012, 30, 363-371.	1.4	197
172	Comparative labelâ€free <scp>LC</scp>â€<scp>MS</scp>/<scp>MS</scp> analysis of colorectal adenocarcinoma and metastatic cells treated with 5â€fluorouracil. Proteomics, 2012, 12, 1928-1937.	1.3	28
173	Cancer stem cells and epithelialâ€“mesenchymal transition: Concepts and molecular links. Seminars in Cancer Biology, 2012, 22, 396-403.	4.3	781
174	To differentiate or not â€” routes towards metastasis. Nature Reviews Cancer, 2012, 12, 425-436.	12.8	547
175	Endocytosis and Signaling: Cell Logistics Shape the Eukaryotic Cell Plan. Physiological Reviews, 2012, 92, 273-366.	13.1	278
176	Circumventing Cancer Drug Resistance in the Era of Personalized Medicine. Cancer Discovery, 2012, 2, 214-226.	7.7	419
177	Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence. Clinical Cancer Research, 2012, 18, 645-653.	3.2	173
178	Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer and Metastasis Reviews, 2012, 31, 733-751.	2.7	58
179	PI3K: A potential therapeutic target for cancer. Journal of Cellular Physiology, 2012, 227, 2818-2821.	2.0	49
180	Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology, 2012, 56, 1004-1014.	3.6	265
181	Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells. Journal of Zhejiang University: Science B, 2012, 13, 11-19.	1.3	11
182	Intratumoral stages of metastatic cells: A synthesis of ontogeny, Rho/Rac GTPases, epithelialâ€mesenchymal transitions, and more. BioEssays, 2012, 34, 748-759.	1.2	18

#	Article	IF	Citations
183	Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene, 2012, 31, 1389-1397.	2.6	66
184	Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacological Reviews, 2012, 64, 706-721.	7.1	737
185	TGF-Î² signalling and its role in cancer progression and metastasis. Cancer and Metastasis Reviews, 2012, 31, 553-568.	2.7	367
186	Cancer stem cells and EMT in carcinoma. Cancer and Metastasis Reviews, 2012, 31, 285-293.	2.7	136
187	The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis. Cancer Microenvironment, 2012, 5, 5-18.	3.1	74
188	The Tumor-Promoting Flow of Cells Into, Within and Out of the Tumor Site: Regulation by the Inflammatory Axis of TNFÎ± and Chemokines. Cancer Microenvironment, 2012, 5, 151-164.	3.1	55
189	Epithelial cell polarity, stem cells and cancer. Nature Reviews Cancer, 2012, 12, 23-38.	12.8	476
190	Glycine Decarboxylase Cleaves a â€œMalignantâ€•Metabolic Path to Promote Tumor Initiation. Cancer Cell, 2012, 21, 143-145.	7.7	5
191	Sensitization of tumor cells by targeting histone deacetylases. Biochemical Pharmacology, 2012, 83, 987-994.	2.0	29
192	The enhancement of cancer stem cell properties of MCF-7 cells in 3D collagen scaffolds for modeling of cancer and anti-cancer drugs. Biomaterials, 2012, 33, 1437-1444.	5.7	241
193	Lung cancer stem cells: Tumor biology and clinical implications. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 217-222.	0.7	8
194	Concepts of metastasis in flux: The stromal progression model. Seminars in Cancer Biology, 2012, 22, 174-186.	4.3	75
195	<scp>D</scp>ickkopfâ€1 inhibits epithelialâ€mesenchymal transition of colon cancer cells and contributes to colon cancer suppression. Cancer Science, 2012, 103, 828-835.	1.7	68
196	Significance of epithelial growth factor in the epithelialâ€“mesenchymal transition of human gallbladder cancer cells. Cancer Science, 2012, 103, 1165-1171.	1.7	15
197	Connective tissue growth factor in tumor pathogenesis. Fibrogenesis and Tissue Repair, 2012, 5, S8.	3.4	45
198	Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Research, 2012, 14, R4.	2.2	54
199	Proteomics analysis of in vitro protein methylation during Srcâ€induced transformation. Electrophoresis, 2012, 33, 451-461.	1.3	10
200	Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer, 2012, 118, 1543-1553.	2.0	21

#	Article	IF	Citations
201	Inactivation of the vitamin D receptor in APC^{min/+} mice reveals a critical role for the vitamin D receptor in intestinal tumor growth. International Journal of Cancer, 2012, 130, 10-19.	2.3	63
202	Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Research and Treatment, 2012, 132, 75-85.	1.1	126
203	Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Molecular and Cellular Biochemistry, 2012, 363, 427-436.	1.4	103
204	TGF-Î² signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-Î². Cell and Tissue Research, 2012, 347, 37-49.	1.5	88
205	Deconstructing the mechanisms and consequences of TGF-Î²-induced EMT during cancer progression. Cell and Tissue Research, 2012, 347, 85-101.	1.5	202
206	ZEB/miRâ€200 feedback loop: At the crossroads of signal transduction in cancer. International Journal of Cancer, 2013, 132, 745-754.	2.3	227
207	Curcumin in VIP-targeted sterically stabilized phospholipid nanomicelles: a novel therapeutic approach for breast cancer and breast cancer stem cells. Drug Delivery and Translational Research, 2013, 3, 562-574.	3.0	33
208	Stat3-coordinated Lin-28â€“let-7â€“HMGA2 and miR-200â€“ZEB1 circuits initiate and maintain oncostatin M-driven epithelialâ€“mesenchymal transition. Oncogene, 2013, 32, 5272-5282.	2.6	171
209	Lung cancer stem cells: a biological and clinical perspective. Cellular Oncology (Dordrecht), 2013, 36, 265-275.	2.1	36
211	Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Human Pathology, 2013, 44, 2373-2384.	1.1	50
212	Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biology, 2013, 14, 7.	3.0	63
213	JNK signaling maintains the mesenchymal properties of multi-drug resistant human epidermoid carcinoma KB cells through snail and twist1. BMC Cancer, 2013, 13, 180.	1.1	20
214	Role of integrated cancer nanomedicine in overcoming drug resistance. Advanced Drug Delivery Reviews, 2013, 65, 1784-1802.	6.6	288
215	The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel. Biomaterials, 2013, 34, 7662-7673.	5.7	93
216	Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Letters, 2013, 339, 70-81.	3.2	134
217	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	1.8	53
218	Breast Cancer Metastasis and Drug Resistance. , 2013, , .		12
219	FOXM1 (Forkhead box M1) in Tumorigenesis. Advances in Cancer Research, 2013, 119, 191-419.	1.9	146

#	Article	IF	Citations
220	Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship?. Amino Acids, 2013, 44, 81-88.	1.2	39
221	SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelialâ€mesenchymal transition. Cancer, 2013, 119, 2247-2257.	2.0	37
222	SIRT1 Suppresses the Epithelial-to-Mesenchymal Transition in Cancer Metastasis and Organ Fibrosis. Cell Reports, 2013, 3, 1175-1186.	2.9	195
223	Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies. Cell Death and Disease, 2013, 4, e828-e828.	2.7	58
224	WNT5A is a Key Regulator of the Epithelial-Mesenchymal Transition and Cancer Stem Cell Properties in Human Gastric Carcinoma Cells. Pathobiology, 2013, 80, 235-244.	1.9	59
225	Epithelialâ€mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4â€ALK translocation. Molecular Oncology, 2013, 7, 1093-1102.	2.1	101
226	SPOCK1 is a novel transforming growth factor-Î² target gene that regulates lung cancer cell epithelial-mesenchymal transition. Biochemical and Biophysical Research Communications, 2013, 440, 792-797.	1.0	64
227	Can nanomedicines kill cancer stem cells?. Advanced Drug Delivery Reviews, 2013, 65, 1763-1783.	6.6	114
228	Breast cancer stem cells and epithelial mesenchymal plasticity â€“ Implications for chemoresistance. Cancer Letters, 2013, 341, 56-62.	3.2	108
229	Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. Gene, 2013, 521, 62-68.	1.0	8
230	Acquisition of epithelialâ€“mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death and Disease, 2013, 4, e875-e875.	2.7	321
231	The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Medicine, 2013, 19, 1438-1449.	15.2	1,030
232	MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene, 2013, 32, 431-443.	2.6	116
233	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Human Pathology, 2013, 44, 1973-1981.	1.1	87
234	Wnt/Î²-catenin signaling enhances hypoxia-induced epithelialâ€“mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1Î± signaling. Carcinogenesis, 2013, 34, 962-973.	1.3	208
235	Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. BMC Systems Biology, 2013, 7, 85.	3.0	16
236	Epigenetic coordination of signaling pathways during the epithelial-mesenchymal transition. Epigenetics and Chromatin, 2013, 6, 28.	1.8	42
237	Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Molecular Cancer, 2013, 12, 94.	7.9	186

#	Article	IF	Citations
238	Roadblocks to translational advances on metastasis research. Nature Medicine, 2013, 19, 1104-1109.	15.2	91
239	Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Letters, 2013, 341, 41-45.	3.2	189
240	Notch3 induces epithelialâ€“mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecologic Oncology, 2013, 130, 200-206.	0.6	61
241	Gastric cancerâ€”molecular and clinical dimensions. Nature Reviews Clinical Oncology, 2013, 10, 643-655.	12.5	376
242	Multiple drug resistant, tumorigenic stem-like cells in oral cancer. Cancer Letters, 2013, 338, 300-316.	3.2	26
243	Colorectal cancer stem cells and their implications for novel anticancer therapy. Expert Review of Anticancer Therapy, 2013, 13, 461-468.	1.1	1
244	The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Molecular Medicine, 2013, 5, 1196-1212.	3.3	337
245	KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival. Science Translational Medicine, 2013, 5, 169ra12.	5.8	70
246	Cancer stem cells niche: A target for novel cancer therapeutics. Cancer Treatment Reviews, 2013, 39, 290-296.	3.4	70
247	Overlapping activities of TGF-Î² and Hedgehog signaling in cancer: Therapeutic targets for cancer treatment. , 2013, 137, 183-199.		51
248	Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelialâ€“mesenchymal transition in squamous cell carcinoma. Archives of Dermatological Research, 2013, 305, 35-47.	1.1	57
249	MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Research and Treatment, 2013, 137, 373-382.	1.1	90
250	miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters, 2013, 334, 211-220.	3.2	83
251	Deconstruction of Medulloblastoma Cellular Heterogeneity Reveals Differences between the Most Highly Invasive and Self-Renewing Phenotypes. Neoplasia, 2013, 15, 384-IN8.	2.3	38
252	Detection and isolation of circulating tumor cells: Principles and methods. Biotechnology Advances, 2013, 31, 1063-1084.	6.0	157
253	TGF-Î²-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition. Cell Reports, 2013, 5, 1228-1242.	2.9	205
254	Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification. Cancer Letters, 2013, 339, 60-69.	3.2	73
255	Epithelial to mesenchymal transition and the generation of stem-like cells in pancreatic cancer. Pancreatology, 2013, 13, 114-117.	0.5	23

#	Article	IF	Citations
256	Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma. Cancer Letters, 2013, 338, 47-56.	3.2	108
257	Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling. Molecular Cancer Therapeutics, 2013, 12, 1796-1804.	1.9	45
258	Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway. Journal of Biological Chemistry, 2013, 288, 17954-17967.	1.6	118
259	Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. FEBS Letters, 2013, 587, 3327-3334.	1.3	24
260	Convergent mechanisms in pluripotent stem cells and cancer: Implications for stem cell engineering. Biotechnology Journal, 2013, 8, 408-419.	1.8	4
261	Helicobacter pylori CagA: A Critical Destroyer of the Gastric Epithelial Barrier. Digestive Diseases and Sciences, 2013, 58, 1830-1837.	1.1	14
262	Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. Cancer Science, 2013, 104, 28-35.	1.7	30
263	Biological roles and prognostic values of the epithelialâ€“mesenchymal transitionâ€mediating transcription factors Twist, ZEB1 and Slug in diffuse large Bâ€cell lymphoma. Histopathology, 2013, 62, 326-333.	1.6	52
264	Epithelial-to-mesenchymal(-like) transition as a relevant molecular event in malignant gliomas. Cancer Letters, 2013, 331, 131-138.	3.2	188
265	TGF-Î² family signaling in stem cells. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 2280-2296.	1.1	134
266	MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology, 2013, 58, 629-641.	3.6	340
267	Claudin-1 induces epithelialâ€“mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene, 2013, 32, 4873-4882.	2.6	182
268	Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Molecular BioSystems, 2013, 9, 1127-1138.	2.9	29
269	Regulation of Lung Cancer Metastasis by Klf4-Numbâ€“like Signaling. Cancer Research, 2013, 73, 2695-2705.	0.4	56
270	Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Delivery and Translational Research, 2013, 3, 165-182.	3.0	66
271	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. Nature Reviews Cancer, 2013, 13, 365-376.	12.8	242
272	Riding the crest of the wave: parallels between the neural crest and cancer in epithelialâ€toâ€mesenchymal transition and migration. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2013, 5, 511-522.	6.6	51
273	The metastasis-promoting roles of tumor-associated immune cells. Journal of Molecular Medicine, 2013, 91, 411-429.	1.7	305

#	Article	IF	Citations
274	Strategies for Isolating and Enriching Cancer Stem Cells: Well Begun Is Half Done. Stem Cells and Development, 2013, 22, 2221-2239.	1.1	74
275	Crosstalk between breast cancer stem cells and metastatic niche: emerging molecular metastasis pathway?. Tumor Biology, 2013, 34, 2019-2030.	0.8	44
276	Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer and Metastasis Reviews, 2013, 32, 423-448.	2.7	154
277	Self-Assembling, Amphiphilic Polymerâ€“Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma. Bioconjugate Chemistry, 2013, 24, 1161-1173.	1.8	84
278	Breast Cancer Stem Cells and miRNAs. , 2013, , 367-383.		0
279	MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nature Communications, 2013, 4, 1393.	5.8	209
280	Targeting GRP78 and antiestrogen resistance in breast cancer. Future Medicinal Chemistry, 2013, 5, 1047-1057.	1.1	26
281	ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters, 2013, 328, 144-151.	3.2	135
282	Prominin-1 (CD133): New Insights on Stem & Cancer Stem Cell Biology. Advances in Experimental Medicine and Biology, 2013, , .	0.8	10
283	Comparative Secretome Analysis of Epithelial and Mesenchymal Subpopulations of Head and Neck Squamous Cell Carcinoma Identifies S100A4 as a Potential Therapeutic Target. Molecular and Cellular Proteomics, 2013, 12, 3778-3792.	2.5	32
284	Inhibition of tumor growth and metastasis by a self-therapeutic nanoparticle. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6700-6705.	3.3	208
285	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors. Cancer Discovery, 2013, 3, 68-81.	7.7	428
286	Targeting ROR1 Inhibits Epithelialâ€“Mesenchymal Transition and Metastasis. Cancer Research, 2013, 73, 3649-3660.	0.4	135
287	Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. British Journal of Cancer, 2013, 109, 2705-2713.	2.9	264
288	Epithelial to mesenchymal transition as a portal to stem cell characters embedded in gene networks. BioEssays, 2013, 35, 191-200.	1.2	16
289	Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 2013, 132, 785-794.	2.3	111
290	MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clinical and Translational Oncology, 2013, 15, 335-342.	1.2	33
291	Epithelialâ€mesenchymal transition as a fundamental mechanism underlying the cancer phenotype. Veterinary and Comparative Oncology, 2013, 11, 169-184.	0.8	56

#	Article	IF	Citations
292	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	0.9	24
293	ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. Oncology Reports, 2013, 29, 1777-1784.	1.2	34
294	Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes and Cancer, 2013, 4, 82-90.	0.6	69
295	Epigenetic Approaches for Chemosensitization of Refractory Diffuse Large B-Cell Lymphomas. Cancer Discovery, 2013, 3, 968-970.	7.7	5
296	Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells. Current Molecular Medicine, 2013, 13, 459-463.	0.6	0
297	Emerging Therapeutic Biomarkers in Endometrial Cancer. BioMed Research International, 2013, 2013, 1-11.	0.9	49
298	Caffeic Acid Phenethyl Ester Inhibits Epithelial-Mesenchymal Transition of Human Pancreatic Cancer Cells. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-7.	0.5	13
299	MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis, 2013, 34, 530-538.	1.3	212
300	Emerging Roles of Claudins in Human Cancer. International Journal of Molecular Sciences, 2013, 14, 18148-18180.	1.8	170
301	NF-ÎºB-Mediated Inflammation Leading to EMT via miR-200c Is Involved in Cell Transformation Induced By Cigarette Smoke Extract. Toxicological Sciences, 2013, 135, 265-276.	1.4	78
302	Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib inEGFRWild-Type Nonâ€“Small Cell Lung Carcinoma Cell Lines. Molecular Cancer Therapeutics, 2013, 12, 520-529.	1.9	21
303	Role of the Microenvironment in Ovarian Cancer Stem Cell Maintenance. BioMed Research International, 2013, 2013, 1-10.	0.9	28
304	MiR-124 targets Slug to regulate epithelialâ€“mesenchymal transition and metastasis of breast cancer. Carcinogenesis, 2013, 34, 713-722.	1.3	176
305	Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells. International Journal of Molecular Sciences, 2013, 14, 6624-6648.	1.8	59
306	Clinicopathologic Correlations of Liver Kinase B1, E-Cadherin, and N-Cadherin Expression in Nonâ€“Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 334-340.	0.6	13
307	Basal/HER2 breast carcinomas. Cell Cycle, 2013, 12, 225-245.	1.3	48
308	PTK6 Activation at the Membrane Regulates Epithelialâ€“Mesenchymal Transition in Prostate Cancer. Cancer Research, 2013, 73, 5426-5437.	0.4	39
309	EZH2 Is Required for Breast and Pancreatic Cancer Stem Cell Maintenance and Can Be Used as a Functional Cancer Stem Cell Reporter. Stem Cells Translational Medicine, 2013, 2, 43-52.	1.6	104

#	Article	IF	Citations
310	Drug Resistance. , 2013, , 418-420.		1
311	Downregulated Expression of the Cyclase-associated Protein 1 (CAP1) Reduces Migration in Esophageal Squamous Cell Carcinoma. Japanese Journal of Clinical Oncology, 2013, 43, 856-864.	0.6	24
312	Is carcinoma a mesenchymal disease? The role of the stromal microenvironment in carcinogenesis. Pathology, 2013, 45, 371-381.	0.3	17
313	Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Frontiers in Oncology, 2012, 2, 209.	1.3	48
314	Pharmacological modulation of betaâ€catenin and its applications in cancer therapy. Journal of Cellular and Molecular Medicine, 2013, 17, 449-456.	1.6	81
315	<scp>KLF</scp>5 strengthens drug resistance of ovarian cancer stemâ€like cells by regulating survivin expression. Cell Proliferation, 2013, 46, 425-435.	2.4	59
316	Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Medicine, 2013, 2, 751-762.	1.3	46
317	Epigenetic Regulation of SOX9 by the NF-Î¹B Signaling Pathway in Pancreatic Cancer Stem Cells. Stem Cells, 2013, 31, 1454-1466.	1.4	111
318	MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. Journal of Cellular and Molecular Medicine, 2013, 17, 1207-1217.	1.6	21
319	Slug promoted vasculogenic mimicry in hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2013, 17, 1038-1047.	1.6	63
320	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	1.3	65
321	TGF-Î²: An emerging player in drug resistance. Cell Cycle, 2013, 12, 2960-2968.	1.3	117
322	Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncogenesis, 2013, 2, e73-e73.	2.1	69
323	Mutant p53 gain-of-function induces epithelialâ€“mesenchymal transition through modulation of the miR-130bâ€“ZEB1 axis. Oncogene, 2013, 32, 3286-3295.	2.6	270
324	FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death and Disease, 2013, 4, e578-e578.	2.7	59
325	Indole-3-Carbinol and 3â€²,3â€²-Diindolylmethane Modulate Androgen's Effect on C-C Chemokine Ligand 2 and Monocyte Attraction to Prostate Cancer Cells. Cancer Prevention Research, 2013, 6, 519-529.	0.7	14
326	Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma. Clinical Cancer Research, 2013, 19, 5879-5889.	3.2	110
327	An Autocrine Loop between TGF-Î²1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype. Molecular Cancer Therapeutics, 2013, 12, 1805-1815.	1.9	57

#	Article	IF	Citations
328	Epigenetic control of epithelial-mesenchymal-transition in human cancer. Molecular and Clinical Oncology, 2013, 1, 3-11.	0.4	100
329	Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. International Journal of Oncology, 2013, 42, 556-564.	1.4	18
330	Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncology Reports, 2013, 30, 1782-1792.	1.2	79
331	Implantation of GL261 neurospheres into C57/BL6 mice: A more reliable syngeneic graft model for research on glioma-initiating cells. International Journal of Oncology, 2013, 43, 477-484.	1.4	15
332	Overexpression of Numb suppresses tumor cell growth and enhances sensitivity to cisplatin in epithelioid malignant pleural mesothelioma. Oncology Reports, 2013, 30, 313-319.	1.2	30
333	Drug-resistant colon cancer cells produce high carcinoembryonic antigen and might not be cancer-initiating cells. Drug Design, Development and Therapy, 2013, 7, 491.	2.0	10
334	Cyclin D1 affects epithelial–mesenchymal transition in epithelial ovarian cancer stem cell-like cells. OncoTargets and Therapy, 2013, 6, 667.	1.0	19
335	Colon cancer stem cells: Controversies and perspectives. World Journal of Gastroenterology, 2013, 19, 2997.	1.4	62
336	miR-655 Is an EMT-Suppressive MicroRNA Targeting ZEB1 and TGFBR2. PLoS ONE, 2013, 8, e62757.	1.1	105
337	SNAI1-Mediated Epithelial-Mesenchymal Transition Confers Chemoresistance and Cellular Plasticity by Regulating Genes Involved in Cell Death and Stem Cell Maintenance. PLoS ONE, 2013, 8, e66558.	1.1	71
338	Amelioration of Cancer Stem Cells in Macrophage Colony Stimulating Factor-Expressing U87MG-Human Glioblastoma upon 5-Fluorouracil Therapy. PLoS ONE, 2013, 8, e83877.	1.1	17
339	The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance. PLoS ONE, 2013, 8, e78675.	1.1	101
340	Roles of Epithelial-Mesenchymal Transition in Cancer Drug Resistance. Current Cancer Drug Targets, 2013, 13, 915-929.	0.8	109
341	Imaging the Urokinase Plasminongen Activator Receptor in Preclinical Breast Cancer Models of Acquired Drug Resistance. Theranostics, 2014, 4, 267-279.	4.6	31
342	Vasohibin 2 Decreases the Cisplatin Sensitivity of Hepatocarcinoma Cell Line by Downregulating p53. PLoS ONE, 2014, 9, e90358.	1.1	16
343	miRNA 17 Family Regulates Cisplatin-Resistant and Metastasis by Targeting TGFbetaR2 in NSCLC. PLoS ONE, 2014, 9, e94639.	1.1	82
344	Ginsenoside 20(S)-Rg3 Targets HIF-1Î± to Block Hypoxia-Induced Epithelial-Mesenchymal Transition in Ovarian Cancer Cells. PLoS ONE, 2014, 9, e103887.	1.1	67
345	Curcumin Suppresses Crosstalk between Colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role of EMT. PLoS ONE, 2014, 9, e107514.	1.1	116

#	Article	IF	Citations
346	Human Equilibrative Nucleoside Transporter-1 Knockdown Tunes Cellular Mechanics through Epithelial-Mesenchymal Transition in Pancreatic Cancer Cells. PLoS ONE, 2014, 9, e107973.	1.1	14
347	Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells. PLoS ONE, 2014, 9, e112438.	1.1	28
349	Tumor Initiating Cells and Chemoresistance: Which Is the Best Strategy to Target Colon Cancer Stem Cells?. BioMed Research International, 2014, 2014, 1-7.	0.9	41
350	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). Current Signal Transduction Therapy, 2014, 8, 219-228.	0.3	67
351	PrPCfrom stem cells to cancer. Frontiers in Cell and Developmental Biology, 2014, 2, 55.	1.8	39
352	Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget, 2014, 5, 8027-8038.	0.8	177
353	Multidrug-resistant hepatocellular carcinoma cells are enriched for CD133+ subpopulation through activation of TGF-1/Smad3 pathway. African Journal of Biotechnology, 2014, 13, 3538-3546.	0.3	0
354	ROS-induced epithelial-mesenchymal transition in mammary epithelial cells is mediated by NF-Î°B-dependent activation of Snail. Oncotarget, 2014, 5, 2827-2838.	0.8	158
355	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition. Oncotarget, 2014, 5, 7328-7341.	0.8	120
356	Correlation between the overexpression of epidermal growth factor receptor and mesenchymal makers in endometrial carcinoma. Journal of Gynecologic Oncology, 2014, 25, 36.	1.0	14
357	Stem Cells in Pancreatic Cancer. , 0, , .		0
358	Tumor Plasticity Interferes with Anti-Tumor Immunity. Critical Reviews in Immunology, 2014, 34, 91-102.	1.0	44
359	Notch signaling in serous ovarian cancer. Journal of Ovarian Research, 2014, 7, 95.	1.3	71
360	Targeting met mediated epithelialâ€mesenchymal transition in the treatment of breast cancer. Clinical and Translational Medicine, 2014, 3, 30.	1.7	20
361	Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer, 2014, 14, 785.	1.1	97
362	Clinical Significance of Epithelial-Mesenchymal Transition-Associated Markers in Malignant Pleural Mesothelioma. Oncology, 2014, 86, 109-116.	0.9	17
363	Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance. Cell Cycle, 2014, 13, 1702-1707.	1.3	52
364	IL-6 secreted by cancer-associated fibroblasts induces tamoxifen resistance in luminal breast cancer. Oncogene, 2014, , .	2.6	49

#	Article	IF	Citations
365	The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers, 2014, 6, 829-859.	1.7	121
366	Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Frontiers in Oncology, 2014, 4, 123.	1.3	147
367	Comparative Proteomic Profiling of Pancreatic Ductal Adenocarcinoma Cell Lines. Molecules and Cells, 2014, 37, 888-898.	1.0	42
368	Resistance to dual blockade of the kinases PI3K and mTOR in KRAS -mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Science Signaling, 2014, 7, ra107.	1.6	30
369	Pien Tze Huang Overcomes Multidrug Resistance and Epithelial-Mesenchymal Transition in Human Colorectal Carcinoma Cells via Suppression of TGF-Î²Pathway. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	0.5	27
370	Engineered reversal of drug resistance in cancer cells--metastases suppressor factors as change agents. Nucleic Acids Research, 2014, 42, 764-773.	6.5	199
371	De-Differentiation Confers Multidrug Resistance Via Noncanonical PERK-Nrf2 Signaling. PLoS Biology, 2014, 12, e1001945.	2.6	94
372	hTERT promoter activity identifies osteosarcoma cells with increased EMT characteristics. Oncology Letters, 2014, 7, 239-244.	0.8	27
373	Twist2 contributes to cisplatin-resistance of ovarian cancer through the AKT/GSK-3Î² signaling pathway. Oncology Letters, 2014, 7, 1102-1108.	0.8	16
374	Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications. Cancers, 2014, 6, 2369-2386.	1.7	23
375	Drug Resistance in Cancer: An Overview. Cancers, 2014, 6, 1769-1792.	1.7	1,810
376	Emerging Understanding of Multiscale Tumor Heterogeneity. Frontiers in Oncology, 2014, 4, 366.	1.3	90
378	Epithelialâ€toâ€mesenchymal transition is involved in <scp>BCNU</scp> resistance in human glioma cells. Neuropathology, 2014, 34, 128-134.	0.7	35
379	Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy, 2014, 10, 2122-2142.	4.3	130
380	Angiopoietinâ€like protein 2 renders colorectal cancer cells resistant to chemotherapy by activating spleen tyrosine kinaseâ€“phosphoinositide 3â€kinaseâ€dependent antiâ€apoptotic signaling. Cancer Science, 2014, 105, 1550-1559.	1.7	22
381	Triptolide reverses hypoxiaâ€induced epithelialâ€“mesenchymal transition and stemâ€like features in pancreatic cancer by NFâ€ºB downregulation. International Journal of Cancer, 2014, 134, 2489-2503.	2.3	129
382	miRâ€185â€3p regulates nasopharyngeal carcinoma radioresistance by targeting <scp>WNT</scp>2B in vitro. Cancer Science, 2014, 105, 1560-1568.	1.7	63
383	Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelialâ€“mesenchymal transition in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2014, 455, 332-338.	1.0	35

#	Article	IF	Citations
384	Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma. International Journal of Oncology, 2014, 44, 129-136.	1.4	21
385	Genome-Wide Activities of RNA Binding Proteins That Regulate Cellular Changes in the Epithelial to Mesenchymal Transition (EMT). Advances in Experimental Medicine and Biology, 2014, 825, 267-302.	0.8	22
386	Cancer stem cells â€“ the current status of an old concept: literature review and clinical approaches. Biological Research, 2014, 47, 66.	1.5	60
387	MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Molecular Cancer, 2014, 13, 245.	7.9	54
388	MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1. Molecular Cancer, 2014, 13, 250.	7.9	77
389	Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells. Cancer & Metabolism, 2014, 2, 20.	2.4	119
390	Novel clinical therapeutics targeting the epithelial to mesenchymal transition. Clinical and Translational Medicine, 2014, 3, 35.	1.7	65
391	Alkylphosphocholine Analogs for Broad-Spectrum Cancer Imaging and Therapy. Science Translational Medicine, 2014, 6, 240ra75.	5.8	92
392	Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Design, Development and Therapy, 2014, 8, 293.	2.0	77
393	The Notch ligand Jagged1 as a target for anti-tumor therapy. Frontiers in Oncology, 2014, 4, 254.	1.3	157
394	Crosstalk of Oncogenic Signaling Pathways during EpithelialÃ¢â‚¬â€œMesenchymal Transition. Frontiers in Oncology, 2014, 4, 358.	1.3	137
395	Plasticity of tumor cell migration: acquisition of new properties or return to the past?. Biochemistry (Moscow), 2014, 79, 947-963.	0.7	15
396	Intratumoral heterogeneity impacts the response to anti-neu antibody therapy. BMC Cancer, 2014, 14, 647.	1.1	18
397	Clinical significance of epithelialâ€“mesenchymal transition. Clinical and Translational Medicine, 2014, 3, 17.	1.7	142
398	Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells. Radiotherapy and Oncology, 2014, 111, 243-251.	0.3	68
399	miR-888 regulates side population properties and cancer metastasis in breast cancer cells. Biochemical and Biophysical Research Communications, 2014, 450, 1234-1240.	1.0	15
400	Emodin represses TWIST1-induced epithelialâ€“mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the Î²-catenin and Akt pathways. European Journal of Cancer, 2014, 50, 366-378.	1.3	77
401	Enrichment of cancer stem cell-like cells by culture in alginate gel beads. Journal of Biotechnology, 2014, 177, 1-12.	1.9	37

#	Article	IF	Citations
402	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelialâ€toâ€mesenchymal transition. International Journal of Cancer, 2014, 134, 552-562.	2.3	286
403	Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Research and Treatment, 2014, 143, 287-299.	1.1	36
404	Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. Annals of Surgical Oncology, 2014, 21, 179-188.	0.7	38
405	The chemosensitivity of testicular germ cell tumors. Cellular Oncology (Dordrecht), 2014, 37, 79-94.	2.1	34
406	MicroRNA control of epithelialâ€mesenchymal transition in cancer stem cells. International Journal of Cancer, 2014, 135, 1019-1027.	2.3	64
407	Cancer Systems Biology: a peek into the future of patient care?. Nature Reviews Clinical Oncology, 2014, 11, 167-176.	12.5	159
408	FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 104-116.	3.3	47
409	Tumor cell plasticity: the challenge to catch a moving target. Journal of Gastroenterology, 2014, 49, 618-627.	2.3	25
410	Implications of Mesenchymal Cells in Cancer Stem Cell Populations: Relevance to EMT. Current Pathobiology Reports, 2014, 2, 21-26.	1.6	37
411	Epistatic interactions and drug response. Journal of Pathology, 2014, 232, 255-263.	2.1	24
412	MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 2014, 20, 332-342.	3.5	592
413	MiR-200c suppresses TGF-Î² signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. International Journal of Cancer, 2014, 135, 1356-1368.	2.3	144
414	An integrinÂÎ²3â€“KRASâ€“RalB complex drives tumour stemness and resistance to EGFR inhibition. Nature Cell Biology, 2014, 16, 457-468.	4.6	325
415	Notch pathway activation is associated with pancreatic cancer treatment failure. Pancreatology, 2014, 14, 48-53.	0.5	30
416	Wnt of the Two Horizons: Putting Stem Cell Self-Renewal and Cell Fate Determination into Context. Stem Cells and Development, 2014, 23, 1975-1990.	1.1	9
417	Molecular Testing in Urothelial Tumors. , 2014, , 301-317.		0
418	Molecular Testing in Cancer. , 2014, , .		2
419	The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Research, 2014, 74, 3579-3590.	0.4	238

#	Article	IF	Citations
420	Therapyâ€induced enrichment of putative lung cancer stemâ€like cells. International Journal of Cancer, 2014, 134, 1270-1278.	2.3	55
421	Mesenchymalâ€Mode Migration Assay and Antimetastatic Drug Screening with Highâ€Throughput Microfluidic Channel Networks. Angewandte Chemie - International Edition, 2014, 53, 2344-2348.	7.2	57
422	B7h Triggering Inhibits the Migration of Tumor Cell Lines. Journal of Immunology, 2014, 192, 4921-4931.	0.4	40
423	The effects of shRNA-mediated gene silencing of transcription factor SNAI1 on the biological phenotypes of breast cancer cell line MCF-7. Molecular and Cellular Biochemistry, 2014, 388, 113-121.	1.4	8
424	Metformin reverses multidrug resistance and epithelialâ€“mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells. Molecular and Cellular Biochemistry, 2014, 386, 63-71.	1.4	137
425	Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene, 2014, 33, 4451-4463.	2.6	213
426	EMT Twists the Road to PI3K. Cancer Discovery, 2014, 4, 149-151.	7.7	12
427	The miR-106bâˆ¼425 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300. Cell Death and Differentiation, 2014, 21, 462-474.	5.0	75
428	Sustained elevation of Snail promotes glial-mesenchymal transition after irradiation in malignant glioma. Neuro-Oncology, 2014, 16, 671-685.	0.6	139
429	Epithelial-Mesenchymal Transition and Drug Resistance: Role, Molecular Mechanisms, and Therapeutic Strategies. Oncology Research and Treatment, 2014, 37, 584-589.	0.8	75
430	Excessive Hyaluronan Production Promotes Acquisition of Cancer Stem Cell Signatures through the Coordinated Regulation of Twist and the Transforming Growth Factor Î² (TGF-Î²)-Snail Signaling Axis. Journal of Biological Chemistry, 2014, 289, 26038-26056.	1.6	78
431	Cancer stem-like cell: a novel target for nasopharyngeal carcinoma therapy. Stem Cell Research and Therapy, 2014, 5, 44.	2.4	35
432	Tumour-promoting role of EMT-inducing transcription factor ZEB1 in mantle cell lymphoma. Cell Death and Differentiation, 2014, 21, 194-195.	5.0	9
433	ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy. Nanoscale, 2014, 6, 10084-10094.	2.8	19
434	Transforming growth factor-Î²1-induced epithelialâ€“mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Letters, 2014, 354, 320-328.	3.2	88
435	SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell. Cellular Signalling, 2014, 26, 2710-2720.	1.7	31
436	Long-term efficiency of mesenchymal stromal cell-mediated CD-MSC/5FC therapy in human melanoma xenograft model. Gene Therapy, 2014, 21, 874-887.	2.3	37
437	ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nature Cell Biology, 2014, 16, 864-875.	4.6	367

#	Article	IF	Citations
439	Acquisition of epithelialâ€“mesenchymal transition and cancer stem-like phenotypes within chitosan-hyaluronan membrane-derived 3D tumor spheroids. Biomaterials, 2014, 35, 10070-10079.	5.7	63
441	ABCG2/BCRP gene expression is related to epithelialâ€“mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1). Journal of Molecular Endocrinology, 2014, 52, 289-300.	1.1	23
442	BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. European Journal of Cancer, 2014, 50, 2251-2262.	1.3	38
443	Collective and individual migration following the epithelialâ€“mesenchymal transition. Nature Materials, 2014, 13, 1063-1071.	13.3	169
444	MicroRNAs and Drug Resistance in Prostate Cancers. Molecular Pharmaceutics, 2014, 11, 2539-2552.	2.3	63
445	Stathmin destabilizing microtubule dynamics promotes malignant potential in cancer cells by epithelial-mesenchymal transition. Hepatobiliary and Pancreatic Diseases International, 2014, 13, 386-394.	0.6	30
446	Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. Cancer Cell, 2014, 26, 207-221.	7.7	452
447	miR-106b modulates cancer stem cell characteristics through TGF-Î²/Smad signaling in CD44-positive gastric cancer cells. Laboratory Investigation, 2014, 94, 1370-1381.	1.7	86
448	Interepithelial signaling with nephric duct is required for the formation of overlying coelomic epithelial cell sheet. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 6660-6665.	3.3	19
449	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. Physiological Genomics, 2014, 46, 699-724.	1.0	26
450	The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells. BMC Cancer, 2014, 14, 477.	1.1	33
451	miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Molecular Cancer, 2014, 13, 193.	7.9	124
452	Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. SpringerPlus, 2014, 3, 417.	1.2	29
453	Prognostic significance of ALDH1A1-positive cancer stem cells in patients with locally advanced, metastasized head and neck squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1151-1158.	1.2	64
454	The SDF-1/CXCR4 axis induces epithelialâ€“mesenchymal transition in hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2014, 392, 77-84.	1.4	55
455	Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer. Journal of Experimental and Clinical Cancer Research, 2014, 33, 38.	3.5	111
456	Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vascular Cell, 2014, 6, 12.	0.2	67
457	Expression and Prognostic Significance of a Comprehensive Epithelial-Mesenchymal Transition Gene Set in Renal Cell Carcinoma. Journal of Urology, 2014, 191, 479-486.	0.2	44

#	Article	IF	Citations
458	Pluronics and MDR Reversal: An Update. Molecular Pharmaceutics, 2014, 11, 2566-2578.	2.3	186
459	AMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Aktâ€“MDM2â€“Foxo3a Signaling Axis. Cancer Research, 2014, 74, 4783-4795.	0.4	153
460	The fundamental role of mechanical properties in the progression of cancer disease and inflammation. Reports on Progress in Physics, 2014, 77, 076602.	8.1	113
461	Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Molecular Cancer, 2014, 13, 137.	7.9	116
462	Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Molecular Cancer, 2014, 13, 55.	7.9	133
463	Pushing tumor cells towards a malignant phenotype: Stimuli from the microenvironment, intercellular communications and alternative roads. International Journal of Cancer, 2014, 135, 1265-1276.	2.3	51
464	Dihydropyrimidine Accumulation Is Required for the Epithelial-Mesenchymal Transition. Cell, 2014, 158, 1094-1109.	13.5	186
465	Nanodelivery Systems for Nucleic Acid Therapeutics in Drug Resistant Tumors. Molecular Pharmaceutics, 2014, 11, 2511-2526.	2.3	44
466	Acquisition of epithelialâ€“mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/Î²-catenin/Snail signaling pathway. European Journal of Pharmacology, 2014, 723, 156-166.	1.7	124
467	Oncofetal H19 RNA promotes tumor metastasis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2014, 1843, 1414-1426.	1.9	204
468	Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer. Journal of the Royal Society Interface, 2014, 11, 20140206.	1.5	30
469	Metformin Sensitizes EGFR-TKIâ€“Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal. Clinical Cancer Research, 2014, 20, 2714-2726.	3.2	212
470	Glial Progenitors as Targets for Transformation in Glioma. Advances in Cancer Research, 2014, 121, 1-65.	1.9	38
471	Obesity and cancerâ€”mechanisms underlying tumour progression and recurrence. Nature Reviews Endocrinology, 2014, 10, 455-465.	4.3	575
472	E-Cadherin Couples Death Receptors to the Cytoskeleton to Regulate Apoptosis. Molecular Cell, 2014, 54, 987-998.	4.5	88
473	MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells. Oncogene, 2014, 33, 269-278.	2.6	92
474	Targeting Smad2 and Smad3 by miR-136 Suppresses Metastasis-Associated Traits of Lung Adenocarcinoma Cells. Oncology Research, 2014, 21, 345-352.	0.6	38
475	Far Beyond the Usual Biomarkers in Breast Cancer: A Review. Journal of Cancer, 2014, 5, 559-571.	1.2	44

#	Article	IF	Citations
476	Genistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1. Oncology Reports, 2014, 31, 673-678.	1.2	60
477	SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance. International Journal of Oncology, 2014, 44, 1521-1528.	1.4	26
479	Radiation promotes malignant phenotypes through <scp>SRC</scp> in breast cancer cells. Cancer Science, 2015, 106, 78-85.	1.7	27
480	Effects of <scp>ADAM</scp>10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinoma. Cancer Science, 2015, 106, 1506-1514.	1.7	35
481	dbEMT: an epithelial-mesenchymal transition associated gene resource. Scientific Reports, 2015, 5, 11459.	1.6	117
482	<scp>ZEB</scp> 1â€associated drug resistance in cancer cells is reversed by the class I <scp>HDAC</scp> inhibitor mocetinostat. EMBO Molecular Medicine, 2015, 7, 831-847.	3.3	191
483	Salinomycin inhibits the tumor growth of glioma stem cells by selectively suppressing glioma-initiating cells. Molecular Medicine Reports, 2015, 11, 2407-2412.	1.1	24
484	Wound Healing and Cancer Stem Cells: Inflammation as a Driver of Treatment Resistance in Breast Cancer. Cancer Growth and Metastasis, 2015, 8, CGM.S11286.	3.5	94
485	Carcinogenesis. , 2015, , 1135-1172.		0
486	Facilitated Anion Transport Induces Hyperpolarization of the Cell Membrane That Triggers Differentiation and Cell Death in Cancer Stem Cells. Journal of the American Chemical Society, 2015, 137, 15892-15898.	6.6	109
487	Development and Characterization of a Novel in vitro Progression Model for UVB-Induced Skin Carcinogenesis. Scientific Reports, 2015, 5, 13894.	1.6	33
488	Differential expression of Mediator complex subunit MED15 in testicular germ cell tumors. Diagnostic Pathology, 2015, 10, 165.	0.9	11
489	Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma. BMC Cancer, 2015, 15, 730.	1.1	33
490	Decreased long noncoding RNA SPRY4-IT1 contributing to gastric cancer cell metastasis partly via affecting epithelialâ€“mesenchymal transition. Journal of Translational Medicine, 2015, 13, 250.	1.8	90
491	Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes. Journal of Cellular Physiology, 2015, 230, 2706-2717.	2.0	35
492	Targeting colorectal cancer stem cells using curcumin and curcumin analogues: insights into the mechanism of the therapeutic efficacy. Cancer Cell International, 2015, 15, 96.	1.8	96
493	Eukaryotic translation initiation factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer through epithelial mesenchymal transition. Cancer Cell International, 2015, 15, 109.	1.8	47
494	Elf5 inhibits TGFâ€Î²â€driven epithelialâ€mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate, 2015, 75, 872-882.	1.2	31

#	Article	IF	Citations
495	SRY and OCT4 Are Required for the Acquisition of Cancer Stem Cell-Like Properties and Are Potential Differentiation Therapy Targets. Stem Cells, 2015, 33, 2652-2663.	1.4	66
496	Regulation of tumor progression via the Snailâ€RKIP signaling pathway by nicotine exposure in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 1712-1721.	0.9	27
498	Sijunzi decoction demolition parties inhibit proliferation and induce apoptosis of human gastric cancer BGC-823 side population. Tropical Journal of Obstetrics and Gynaecology, 2015, 12, 77.	0.3	1
499	Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control. International Journal of Nanomedicine, 2015, 10, 2485.	3.3	9
500	Akt inhibition improves irinotecan treatment and prevents cell emergence by switching the senescence response to apoptosis. Oncotarget, 2015, 6, 43342-43362.	0.8	27
501	Targeting Cancer Stem Cells: Promises and Challenges. Anti-Cancer Agents in Medicinal Chemistry, 2015, 16, 38-58.	0.9	33
502	Editorial (Thematic Issue: Gene Therapy for Gastrointestinal and Liver Cancers: Past Experience,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 50	0.9	0
503	Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. Frontiers in Oncology, 2015, 5, 140.	1.3	27
504	New Findings on Breast Cancer Stem Cells: A Review. Journal of Breast Cancer, 2015, 18, 303.	0.8	92
505	B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0135528.	1.1	57
506	Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop. Oncotarget, 2015, 6, 5072-5087.	0.8	91
508	Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-13.	1.9	63
509	Review Regulation of breast cancer stem cell features. Wspolczesna Onkologia, 2015, 1A, 7-15.	0.7	42
510	EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget, 2015, 6, 10697-10711.	0.8	408
511	Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget, 2015, 6, 40158-40171.	0.8	98
512	TGFÎ² and BMP signaling in cancer. , 2015, , 204-221.		1
513	CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget, 2015, 6, 5846-5859.	0.8	71
514	Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells. Molecular Imaging, 2015, 14, 7290.2015.00016.	0.7	11

#	Article	IF	Citations
515	Clinical Significance of Subtype Classification in Metastatic Lymph Nodes of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. International Journal of Biological Markers, 2015, 30, 174-183.	0.7	2
516	Acquired resistance to 5-fluorouracilviaHSP90/Src-mediated increase in thymidylate synthase expression in colon cancer. Oncotarget, 2015, 6, 32622-32633.	0.8	45
517	Novel Strategy for Colorectal Liver Metastases -Estimated by the Concept for Hepatocyte Growth Factor. Archives in Cancer Research, 2015, 3, .	0.3	0
518	A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors. Scientific Reports, 2015, 5, 11012.	1.6	29
519	Quantifying the Landscape for Development and Cancer from a Core Cancer Stem Cell Circuit. Cancer Research, 2015, 75, 2607-2618.	0.4	77
520	EGFR and NF-ÎºB: partners in cancer. Trends in Molecular Medicine, 2015, 21, 385-393.	3.5	180
521	LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells. International Journal of Biological Macromolecules, 2015, 72, 1081-1089.	3.6	30
522	Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: â€˜What does not kill me strengthens meâ€™. British Journal of Cancer, 2015, 112, 1725-1732.	2.9	252
523	BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Letters, 2015, 365, 190-200.	3.2	78
524	Epigenetics in lung cancer diagnosis and therapy. Cancer and Metastasis Reviews, 2015, 34, 229-241.	2.7	139
525	Co-culture of 3D tumor spheroids with fibroblasts as a model for epithelialâ€“mesenchymal transition in vitro. Experimental Cell Research, 2015, 335, 187-196.	1.2	86
526	Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Molecular Cancer Therapeutics, 2015, 14, 1848-1857.	1.9	79
527	Evidence for induction of a tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs as an unwanted and underestimated side effect of chemotherapy/radiotherapy. Journal of Ovarian Research, 2015, 8, 20.	1.3	38
528	Elevated Expression of Nrf-2 and ABCG2 Involved in Multi-drug Resistance of Lung Cancer SP Cells. Drug Research, 2015, 65, 526-531.	0.7	19
529	Inhibitory effects of metformin at low concentration on epithelialâ€“mesenchymal transition of CD44+CD117+ ovarian cancer stem cells. Stem Cell Research and Therapy, 2015, 6, 262.	2.4	75
530	Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer. DMM Disease Models and Mechanisms, 2015, 9, 131-40.	1.2	9
531	A Concept of Cancer Stem Cells: Entity and Theories. , 2015, , 43-56.		0
533	Cancer Stem Cell Markers: Classification and Their Significance in Cancer Stem Cells. , 2015, , 57-70.		1

#	Article	IF	Citations
534	Smad7 maintains epithelial phenotype of ovarian cancer stem-like cells and supports tumor colonization by mesenchymal-epithelial transition. Molecular Medicine Reports, 2015, 11, 309-316.	1.1	17
535	Enrichment and characterization of cancer stem cells from a human non-small cell lung cancer cell line. Oncology Reports, 2015, 34, 2126-2132.	1.2	21
536	Downregulation of UHRF1 promotes EMT via inducing CXCR4 in human cancer cells. International Journal of Oncology, 2015, 46, 1232-1242.	1.4	16
537	Cancer stem cells: The potential of carbon ion beam radiation and new radiosensitizers (Review). Oncology Reports, 2015, 34, 2233-2237.	1.2	20
538	A model for cell density effect on stress fiber alignment and collective directional migration. Physical Biology, 2015, 12, 066023.	0.8	5
539	Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends in Cell Biology, 2015, 25, 234-240.	3.6	568
540	STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer. Oncogene, 2015, 34, 4808-4820.	2.6	102
541	Junctional adhesion molecule-A, an epithelialâ€“mesenchymal transition inducer, correlates with metastasis and poor prognosis in human nasopharyngeal cancer. Carcinogenesis, 2015, 36, 41-48.	1.3	52
542	Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis, 2015, 36, 355-367.	1.3	200
543	MIR210 as a potential molecular target to block invasion and metastasis of gastric cancer. Medical Hypotheses, 2015, 84, 209-212.	0.8	27
544	p53 and Î”Np63Î± Coregulate the Transcriptional and Cellular Response to TGFÎ² and BMP Signals. Molecular Cancer Research, 2015, 13, 732-742.	1.5	16
545	Hypoxia-inducible factor 1 and breast cancer metastasis. Journal of Zhejiang University: Science B, 2015, 16, 32-43.	1.3	171
546	Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: therapeutic approaches in cancer. Expert Opinion on Therapeutic Targets, 2015, 19, 285-297.	1.5	58
547	Role of miR-155 in drug resistance of breast cancer. Tumor Biology, 2015, 36, 1395-1401.	0.8	51
548	A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer. British Journal of Cancer, 2015, 112, 819-824.	2.9	11
549	PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma. Cellular and Molecular Life Sciences, 2015, 72, 2395-2409.	2.4	32
550	TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Research, 2015, 75, 1908-1921.	0.4	56
551	The Role of Matrix Compliance on Cell Responses to Drugs and Toxins: Towards Predictive Drug Screening Platforms. Macromolecular Bioscience, 2015, 15, 589-599.	2.1	14

#	Article	IF	Citations
552	Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelialâ€“mesenchymal transition. Carcinogenesis, 2015, 36, 459-468.	1.3	113
553	Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. Journal of Pharmacology and Experimental Therapeutics, 2015, 354, 261-268.	1.3	23
554	Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells. Biochemical Pharmacology, 2015, 97, 147-157.	2.0	31
555	Negative feedback loop between p66Shc and ZEB1 regulates fibrotic EMT response in lung cancer cells. Cell Death and Disease, 2015, 6, e1708-e1708.	2.7	18
556	Role of Autophagy in Cancer Therapy. , 2015, , 91-103.		0
557	Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer. Pharmaceutical Research, 2015, 32, 3756-3767.	1.7	25
558	Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT. Cell Death and Disease, 2015, 6, e1829-e1829.	2.7	57
559	Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAMâ^' Lung Cancerâ€“Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. Cancer Research, 2015, 75, 3636-3649.	0.4	83
560	Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discovery Today, 2015, 20, 1205-1216.	3.2	44
561	Enhanced Adhesion of Stromal Cells to Invasive Cancer Cells Regulated by Cadherin 11. ACS Chemical Biology, 2015, 10, 1932-1938.	1.6	21
562	Lanthanum strontium manganese oxide (LSMO) nanoparticles: a versatile platform for anticancer therapy. RSC Advances, 2015, 5, 60254-60263.	1.7	30
563	Multiple drug resistance due to resistance to stem cells and stem cell treatment progress in cancer (Review). Experimental and Therapeutic Medicine, 2015, 9, 289-293.	0.8	58
564	Roles of Nrf2 in cell proliferation and differentiation. Free Radical Biology and Medicine, 2015, 88, 168-178.	1.3	189
565	Transcriptome sequencing uncovers novel long noncoding and small nucleolar RNAs dysregulated in head and neck squamous cell carcinoma. Rna, 2015, 21, 1122-1134.	1.6	74
566	Benzidine induces epithelialâ€“mesenchymal transition in human uroepithelial cells through ERK1/2 pathway. Biochemical and Biophysical Research Communications, 2015, 459, 643-649.	1.0	24
567	Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer, 2015, 15, 261-275.	12.8	319
568	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
569	The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Endocrine, 2015, 50, 442-452.	1.1	17

#	Article	IF	Citations
570	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology and Oncology, 2015, 8, 16.	6.9	80
571	Utilizing a high-throughput microfluidic platform to study hypoxia-driven mesenchymal-mode cell migration. Integrative Biology (United Kingdom), 2015, 7, 672-680.	0.6	20
572	Snail predicts recurrence and survival of patients with localized clear cell renal cell carcinoma after surgical resection. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 69.e1-69.e10.	0.8	13
573	The epithelial to mesenchymal transition in pancreatic cancer: AÂsystematic review. Pancreatology, 2015, 15, 217-225.	0.5	111
574	Biology and immunology of cancer stem(-like) cells in head and neck cancer. Critical Reviews in Oncology/Hematology, 2015, 95, 337-345.	2.0	39
575	The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro. Cancer Letters, 2015, 364, 142-155.	3.2	79
576	Recurrence and metastasis of breast cancer is influenced by ovarian hormone's effect on breast cancer stem cells. Future Oncology, 2015, 11, 983-995.	1.1	22
578	MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. Melanoma Research, 2015, 25, 113-118.	0.6	11
579	Crosstalk of carcinoembryonic antigen and transforming growth factor-Î² via their receptors: comparing human and canine cancer. Cancer Immunology, Immunotherapy, 2015, 64, 531-537.	2.0	18
580	Progress on the relationship between miR-125 family and tumorigenesis. Experimental Cell Research, 2015, 339, 252-260.	1.2	93
581	Roles for miRNAs in endocrine resistance in breast cancer. Endocrine-Related Cancer, 2015, 22, R279-R300.	1.6	63
582	Unbiased Selection of Peptideâ€“Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. ACS Chemical Biology, 2015, 10, 2891-2899.	1.6	28
583	Gamma tocotrienol targets tyrosine phosphatase SHP2 in mammospheres resulting in cell death through RAS/ERK pathway. BMC Cancer, 2015, 15, 609.	1.1	19
584	STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nature Communications, 2015, 6, 8499.	5.8	34
585	Effect of proton and gamma irradiation on human lung carcinoma cells: Gene expression, cell cycle, cell death, epithelialâ€“mesenchymal transition and cancer-stem cell trait as biological end points. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 780, 35-46.	0.4	32
586	A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhesion and Migration, 2015, 9, 317-324.	1.1	469
587	Epithelialâ€“Mesenchymal Plasticity: A Central Regulator of Cancer Progression. Trends in Cell Biology, 2015, 25, 675-686.	3.6	832
588	Development of novel radiochemotherapy approaches targeting prostate tumor progenitor cells using nanohybrids. International Journal of Cancer, 2015, 137, 2492-2503.	2.3	29

#	Article	IF	Citations
589	Cancer Stem Cells: Formidable Allies of Cancer. Indian Journal of Surgical Oncology, 2015, 6, 400-414.	0.3	5
590	Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition. Cell Death and Disease, 2015, 6, e1805-e1805.	2.7	39
591	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	1.6	114
592	Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients. Clinical Cancer Research, 2015, 21, 5630-5638.	3.2	77
593	Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. Cancer Research, 2015, 75, 3970-3979.	0.4	25
594	The role of EMT and MET in cancer dissemination. Connective Tissue Research, 2015, 56, 403-413.	1.1	177
595	Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Nonâ€“Small Cell Lung Cancer. Neoplasia, 2015, 17, 538-551.	2.3	104
596	Chitosan polyplex nanoparticle vector for miR-145 expression in MCF-7: Optimization by design of experiment. International Journal of Biological Macromolecules, 2015, 81, 828-837.	3.6	30
597	Breast Cancer Cells Respond Differentially to Modulation of TGFÎ²2 Signaling after Exposure to Chemotherapy or Hypoxia. Cancer Research, 2015, 75, 4605-4616.	0.4	9
598	The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis. Stem Cell Reviews and Reports, 2015, 11, 919-943.	5.6	72
599	Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials, 2015, 72, 74-89.	5.7	183
600	The Role of the Cytoskeleton in Cell Migration, Its Influence on Stem Cells and the Special Role of GFAP in Glial Functions. , 2015, , 87-117.		0
601	p21-activated kinase 1 determines stem-like phenotype and sunitinib resistance via NF-ÎºB/IL-6 activation in renal cell carcinoma. Cell Death and Disease, 2015, 6, e1637-e1637.	2.7	43
602	Identifying therapeutic targets in gastric cancer: the current status and future direction. Acta Biochimica Et Biophysica Sinica, 2016, 48, 90-96.	0.9	16
603	AMPK Inhibits the Stimulatory Effects of TGF-Î²on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition. Molecular Pharmacology, 2015, 88, 1062-1071.	1.0	69
604	Epithelialâ€“mesenchymal transition in prostatic disease. Future Oncology, 2015, 11, 3197-3206.	1.1	26
605	Development of anex vivobreast cancer lung colonization model utilizing a decellularized lung matrix. Integrative Biology (United Kingdom), 2015, 7, 1518-1525.	0.6	43
606	Targeting CD146 with a ⁶⁴ Cu-labeled antibody enables in vivo immunoPET imaging of high-grade gliomas. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6525-34.	3.3	54

#	Article	IF	Citations
607	Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature, 2015, 527, 472-476.	13.7	1,498
608	Transition loses its invasive edge. Nature, 2015, 527, 452-453.	13.7	27
609	The <scp>H</scp>ippo pathway in chemotherapeutic drug resistance. International Journal of Cancer, 2015, 137, 2767-2773.	2.3	74
610	Effects of Second and Subsequent Lines of Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer, 2015, 15, e55-e62.	1.1	40
611	The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. International Journal of Cancer, 2015, 137, 2785-2794.	2.3	72
612	Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Translational Research, 2015, 165, 558-577.	2.2	40
613	Targeting cancer stem cells in solid tumors by vitamin D. Journal of Steroid Biochemistry and Molecular Biology, 2015, 148, 79-85.	1.2	48
614	CD58, aÂnovel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer. Oncogene, 2015, 34, 1520-1531.	2.6	40
615	Epithelialâ€“mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene, 2015, 34, 1899-1907.	2.6	108
616	Reprogramming of mesenchymal stem cells by oncogenes. Seminars in Cancer Biology, 2015, 32, 18-31.	4.3	17
617	Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells. Cell Death and Differentiation, 2015, 22, 898-911.	5.0	54
618	FRA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer. Oncogene, 2015, 34, 4421-4428.	2.6	60
619	The network of epithelialâ€“mesenchymal transition: potential new targets for tumor resistance. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1697-1713.	1.2	118
621	Importance and Detection of Epithelial-to-Mesenchymal Transition (EMT) Phenotype in CTCs. , 0, , .		0
622	Aquaporin 3 promotes the stem-like properties of gastric cancer cells via Wnt/GSK-3Î²/Î²-catenin pathway. Oncotarget, 2016, 7, 16529-16541.	0.8	38
623	Activation of anaphase-promoting complex by p53 induces a state of dormancy in cancer cells against chemotherapeutic stress. Oncotarget, 2016, 7, 25478-25492.	0.8	36
624	Targeting hypoxic response for cancer therapy. Oncotarget, 2016, 7, 13464-13478.	0.8	80
625	The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance. Oncotarget, 2016, 7, 45745-45756.	0.8	214

#	Article	IF	Citations
626	Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells. Journal of Carcinogenesis & Mutagenesis, 2016, 07, .	0.3	28
627	MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells. Oncotarget, 2016, 7, 23182-23196.	0.8	58
628	DIFFERENT CONCENTRATIONS OF SIJUNZI DECOCTION INHIBIT PROLIFERATION AND INDUCE APOPTOSIS OF HUMAN GASTRIC CANCER SGC-7901 SIDE POPULATION. Tropical Journal of Obstetrics and Gynaecology, 2016, 13, 145-156.	0.3	11
629	Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy. Oncotarget, 2016, 7, 11539-11552.	0.8	27
630	The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget, 2016, 7, 3748-3765.	0.8	115
631	MicroRNA-421 regulated by HIF-1Î± promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget, 2016, 7, 24466-24482.	0.8	103
632	Repurposing atovaquone: Targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 2016, 7, 34084-34099.	0.8	171
633	Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget, 2016, 7, 1619-1632.	0.8	123
634	Highly Expressed Integrin-Î±8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. Molecules and Cells, 2016, 39, 898-908.	1.0	31
635	The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Translational Lung Cancer Research, 2016, 5, 172-182.	1.3	80
636	Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells. Oncotarget, 2016, 7, 60575-60592.	0.8	40
637	CCL21 Facilitates Chemoresistance and Cancer Stem Cell-Like Properties of Colorectal Cancer Cells through AKT/GSK-3Î²/Snail Signals. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-14.	1.9	37
638	Endothelial Transdifferentiation of Tumor Cells Triggered by the Twist1-Jagged1-KLF4 Axis: Relationship between Cancer Stemness and Angiogenesis. Stem Cells International, 2016, 2016, 1-10.	1.2	30
639	Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy. Stem Cells International, 2016, 2016, 1-16.	1.2	288
640	Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-17.	1.9	36
641	Effect of Cigarette Smoking on Epithelial to Mesenchymal Transition (EMT) in Lung Cancer. Journal of Clinical Medicine, 2016, 5, 44.	1.0	69
642	Suppression of miR-204 enables oral squamous cell carcinomas to promote cancer stemness, EMT traits, and lymph node metastasis. Oncotarget, 2016, 7, 20180-20192.	0.8	75
643	Ovatodiolide Inhibits Breast Cancer Stem/Progenitor Cells through SMURF2-Mediated Downregulation of Hsp27. Toxins, 2016, 8, 127.	1.5	23

#	Article	IF	Citations
644	The Effect of X-Ray and Heavy Ions Radiations on Chemotherapy Refractory Tumor Cells. Frontiers in Oncology, 2016, 6, 64.	1.3	4
645	Hijacking the Hexosamine Biosynthetic Pathway to Promote EMT-Mediated Neoplastic Phenotypes. Frontiers in Oncology, 2016, 6, 85.	1.3	41
646	Anti-Cancer Stem-like Cell Compounds in Clinical Development â€“ An Overview and Critical Appraisal. Frontiers in Oncology, 2016, 6, 115.	1.3	42
647	Targeting Epithelialâ€“Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. Molecules, 2016, 21, 965.	1.7	548
648	Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers, 2016, 8, 8.	1.7	132
649	The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients, 2016, 8, 581.	1.7	118
650	Unexploited Antineoplastic Effects of Commercially Available Anti-Diabetic Drugs. Pharmaceuticals, 2016, 9, 24.	1.7	19
651	Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer. Genome Medicine, 2016, 8, 66.	3.6	18
652	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0147344.	1.1	81
653	Perfluorooctanoic acid induces human Ishikawa endometrial cancer cell migration and invasion through activation of ERK/mTOR signaling. Oncotarget, 2016, 7, 66558-66568.	0.8	23
654	Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Oncotarget, 2016, 7, 45876-45888.	0.8	36
655	Molecular Mechanisms Involved in the Acquisition of Resistance to Treatment of Colon Cancer Cells. , 2016, , .		2
656	<scp>SLUG</scp> expression is an indicator of tumour recurrence in highâ€grade endometrial carcinomas. Histopathology, 2016, 69, 374-382.	1.6	11
657	Biology of lung cancer: genetic mutation, epithelial-mesenchymal transition, and cancer stem cells. General Thoracic and Cardiovascular Surgery, 2016, 64, 517-523.	0.4	13
658	Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. Journal of Cellular Biochemistry, 2016, 117, 267-278.	1.2	85
659	PDLIM2 suppression efficiently reduces tumor growth and invasiveness of human castrationâ€resistant prostate cancerâ€like cells. Prostate, 2016, 76, 273-285.	1.2	20
660	Quantifying the landscape and kinetic paths for epithelialâ€“mesenchymal transition from a core circuit. Physical Chemistry Chemical Physics, 2016, 18, 17949-17956.	1.3	55
661	Oncogenic PKCÎ¹ decides tumor-initiating cell fate. Cell Cycle, 2016, 15, 2383-2384.	1.3	0

#	Article	IF	Citations
662	EMT: 2016. Cell, 2016, 166, 21-45.	13.5	3,573
663	Extracellular matrix composition and rigidity regulate invasive behavior and response to PDT in 3D pancreatic tumor models. Proceedings of SPIE, 2016, , .	0.8	0
665	CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors. Hepatology, 2016, 63, 1544-1559.	3.6	32
666	MicroRNA-129 in Human Cancers: from Tumorigenesis to Clinical Treatment. Cellular Physiology and Biochemistry, 2016, 39, 2186-2202.	1.1	56
667	Resistance to Targeted Therapies Against Adult Brain Cancers. Resistance To Targeted Anti-cancer Therapeutics, 2016, , .	0.1	4
668	FAT4 functions as a tumor suppressor in triple-negative breast cancer. Tumor Biology, 2016, 37, 16337-16343.	0.8	34
669	Overexpression of CAP1 and its significance in tumor cell proliferation, migration and invasion in glioma. Oncology Reports, 2016, 36, 1619-1625.	1.2	15
670	<scp>ZEB</scp> 1â€mediated melanoma cell plasticity enhances resistance to <scp>MAPK</scp> inhibitors. EMBO Molecular Medicine, 2016, 8, 1143-1161.	3.3	98
672	Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Scientific Reports, 2016, 6, 21629.	1.6	58
673	The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays, 2016, 38, S65-74.	1.2	164
674	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery, 2016, 2, 16028.	3.1	57
675	Effect of PPM1H on malignant phenotype of human pancreatic cancer cells. Oncology Reports, 2016, 36, 2926-2934.	1.2	14
676	Rubus coreanus Miquel extract causes apoptosis of doxorubicin-resistant NCI/ADR-RES ovarian cancer cells via JNK phosphorylation. Molecular Medicine Reports, 2016, 13, 4065-4072.	1.1	16
677	Elevated expression of Nrf2 mediates multidrug resistance in CD133+ head and neck squamous cell carcinoma stem cells. Oncology Letters, 2016, 12, 4333-4338.	0.8	35
678	SHP-2-upregulated ZEB1 is important for PDGFRÎ±-driven glioma epithelialâ€“mesenchymal transition and invasion in mice and humans. Oncogene, 2016, 35, 5641-5652.	2.6	72
679	Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. European Journal of Cancer, 2016, 59, 109-112.	1.3	45
680	Multifunctional drug nanocarriers facilitate more specific entry of therapeutic payload into tumors and control multiple drug resistance in cancer. , 2016, , 203-251.		9
681	Design of a PKCÎ´-specific small peptide as a theragnostic agent for glioblastoma. Analytical Biochemistry, 2016, 496, 63-70.	1.1	3

#	Article	IF	Citations
682	miR-17-92/p38Î± Dysregulation Enhances Wnt Signaling and Selects Lgr6+ Cancer Stem-like Cells during Lung Adenocarcinoma Progression. Cancer Research, 2016, 76, 4012-4022.	0.4	47
683	Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumor Biology, 2016, 37, 11843-11859.	0.8	19
684	High-throughput biomimetic 3D gel-island chip for investigating cancer cell heterogeneity. , 2016, , .		0
685	Determination of a Comprehensive Alternative Splicing Regulatory Network and Combinatorial Regulation by Key Factors during the Epithelial-to-Mesenchymal Transition. Molecular and Cellular Biology, 2016, 36, 1704-1719.	1.1	118
686	The hypoxia-related signaling pathways of vasculogenic mimicry in tumor treatment. Biomedicine and Pharmacotherapy, 2016, 80, 127-135.	2.5	72
687	Induction of integrin Î²3 by sustained ERK activity promotes the invasiveness of TGFÎ²-induced mesenchymal tumor cells. Cancer Letters, 2016, 376, 339-346.	3.2	23
688	miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. Journal of Molecular Medicine, 2016, 94, 629-644.	1.7	112
689	Radiogenomic Analysis Demonstrates Associations between¹⁸F-Fluoro-2-Deoxyglucose PET, Prognosis, and Epithelial-Mesenchymal Transition in Nonâ€“Small Cell Lung Cancer. Radiology, 2016, 280, 261-270.	3.6	35
690	Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer. Cancer Discovery, 2016, 6, 754-769.	7.7	132
691	Discovery of novel selenium derivatives as Pin1 inhibitors by high-throughput screening. Biochemical and Biophysical Research Communications, 2016, 474, 528-533.	1.0	16
692	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
693	A Case Report of Late Onset Mania Caused by Hyponatremia in a Patient With Empty Sella Syndrome. Medicine (United States), 2016, 95, e2629.	0.4	8
694	Resisting Resistance: Targeted Therapies in Lung Cancer. Trends in Cancer, 2016, 2, 350-364.	3.8	162
695	Aptamers: Promising Tools for the Detection of Circulating Tumor Cells. Nucleic Acid Therapeutics, 2016, 26, 335-347.	2.0	37
696	Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Human Pathology, 2016, 57, 68-77.	1.1	22
697	Morphological single cell profiling of the epithelialâ€“mesenchymal transition. Integrative Biology (United Kingdom), 2016, 8, 1133-1144.	0.6	56
698	DUOX1 silencing in lung cancer promotes EMT, cancer stem cell characteristics and invasive properties. Oncogenesis, 2016, 5, e261-e261.	2.1	52
699	Site-specific Hypermethylation of RUNX3 Predicts Poor Prognosis in Gastric Cancer. Archives of Medical Research, 2016, 47, 285-292.	1.5	16

#	Article	IF	Citations
700	The multifaceted roles of fatty acid synthesis in cancer. Nature Reviews Cancer, 2016, 16, 732-749.	12.8	1,022
701	Liver protects metastatic prostate cancer from induced death by activating Eâ€cadherin signaling. Hepatology, 2016, 64, 1725-1742.	3.6	32
702	Ferulic acid exerts antitumor activity and inhibits metastasis in breast cancer cells by regulating epithelial to mesenchymal transition. Oncology Reports, 2016, 36, 271-278.	1.2	135
703	Promotion of epithelial-mesenchymal transition by Frizzled2 is involved in the metastasis of endometrial cancer. Oncology Reports, 2016, 36, 803-810.	1.2	27
704	The hypoxic microenvironment: A determinant of cancer stem cell evolution. Inside the Cell, 2016, 1, 96-105.	0.4	7
705	Elevated hepatocyte growth factor expression as an autocrine câ€Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Science, 2016, 107, 407-416.	1.7	103
706	Pluripotent Stem Cells From Livestock. , 2016, , 312-354.		0
707	Vimentin, colon cancer progression and resistance to butyrate and other <scp>HDAC</scp>is. Journal of Cellular and Molecular Medicine, 2016, 20, 989-993.	1.6	50
708	Overexpression of SPARC correlates with poor prognosis in patients with cervical carcinoma and regulates cancer cell epithelial-mesenchymal transition. Oncology Letters, 2016, 11, 3251-3258.	0.8	31
709	Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biology and Therapy, 2016, 17, 1079-1088.	1.5	6
710	Ascochlorin Enhances the Sensitivity of Doxorubicin Leading to the Reversal of Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma. Molecular Cancer Therapeutics, 2016, 15, 2966-2976.	1.9	86
711	Looking beyond the cancer cell for effective drug combinations. Genome Medicine, 2016, 8, 125.	3.6	31
712	Glucocorticoid receptor-mediated delivery of nano goldâ€“withaferin conjugates for reversal of epithelial-to-mesenchymal transition and tumor regression. Nanomedicine, 2016, 11, 2529-2546.	1.7	31
713	Breast Cancer Stem Cells and the Move Toward High-Resolution Stem Cell Systems. , 2016, , 121-148.		2
714	The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Molecular Cell, 2016, 63, 1021-1033.	4.5	82
715	Plasma membrane ion channels and epithelial to mesenchymal transition in cancer cells. Endocrine-Related Cancer, 2016, 23, R517-R525.	1.6	33
716	TGFÎ²-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme. Stem Cells, 2016, 34, 2276-2289.	1.4	38
717	Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/Î²-catenin signalling in NSCLC. Journal of Pathology, 2016, 240, 184-196.	2.1	41

#	Article	IF	Citations
718	Therapeutic resistance and cancer recurrence mechanisms: Unfolding the story of tumour coming back. Journal of Biosciences, 2016, 41, 497-506.	0.5	31
719	Targeting pancreatic cancer stem cells. Pancreatology, 2016, 16, S5.	0.5	0
720	Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Scientific Reports, 2016, 6, 18669.	1.6	155
721	Exposure to polychlorinated biphenyls and prostate cancer: population-based prospective cohort and experimental studies. Carcinogenesis, 2016, 37, bgw105.	1.3	22
722	Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacologica Sinica, 2016, 37, 1606-1622.	2.8	101
723	Identification of lesion subtypes in biopsies of ductal carcinoma in situ of the breast using biomarker ratio imaging microscopy. Scientific Reports, 2016, 6, 27039.	1.6	5
724	MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features. Scientific Reports, 2016, 6, 23932.	1.6	51
725	Epithelial-mesenchymal transition induction is associated with augmented glucose uptake and lactate production in pancreatic ductal adenocarcinoma. Cancer & Metabolism, 2016, 4, 19.	2.4	72
726	Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. , 2016, 4, 33.		11
727	Anti-cancer efficacy of nonthermal plasma dissolved in a liquid, liquid plasma in heterogeneous cancer cells. Scientific Reports, 2016, 6, 29020.	1.6	42
728	Accumulation of arachidonic acid-containing phosphatidylinositol at the outer edge of colorectal cancer. Scientific Reports, 2016, 6, 29935.	1.6	37
729	Characterization of different CTC subpopulations in non-small cell lung cancer. Scientific Reports, 2016, 6, 28010.	1.6	91
730	Linifanib (ABT-869) Potentiates the Efficacy of Chemotherapeutic Agents through the Suppression of Receptor Tyrosine Kinase-Mediated AKT/mTOR Signaling Pathways in Gastric Cancer. Scientific Reports, 2016, 6, 29382.	1.6	22
731	Molecular Pathogenesis of Pancreatic Cancer. Progress in Molecular Biology and Translational Science, 2016, 144, 241-275.	0.9	113
732	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care. Therapeutic Advances in Gastroenterology, 2016, 9, 861-886.	1.4	44
733	Melanoma and immunotherapy bridge 2015. Journal of Translational Medicine, 2016, 14, 65.	1.8	12
734	Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis. Annals of Surgery, 2016, 263, 138-145.	2.1	44
735	Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. Journal of Experimental and Clinical Cancer Research, 2016, 35, 5.	3.5	51

#	Article	IF	Citations
736	RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Experimental and Molecular Medicine, 2016, 48, e238-e238.	3.2	45
737	Musashi-2 (MSI2) supports TGF-Î² signaling and inhibits claudins to promote non-small cell lung cancer (NSCLC) metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6955-6960.	3.3	120
738	MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-Î² signaling in human breast cancer cells. Phytomedicine, 2016, 23, 1053-1063.	2.3	24
739	The Nuclear Receptor, RORÎ³, Regulates Pathways Necessary for Breast Cancer Metastasis. EBioMedicine, 2016, 6, 59-72.	2.7	40
740	NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?. Journal of Nanobiotechnology, 2016, 14, 17.	4.2	35
741	Toward precision medicine of breast cancer. Theoretical Biology and Medical Modelling, 2016, 13, 7.	2.1	48
742	MiR-548c impairs migration and invasion of endometrial and ovarian cancer cells via downregulation of Twist. Journal of Experimental and Clinical Cancer Research, 2016, 35, 10.	3.5	33
743	Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sciences, 2016, 157, 52-61.	2.0	115
744	Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a026203.	2.9	42
745	The relationship between EMT, CD44^{high}/EGFR^{low} phenotype, and treatment response in head and neck cancer cell lines. Journal of Oral Pathology and Medicine, 2016, 45, 640-646.	1.4	22
746	Enhanced Sensitivity of Cancer Stem Cells to Chemotherapy Using Functionalized Mesoporous Silica Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2749-2759.	2.3	30
747	Hypoxic Microenvironment Induces EMT and Upgrades Stem-Like Properties of Gastric Cancer Cells. Technology in Cancer Research and Treatment, 2016, 15, 60-68.	0.8	41
748	VEGF/NRP-1 axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-ÎºB and Î²-catenin. Cancer Letters, 2016, 373, 1-11.	3.2	114
749	Lung cancer stem cells: The root of resistance. Cancer Letters, 2016, 372, 147-156.	3.2	130
750	Aberrant lysine acetylation in tumorigenesis: Implications in the development of therapeutics. , 2016, 162, 98-119.		65
751	Glyoxalase I drives epithelial-to-mesenchymal transition via argpyrimidine-modified Hsp70, miR-21 and SMAD signalling in human bronchial cells BEAS-2B chronically exposed to crystalline silica Min-U-Sil 5: Transformation into a neoplastic-like phenotype. Free Radical Biology and Medicine, 2016, 92, 110-125.	1.3	29
752	Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clinical Cancer Research, 2016, 22, 1313-1317.	3.2	92
753	Twist mediates an aggressive phenotype in human colorectal cancer cells. International Journal of Oncology, 2016, 48, 1117-1124.	1.4	58

#	Article	IF	Citations
754	Overexpression of SDF-1 activates the NF-Î¹B pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells. International Journal of Oncology, 2016, 48, 1085-1094.	1.4	39
755	NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Tumor Biology, 2016, 37, 9671-9680.	0.8	62
756	Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer. Cancer Research, 2016, 76, 912-926.	0.4	71
757	High Infiltration of Tumor-Associated Macrophages Influences Poor Prognosis in Human Gastric Cancer Patients, Associates With the Phenomenon of EMT. Medicine (United States), 2016, 95, e2636.	0.4	84
758	Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer, 2016, 16, 245.	1.1	49
759	Tumor-Initiating Cells: Emerging Biophysical Methods of Isolation. Current Stem Cell Reports, 2016, 2, 21-32.	0.7	5
760	ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nature Communications, 2016, 7, 10498.	5.8	273
761	An integrated microfluidic chip for immunomagnetic detection and isolation of rare prostate cancer cells from blood. Biomedical Microdevices, 2016, 18, 22.	1.4	23
762	Genesis of Circulating Tumor Cells Through Epithelialâ€“Mesenchymal Transition as a Mechanism for Distant Dissemination. Current Cancer Research, 2016, , 139-182.	0.2	5
763	Development of Liposomal Formulation for Delivering Anticancer Drug to Breast Cancer Stem-Cell-Like Cells and its Pharmacokinetics in an Animal Model. Molecular Pharmaceutics, 2016, 13, 1081-1088.	2.3	38
764	Hypoxia-Induced Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma Induces an Immunosuppressive Tumor Microenvironment to Promote Metastasis. Cancer Research, 2016, 76, 818-830.	0.4	225
765	Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFÎ¹Bâ€“IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. Cancer Research, 2016, 76, 2000-2012.	0.4	98
766	Circulating Tumor Cells. Current Cancer Research, 2016, , .	0.2	6
767	Acquisition of Chemoresistance and Other Malignancy-related Features of Colorectal Cancer Cells Are Incremented by Ribosome-inactivating Stress. Journal of Biological Chemistry, 2016, 291, 10173-10183.	1.6	8
768	Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing Malignancies. , 2016, , .		17
769	EMT: Matter of Life or Death?. Cell, 2016, 164, 840-842.	13.5	45
770	Cancer stem cell drugs target K-ras signaling in a stemness context. Oncogene, 2016, 35, 5248-5262.	2.6	78
771	Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4+ migrating cancer stem cells. Oncogene, 2016, 35, 4937-4948.	2.6	52

#	Article	IF	Citations
772	E-Cadherin repression increases amount of cancer stem cells in human A549 lung adenocarcinoma and stimulates tumor growth. Cell Cycle, 2016, 15, 1084-1092.	1.3	30
773	Differentiation therapy of hepatocellular carcinoma by inhibiting the activity of AKT/GSK-3Î²/Î²-catenin axis and TGF-Î² induced EMT with sophocarpine. Cancer Letters, 2016, 376, 95-103.	3.2	48
774	Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelialâ€“mesenchymal transition phenotype. Laboratory Investigation, 2016, 96, 391-398.	1.7	24
775	LKB1/AMPK inhibits TGF-Î²1 production and the TGF-Î² signaling pathway in breast cancer cells. Tumor Biology, 2016, 37, 8249-8258.	0.8	41
776	Bet on drug resistance. Nature, 2016, 529, 289-290.	13.7	34
777	Mitochondria: An intriguing target for killing tumour-initiating cells. Mitochondrion, 2016, 26, 86-93.	1.6	35
778	The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 890, 57-74.	0.8	91
779	Epithelial Mesenchymal Transition in Aggressive Lung Cancers. Advances in Experimental Medicine and Biology, 2016, 890, 37-56.	0.8	66
780	Epithelialâ€“Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitorâ€“Mediated Apoptosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	3.2	41
781	SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer. Tumor Biology, 2016, 37, 4743-4753.	0.8	43
782	CHD1L Regulates Cell Cycle, Apoptosis, and Migration in Glioma. Cellular and Molecular Neurobiology, 2016, 36, 565-576.	1.7	21
783	TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene, 2016, 35, 2684-2686.	2.6	16
784	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	3.2	388
785	Molecular docking study of natural alkaloids as multi-targeted hedgehog pathway inhibitors in cancer stem cell therapy. Computational Biology and Chemistry, 2016, 62, 145-154.	1.1	29
786	CXCR7 mediates TGFÎ²1-promoted EMT and tumor-initiating features in lung cancer. Oncogene, 2016, 35, 2123-2132.	2.6	87
787	Twist as a new prognostic marker in hematological malignancies. Clinical and Translational Oncology, 2016, 18, 113-124.	1.2	19
788	Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. Journal of Neurosurgery, 2017, 126, 249-259.	0.9	19
789	Effects of titanium dioxide nanoparticles on human keratinocytes. Drug and Chemical Toxicology, 2017, 40, 90-100.	1.2	33

#	Article	IF	Citations
790	Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. Journal of Steroid Biochemistry and Molecular Biology, 2017, 166, 84-90.	1.2	49
791	CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro-Oncology, 2017, 19, 66-77.	0.6	82
792	Stress granule-associated protein G3BP2 regulates breast tumor initiation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1033-1038.	3.3	60
793	The neuropilin 2 isoform NRP2b uniquely supports TGFÎ²-mediated progression in lung cancer. Science Signaling, 2017, 10, .	1.6	41
794	A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics. Scientific Reports, 2017, 7, 40633.	1.6	35
795	Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets. Clinical Cancer Research, 2017, 23, 2143-2153.	3.2	215
796	Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells. Stem Cells, 2017, 35, 839-850.	1.4	34
797	Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia. Stem Cells and Development, 2017, 26, 656-677.	1.1	17
798	Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Molecular Cancer, 2017, 16, 10.	7.9	383
799	The role of epithelialâ€“mesenchymal transition drivers <scp>ZEB</scp>1 and <scp>ZEB</scp>2 in mediating docetaxelâ€resistant prostate cancer. Molecular Oncology, 2017, 11, 251-265.	2.1	100
800	The anti-tumor activities of Neferine on cell invasion and oxaliplatin sensitivity regulated by EMT via Snail signaling in hepatocellular carcinoma. Scientific Reports, 2017, 7, 41616.	1.6	62
801	Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer. Molecular Cancer, 2017, 16, 32.	7.9	39
802	Down-regulation of BORIS/CTCFL efficiently regulates cancer stemness and metastasis in MYCN amplified neuroblastoma cell line by modulating Wnt/Î²-catenin signaling pathway. Biochemical and Biophysical Research Communications, 2017, 484, 93-99.	1.0	29
803	Forkhead box P3 regulates <scp>ARHGAP</scp>15 expression and affects migration of glioma cells through the Rac1 signaling pathway. Cancer Science, 2017, 108, 61-72.	1.7	19
804	A Transcriptional Program for Detecting TGFÎ²-Induced EMT in Cancer. Molecular Cancer Research, 2017, 15, 619-631.	1.5	63
805	Cancer cells exhibit clonal diversity in phenotypic plasticity. Open Biology, 2017, 7, 160283.	1.5	30
806	miRNA-520f Reverses Epithelial-to-Mesenchymal Transition by TargetingADAM9andTGFBR2. Cancer Research, 2017, 77, 2008-2017.	0.4	55
807	Is mucin a determinant of peritoneal dissemination of gastrointestinal cancer? Analysis of mucin depletion in two preclinical models. Clinical and Translational Oncology, 2017, 19, 261-264.	1.2	1

#	Article	IF	Citations
808	Loss of NDRG2 Expression Confers Oral Squamous Cell Carcinoma with Enhanced Metastatic Potential. Cancer Research, 2017, 77, 2363-2374.	0.4	35
809	Harnessing the BMP signaling pathway to control the formation of cancer stem cells by effects on epithelial-to-mesenchymal transition. Biochemical Society Transactions, 2017, 45, 223-228.	1.6	15
810	SOX2 Drives Bronchial Dysplasia in a Novel Organotypic Model of Early Human Squamous Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1494-1508.	2.5	26
811	The role of autophagy in the cross-talk between epithelial-mesenchymal transitioned tumor cells and cancer stem-like cells. Molecular Cancer, 2017, 16, 3.	7.9	59
812	Modulating Three-Dimensional Microenvironment with Hyaluronan of Different Molecular Weights Alters Breast Cancer Cell Invasion Behavior. ACS Applied Materials & Interfaces, 2017, 9, 9327-9338.	4.0	41
813	Epithelialâ€“mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Laboratory Investigation, 2017, 97, 567-576.	1.7	40
814	Reduced chromatin acetylation of malignant salivary gland tumors correlates with enhanced proliferation. Journal of Oral Pathology and Medicine, 2017, 46, 792-797.	1.4	15
815	Emerging Biological Principles of Metastasis. Cell, 2017, 168, 670-691.	13.5	2,208
816	Fructose-bisphosphate aldolase A is a key regulator of hypoxic adaptation in colorectal cancer cells and involved in treatment resistance and poor prognosis. International Journal of Oncology, 2017, 50, 525-534.	1.4	55
817	MicroRNAs in the etiology of colorectal cancer: pathways and clinical implications. DMM Disease Models and Mechanisms, 2017, 10, 197-214.	1.2	113
818	Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. Current Oncology Reports, 2017, 19, 19.	1.8	98
819	Targeting TGF-Î² Signaling for Therapeutic Gain. Cold Spring Harbor Perspectives in Biology, 2017, 9, a022301.	2.3	153
820	The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer. Molecular Cancer, 2017, 16, 52.	7.9	241
821	Luteolin suppresses the metastasis of triple-negative breast cancer by reversing epithelial-to-mesenchymal transition via downregulation of Î²-catenin expression. Oncology Reports, 2017, 37, 895-902.	1.2	96
822	A zebrafish xenograft model for studying human cancer stem cells in distant metastasis and therapy response. Methods in Cell Biology, 2017, 138, 471-496.	0.5	37
823	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	7.7	190
824	A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelialâ€“mesenchymal transition in cancer. Oncogene, 2017, 36, 3706-3717.	2.6	54
825	IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Molecular Cancer, 2017, 16, 6.	7.9	92

#	Article	IF	Citations
826	Current Status and Perspectives in Stem Cell Research: The Concept of Normal Stem (NSC) and Cancer Stem Cell (CSC). , 2017, , 7-16.		0
827	Concept of Targeted Cancer Stem Cell Therapy and New Versions. , 2017, , 113-123.		0
828	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 611-629.	12.5	1,865
829	Effects of quantum dots on the ROS amount of liver cancer stem cells. Colloids and Surfaces B: Biointerfaces, 2017, 155, 193-199.	2.5	13
830	Overexpression of KAI1 inhibits retinoblastoma metastasis in vitro. Oncology Letters, 2017, 13, 827-833.	0.8	0
831	Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas. Cancer Research, 2017, 77, 3982-3989.	0.4	294
832	The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nature Cell Biology, 2017, 19, 518-529.	4.6	748
833	Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway. International Journal of Oncology, 2017, 50, 1513-1530.	1.4	41
835	The Notch-1 receptor in prostate tumorigenesis. Cancer Treatment Reviews, 2017, 56, 36-46.	3.4	25
836	MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells. Oncogene, 2017, 36, 5023-5034.	2.6	28
837	MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells. Tumor Biology, 2017, 39, 101042831769836.	0.8	53
838	Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis. International Journal of Cancer, 2017, 141, 1091-1109.	2.3	29
839	Prediction of therapy response in ovarian cancer: Where are we now?. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 233-266.	2.7	28
840	A functional nanocarrier that copenetrates extracellular matrix and multiple layers of tumor cells for sequential and deep tumor autophagy inhibitor and chemotherapeutic delivery. Autophagy, 2017, 13, 359-370.	4.3	15
841	Targeting fibronectin for cancer imaging and therapy. Journal of Materials Chemistry B, 2017, 5, 639-654.	2.9	82
842	Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. Cancer Letters, 2017, 402, 190-202.	3.2	57
843	Connective tissue growth factor promotes temozolomide resistance in glioblastoma through TGF-Î²1-dependent activation of Smad/ERK signaling. Cell Death and Disease, 2017, 8, e2885-e2885.	2.7	35
844	Telomerase and drug resistance in cancer. Cellular and Molecular Life Sciences, 2017, 74, 4121-4132.	2.4	61

#	Article	IF	Citations
845	MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. Acta Biochimica Et Biophysica Sinica, 2017, 49, 159-169.	0.9	30
846	MicroRNA-30a-5p suppresses epithelial-mesenchymal transition by targeting profilin-2 in high invasive non-small cell lung cancer cell lines. Oncology Reports, 2017, 37, 3146-3154.	1.2	31
847	Cancer stem cell marker glycosylation: Nature, function and significance. Glycoconjugate Journal, 2017, 34, 441-452.	1.4	39
848	Nanoformulations for combination or cascade anticancer therapy. Advanced Drug Delivery Reviews, 2017, 115, 3-22.	6.6	145
849	Simultaneous overactivation of Wnt/Î²-catenin and TGFÎ² signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC. Nature Communications, 2017, 8, 15870.	5.8	159
850	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. Scientific Reports, 2017, 7, 3614.	1.6	22
851	Glioblastoma-derived cells in vitro unveil the spectrum of drug resistance capability â€“ comparative study of tumour chemosensitivity in different culture systems. Bioscience Reports, 2017, 37, .	1.1	8
852	Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells. Journal of Biological Chemistry, 2017, 292, 12842-12859.	1.6	46
853	Expression of epithelialâ€“mesenchymal transition driver brachyury and status of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in predicting treatment responses to neoadjuvant chemotherapy of breast cancer. Tumor Biology, 2017, 39, 101042831771057.	0.8	3
854	Mithramycin inhibits epithelial-to-mesenchymal transition and invasion by downregulating SP1 and SNAI1 in salivary adenoid cystic carcinoma. Tumor Biology, 2017, 39, 101042831770869.	0.8	10
855	Imaging of anticancer drug action in single cells. Nature Reviews Cancer, 2017, 17, 399-414.	12.8	80
856	Epithelialâ€mesenchymal transition in cancer metastasis through the lymphatic system. Molecular Oncology, 2017, 11, 781-791.	2.1	106
857	Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. Journal of Cellular Biochemistry, 2017, 118, 3531-3548.	1.2	105
858	Downregulation of feline sarcoma-related protein inhibits cell migration, invasion and epithelial-mesenchymal transition via the ERK/AP-1 pathway in bladder urothelial cell carcinoma. Oncology Letters, 2017, 13, 686-694.	0.8	5
859	Accumulation of low-dose BIX01294 promotes metastatic potential of U251 glioblastoma cells. Oncology Letters, 2017, 13, 1767-1774.	0.8	11
860	The meaning of PIWI proteins in cancer development. Oncology Letters, 2017, 13, 3354-3362.	0.8	36
861	Tg737 regulates epithelialâ€“mesenchymal transition and cancer stemÂcell properties via a negative feedback circuit between Snail andÂHNF4Î± during liver stem cell malignant transformation. Cancer Letters, 2017, 402, 52-60.	3.2	16
862	Paradoxical roles of dual oxidases in cancer biology. Free Radical Biology and Medicine, 2017, 110, 117-132.	1.3	34

#	Article	IF	Citations
864	Mesenchymal-Epithelial Transition and Circulating Tumor Cells in Small Cell Lung Cancer. Advances in Experimental Medicine and Biology, 2017, 994, 229-245.	0.8	46
865	CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. British Journal of Cancer, 2017, 117, 102-112.	2.9	28
866	Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. Advances in Experimental Medicine and Biology, 2017, 994, 205-228.	0.8	34
867	Epithelial-to-mesenchymal transition in tumor progression. Medical Oncology, 2017, 34, 122.	1.2	97
868	Autophagy inhibition impairs the epithelial-mesenchymal transition and enhances cisplatin sensitivity in nasopharyngeal carcinoma. Oncology Letters, 2017, 13, 4147-4154.	0.8	29
869	Induction of Slug by Chronic Exposure to Single-Walled Carbon Nanotubes Promotes Tumor Formation and Metastasis. Chemical Research in Toxicology, 2017, 30, 1396-1405.	1.7	18
870	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	2.1	332
871	Emerging Themes in Drug Resistance. , 2017, , 1-24.		0
872	WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. Scientific Reports, 2017, 7, 43517.	1.6	45
873	Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance. , 2017, , 483-510.		7
874	Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Research and Treatment, 2017, 163, 461-474.	1.1	64
875	Nitroxide radical-containing nanoparticles as potential candidates for overcoming drug resistance in epidermoid cancers. Polymer, 2017, 116, 429-438.	1.8	22
877	Drug Resistance in Cancer. , 2017, , 449-473.		2
878	Salinomycin: A new paradigm in cancer therapy. Tumor Biology, 2017, 39, 101042831769503.	0.8	102
879	Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunological Investigations, 2017, 46, 221-238.	1.0	77
880	Computational analysis of the mesenchymal signature landscape in gliomas. BMC Medical Genomics, 2017, 10, 13.	0.7	3
881	PI3K/AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407. Cell Death and Disease, 2017, 8, e2686-e2686.	2.7	82
882	The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors. Critical Reviews in Oncology/Hematology, 2017, 113, 111-121.	2.0	30

#	Article	IF	Citations
883	Involvement of Notch1 signaling in malignant progression of A549 cells subjected to prolonged cadmium exposure. Journal of Biological Chemistry, 2017, 292, 7942-7953.	1.6	55
884	Cancer stem cell molecular markers verified in vivo. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2017, 11, 43-54.	0.2	14
885	The challenge of targeting cancer stem cells to halt metastasis. Seminars in Cancer Biology, 2017, 44, 25-42.	4.3	154
886	Drug Resistance in Bacteria, Fungi, Malaria, and Cancer. , 2017, , .		13
887	New 3â€alkylpyridine marine alkaloid analogues as promising antitumor agents against the <scp>CD</scp>44^{+/high}/<scp>CD</scp>24^{â˜/low} subset of tripleâ€negative breast cancer cell line. Chemical Biology and Drug Design, 2017, 90, 5-11.	1.5	6
888	Biomaterials to suppress cancer stem cells and disrupt their tumoral niche. International Journal of Pharmaceutics, 2017, 523, 490-505.	2.6	15
889	Stepwise growth of gold coated cancer targeting carbon nanotubes for the precise delivery of doxorubicin combined with photothermal therapy. Journal of Materials Chemistry B, 2017, 5, 1380-1387.	2.9	27
890	Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional pRNA Nanoparticles. ACS Nano, 2017, 11, 335-346.	7.3	112
891	Isolation and identification of tumorâ€initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. Oncology Letters, 2017, 14, 7111-7120.	0.8	3
892	Interleukin-6 blockade attenuates lung cancer tissue construction integrated by cancer stem cells. Scientific Reports, 2017, 7, 12317.	1.6	30
893	Interleukin-6 identified as an important factor in hypoxia- and aldehyde dehydrogenase-based gefitinib adaptive resistance in non-small cell lung cancer cells. Oncology Letters, 2017, 14, 3445-3454.	0.8	13
894	New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 564-570.	3.3	159
895	Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-Î²1/STAT3 axis-regulated EMT. Cell Death and Disease, 2017, 8, e3007-e3007.	2.7	84
896	Semaphorin 3â€‰C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells. Scientific Reports, 2017, 7, 11501.	1.6	33
897	DNA and Histone Methylation in Lung Cancer. Cancer Drug Discovery and Development, 2017, , 403-436.	0.2	3
898	Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. Pancreatology, 2017, 17, 990-996.	0.5	22
899	A20 promotes metastasis of aggressive basal-like breast cancers through multi-monoubiquitylation ofÂSnail1. Nature Cell Biology, 2017, 19, 1260-1273.	4.6	91
900	WNT SIGNALING IN ORAL CANCER INITIATING CELLS. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2017, 124, e202.	0.2	2

#	Article	IF	Citations
901	Biological and Molecular Characterization of Circulating Tumor Cells: A Creative Strategy for Precision Medicine?. Advances in Clinical Chemistry, 2017, 82, 71-103.	1.8	3
902	Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling. Oncology Reports, 2017, 38, 1941-1948.	1.2	19
903	Targeting epithelialâ€“mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochemical Journal, 2017, 474, 3269-3306.	1.7	53
904	The Effects of the Organ Microenvironment on Metastatic Cell Gene Signatures. Molecular and Translational Medicine, 2017, , 55-69.	0.4	0
905	Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer. International Journal of Oncology, 2017, 51, 515-524.	1.4	36
906	Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment. Scientific Reports, 2017, 7, 10382.	1.6	112
907	Advances in cancer stem cell targeting: How to strike the evil at its root. Advanced Drug Delivery Reviews, 2017, 120, 89-107.	6.6	58
908	Mesenchymal Stromal Cell-Derived Interleukin-6 Promotes Epithelialâ€“Mesenchymal Transition and Acquisition of Epithelial Stem-Like Cell Properties in Ameloblastoma Epithelial Cells. Stem Cells, 2017, 35, 2083-2094.	1.4	30
909	A novel bifunctional anti-PD-L1/TGF-Î² Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. OncoImmunology, 2017, 6, e1349589.	2.1	137
910	Non-canonical WNT/PCP signalling in cancer: Fzd6 takes centre stage. Oncogenesis, 2017, 6, e364-e364.	2.1	90
911	Terfenadine combined with epirubicin impedes the chemo-resistant human non-small cell lung cancer both in vitro and in vivo through EMT and Notch reversal. Pharmacological Research, 2017, 124, 105-115.	3.1	57
912	Colony Lysate Arrays for Proteomic Profiling of Drug-Tolerant Persisters of Cancer Cell. Analytical Chemistry, 2017, 89, 8626-8631.	3.2	3
913	Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/Î²-catenin signaling pathway. Scientific Reports, 2017, 7, 6215.	1.6	39
914	Visfatin mediates doxorubicin resistance in human nonâ€“smallâ€cell lung cancer via Aktâ€mediated upâ€regulation of <scp>ABCC</scp>1. Cell Proliferation, 2017, 50, .	2.4	21
915	Molecular factors regulating E-cadherin expression in urothelial bladder cancer and their correlations with the clinicopathological features. Molecular Biology Reports, 2017, 44, 365-377.	1.0	9
916	Mechanoresponsive stem cells to target cancer metastases through biophysical cues. Science Translational Medicine, 2017, 9, .	5.8	74
917	Sustainability of CD24 expression, cell proliferation and migration, cisplatin-resistance, and caspase-3 expression during mesenchymal-epithelial transition induced by the removal of TGF-Î²1 in A549 lung cancer cells. Oncology Letters, 2017, 14, 2410-2416.	0.8	7
918	Eupatolide inhibits the TGFâ€Î²1â€induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5. Oncology Letters, 2017, 14, 6031-6039.	0.8	23

#	Article	IF	Citations
919	Numb prevents a complete epithelialâ€“mesenchymal transition by modulating Notch signalling. Journal of the Royal Society Interface, 2017, 14, 20170512.	1.5	104
921	Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells. Scientific Reports, 2017, 7, 15140.	1.6	99
922	Therapeutic strategies against cancer stem cells in human colorectal cancer (Review). Oncology Letters, 2017, 14, 7653-7668.	0.8	26
923	Downregulation of UHRF1 increases tumor malignancy by activating the CXCR4/AKT-JNK/IL-6/Snail signaling axis in hepatocellular carcinoma cells. Scientific Reports, 2017, 7, 2798.	1.6	22
924	Cancer Stem Cells in Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2017, 48, 241-245.	0.6	17
925	miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer. Scientific Reports, 2017, 7, 4002.	1.6	45
926	A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells. Breast Cancer Research and Treatment, 2017, 166, 55-68.	1.1	30
927	Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells. Scientific Reports, 2017, 7, 5081.	1.6	23
928	Near infrared light triggered nitric oxide releasing platform based on upconversion nanoparticles for synergistic therapy of cancer stem-like cells. Science Bulletin, 2017, 62, 985-996.	4.3	45
929	5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells. Scientific Reports, 2017, 7, 4859.	1.6	27
930	Circulating tumor cell clusters-associated gene plakoglobin is a significant prognostic predictor in patients with breast cancer. Biomarker Research, 2017, 5, 19.	2.8	29
931	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cellular and Molecular Life Sciences, 2017, 74, 1457-1474.	2.4	77
932	Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma. MedChemComm, 2017, 8, 88-95.	3.5	4
933	Withaferin A induces cell death and differentiation in multiple myeloma cancer stem cells. MedChemComm, 2017, 8, 112-121.	3.5	12
934	Targeting aberrant expression of Notchâ€1 in ALDH⁺ cancer stem cells in breast cancer. Molecular Carcinogenesis, 2017, 56, 1127-1136.	1.3	39
935	Adaptive mechanisms of resistance to anti-neoplastic agents. MedChemComm, 2017, 8, 53-66.	3.5	12
936	Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms. Free Radical Biology and Medicine, 2017, 105, 3-15.	1.3	84
937	Biodistribution of Self-Assembling Polymerâ€“Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. Molecular Pharmaceutics, 2017, 14, 1365-1372.	2.3	25

#	Article	IF	Citations
938	Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target. Amino Acids, 2017, 49, 425-439.	1.2	41
939	A photodynamic bifunctional conjugate for prostate cancer: an in vitro mechanistic study. Investigational New Drugs, 2017, 35, 115-123.	1.2	16
940	Metabolic Reconfiguration Supports Reacquisition of Primitive Phenotype in Human Mesenchymal Stem Cell Aggregates. Stem Cells, 2017, 35, 398-410.	1.4	43
941	HepatitisÂC virus core protein increases Snail expression and induces epithelialâ€“mesenchymal transition through the signal transducer and activator of transcriptionÂ3 pathway in hepatoma cells. Hepatology Research, 2017, 47, 574-583.	1.8	14
942	Cancer stem cell-targeted therapeutics and delivery strategies. Expert Opinion on Drug Delivery, 2017, 14, 997-1008.	2.4	32
943	Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment. Cancer Letters, 2017, 388, 1-11.	3.2	41
944	Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation. Journal of Controlled Release, 2017, 245, 1-14.	4.8	27
945	Claudins in cancer: bench to bedside. Pflugers Archiv European Journal of Physiology, 2017, 469, 55-67.	1.3	76
946	Inflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple Opponents. Cancer Growth and Metastasis, 2017, 10, 117906441770928.	3.5	24
947	Prognostic significance of expression of epithelialâ€˜mesenchymal transition driver brachyury in breast cancer and its association with subtype and characteristics. Oncology Letters, 2017, 15, 1037-1045.	0.8	5
948	ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cellsThis article has been corrected since Advance Online Publication and an erratum is also printed in this issue. Oncogenesis, 2017, 6, e389-e389.	2.1	56
949	Paradigm shift in cancer treatment: Cancer treatment as a metabolic disease â€“ fusion of Eastern and Western medicine. Journal of Traditional Chinese Medical Sciences, 2017, 4, 322-327.	0.1	2
950	Knocking down MiR-15a expression promotes the occurrence and development and induces the EMT of NSCLC cells in vitro. Saudi Journal of Biological Sciences, 2017, 24, 1859-1865.	1.8	17
951	Electrospun Biomaterials for Cancer Research. , 2017, , 169-205.		1
952	FOXP3 promotes tumor growth and metastasis by activating Wnt/Î²-catenin signaling pathway and EMT in non-small cell lung cancer. Molecular Cancer, 2017, 16, 124.	7.9	276
953	The influence of Osmunda regalis root extract on head and neck cancer cell proliferation, invasion and gene expression. BMC Complementary and Alternative Medicine, 2017, 17, 518.	3.7	13
954	Numerical Simulation of a Contractivity Based Multiscale Cancer Invasion Model. Lecture Notes in Computational Science and Engineering, 2017, , 73-91.	0.1	1
955	Knockdown of Arf6 increases drug sensitivity and inhibits proliferation, migration and invasion in gastric cancer SGCâ€˜7901 cells. Oncology Letters, 2017, 15, 2147-2152.	0.8	5

#	Article	IF	Citations
956	Periostin promotes epithelial-mesenchymal transition via the MAPK/miR-381 axis in lung cancer. Oncotarget, 2017, 8, 62248-62260.	0.8	45
957	Sinomenine hydrochloride inhibits breast cancer metastasis by attenuating inflammation-related epithelial-mesenchymal transition and cancer stemness. Oncotarget, 2017, 8, 13560-13574.	0.8	43
958	Epithelial-to-Mesenchymal Transition: Liaison between Cancer Metastasis and Drug Resistance. Critical Reviews in Oncogenesis, 2017, 22, 275-282.	0.2	24
959	Potential of Central, Eastern and Western Africa Medicinal Plants for Cancer Therapy: Spotlight on Resistant Cells and Molecular Targets. Frontiers in Pharmacology, 2017, 8, 343.	1.6	95
960	Colocynth Extracts Prevent Epithelial to Mesenchymal Transition and Stemness of Breast Cancer Cells. Frontiers in Pharmacology, 2017, 8, 593.	1.6	32
961	Withanolide D Exhibits Similar Cytostatic Effect in Drug-Resistant and Drug-Sensitive Multiple Myeloma Cells. Frontiers in Pharmacology, 2017, 8, 610.	1.6	16
962	Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin. OncoTargets and Therapy, 2017, Volume 10, 2341-2348.	1.0	27
963	ZEB1 Mediates Drug Resistance and EMT in p300-Deficient CRC. Journal of Cancer, 2017, 8, 1453-1459.	1.2	42
964	Epithelial-Mesenchymal Transition Phenotype, Metformin, and Survival for Colorectal Cancer Patients with Diabetes Mellitus II. Gastroenterology Research and Practice, 2017, 2017, 1-10.	0.7	15
965	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. Cancers, 2017, 9, 38.	1.7	143
966	Regulation of EMT in Colorectal Cancer: A Culprit in Metastasis. Cancers, 2017, 9, 171.	1.7	365
967	Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology. Frontiers in Oncology, 2017, 7, 145.	1.3	99
968	Alternative mechanisms of miR-34a regulation in cancer. Cell Death and Disease, 2017, 8, e3100-e3100.	2.7	205
969	Multiscale Models in Mechano and Tumor Biology. Lecture Notes in Computational Science and Engineering, 2017, , .	0.1	3
970	Epithelial-Mesenchymal Transition in Pancreatic Cancer: A Review. BioMed Research International, 2017, 2017, 1-10.	0.9	99
971	miR-15a-3p and miR-16-1-3p Negatively Regulate Twist1 to Repress Gastric Cancer Cell Invasion and Metastasis. International Journal of Biological Sciences, 2017, 13, 122-134.	2.6	65
972	Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory. Cancers, 2017, 9, 70.	1.7	70
973	The propensity for epithelial-mesenchymal transitions is dictated by chromatin states in the cancer cell of origin. Stem Cell Investigation, 2017, 4, 44-44.	1.3	1

#	Article	IF	Citations
974	Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures. PLoS ONE, 2017, 12, e0181342.	1.1	17
975	Nitric Oxide Donors Sensitize Resistant Cancer Cells to Apoptosis Induced by Chemotherapy: Molecular Mechanisms of Sensitization. , 2017, , 15-34.		2
976	Site-specific gene expression profiling as a novel strategy for unravelling keloid disease pathobiology. PLoS ONE, 2017, 12, e0172955.	1.1	43
977	Screening of breast cancer stem cell inhibitors using a protein kinase inhibitor library. Cancer Cell International, 2017, 17, 25.	1.8	31
978	AXL is a marker for epithelialâ€'mesenchymal transition in esophageal squamous cell carcinoma. Oncology Letters, 2018, 15, 1900-1906.	0.8	18
979	PRPF overexpression induces drug resistance through actin cytoskeleton rearrangement and epithelial-mesenchymal transition. Oncotarget, 2017, 8, 56659-56671.	0.8	20
980	E-cadherin and Vimentin as Predictors of Resistance to Preoperative Systemic Therapy in Patients with Advanced Breast Cancer. Journal Kedokteran Indonesia, 2017, 4, .	0.0	0
981	Epithelial-to-mesenchymal transition, circulating tumor cells and cancer metastasis: Mechanisms and clinical applications. Oncotarget, 2017, 8, 81558-81571.	0.8	146
982	Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer. Oncotarget, 2017, 8, 7094-7115.	0.8	36
983	Fibulin-4 is associated with prognosis of endometrial cancer patients and inhibits cancer cell invasion and metastasis via Wnt/Î²-catenin signaling pathway. Oncotarget, 2017, 8, 18991-19012.	0.8	27
984	Reprogramming Factors Remodel Melanoma Cell Phenotype by Changing Stat3 Expression. International Journal of Medical Sciences, 2017, 14, 1402-1409.	1.1	9
985	Wnt3a Expression Is Associated with Epithelial-Mesenchymal Transition and Impacts Prognosis of Lung Adenocarcinoma Patients. Journal of Cancer, 2017, 8, 2523-2531.	1.2	14
986	Quantitative proteomics analysis of the role of tetraspanin-8 in the drug resistance of gastric cancer. International Journal of Oncology, 2018, 52, 473-484.	1.4	7
987	Cancer Biophysics. , 2017, , .		2
988	HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. OncoTargets and Therapy, 2017, Volume 10, 1389-1402.	1.0	16
989	Exostosin 1 regulates cancer cell stemness in doxorubicin-resistant breast cancer cells. Oncotarget, 2017, 8, 70521-70537.	0.8	23
990	Secreted heat shock protein 90 promotes prostate cancer stem cell heterogeneity. Oncotarget, 2017, 8, 19323-19341.	0.8	33
991	MECHANISMS IN ENDOCRINOLOGY: Lessons from growth hormone receptor gene-disrupted mice: are there benefits of endocrine defects?. European Journal of Endocrinology, 2018, 178, R155-R181.	1.9	52

#	Article	IF	Citations
992	Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer. Scientific Reports, 2018, 8, 3335.	1.6	56
993	Pharmacological targets of breast cancer stem cells: a review. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 463-479.	1.4	21
994	Î³-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway. Gynecologic Oncology, 2018, 149, 163-172.	0.6	16
995	Cellular Plasticityâ€"Targeted Therapy in Head and Neck Cancers. Journal of Dental Research, 2018, 97, 654-664.	2.5	13
996	Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer. Cancer Letters, 2018, 423, 47-59.	3.2	53
997	Epithelialâ€toâ€mesenchymal transition in the context of epidermal growth factor receptor inhibition in nonâ€smallâ€cell lung cancer. Biological Reviews, 2018, 93, 1735-1746.	4.7	23
998	Combination Therapy and the Evolution of Resistance: The Theoretical Merits of Synergism and Antagonism in Cancer. Cancer Research, 2018, 78, 2419-2431.	0.4	58
999	Targeting <scp>LMW</scp>â€<scp>PTP</scp> to sensitize melanoma cancer cells toward chemoâ€and radiotherapy. Cancer Medicine, 2018, 7, 1933-1943.	1.3	14
1000	Naturally occurring compounds in differentiation based therapy of cancer. Biotechnology Advances, 2018, 36, 1622-1632.	6.0	31
1001	Strategy to targeting the immune resistance and novel therapy in colorectal cancer. Cancer Medicine, 2018, 7, 1578-1603.	1.3	23
1002	High ALDH activity defines ovarian cancer stem-like cells with enhanced invasiveness and EMT progress which are responsible for tumor invasion. Biochemical and Biophysical Research Communications, 2018, 495, 1081-1088.	1.0	41
1003	Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial. ACS Central Science, 2018, 4, 567-581.	5.3	49
1004	WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma. Oncogene, 2018, 37, 3753-3762.	2.6	24
1005	PGD2/PTGDR2 Signaling Restricts the Self-Renewal and Tumorigenesis of Gastric Cancer. Stem Cells, 2018, 36, 990-1003.	1.4	64
1006	Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Development and Industrial Pharmacy, 2018, 44, 1434-1442.	0.9	14
1007	Mesenchymal Stromal Cells-Derived Î²2-Microglobulin Promotes Epithelialâ€"Mesenchymal Transition of Esophageal Squamous Cell Carcinoma Cells. Scientific Reports, 2018, 8, 5422.	1.6	15
1008	Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis. Molecular Medicine Reports, 2018, 17, 6211-6226.	1.1	27
1009	Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Materials Science and Engineering C, 2018, 89, 328-335.	3.8	52

#	Article	IF	Citations
1010	The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres. Scientific Reports, 2018, 8, 2982.	1.6	50
1011	Safer approaches to therapeutic modulation of TGF-Î² signaling for respiratory disease. , 2018, 187, 98-113.		35
1012	Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer (Review). Biomedical Reports, 2018, 8, 215-223.	0.9	9
1013	The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coordination Chemistry Reviews, 2018, 360, 17-33.	9.5	94
1014	Targeting cancer stem cells in the clinic: Current status and perspectives. , 2018, 187, 13-30.		61
1015	Anticancer Activity in Honeybee Propolis: Functional Insights to the Role of Caffeic Acid Phenethyl Ester and Its Complex With Î³-Cyclodextrin. Integrative Cancer Therapies, 2018, 17, 867-873.	0.8	45
1016	Mixed lineage kinase ZAK promotes epithelialâ€“mesenchymal transition in cancer progression. Cell Death and Disease, 2018, 9, 143.	2.7	16
1017	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer, 2018, 118, 111-118.	0.9	38
1018	Epithelial Mesenchymal Transition in Tumor Metastasis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 395-412.	9.6	896
1019	Development and characterisation of a panel of phosphatidylinositide 3-kinase â€“ mammalian target of rapamycin inhibitor resistant lung cancer cell lines. Scientific Reports, 2018, 8, 1652.	1.6	9
1020	Multifunctional Nanoflowers for Simultaneous Multimodal Imaging and High-Sensitivity Chemo-Photothermal Treatment. Bioconjugate Chemistry, 2018, 29, 559-570.	1.8	36
1021	MUC1-C activates polycomb repressive complexes and downregulates tumor suppressor genes in human cancer cells. Oncogene, 2018, 37, 2079-2088.	2.6	50
1022	Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 616-628.	1.9	42
1023	L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer. Experimental and Therapeutic Medicine, 2018, 15, 2792-2797.	0.8	24
1024	Targeting histone deacetylase and NFÎºB signaling as a novel therapy for Mucoepidermoid Carcinomas. Scientific Reports, 2018, 8, 2065.	1.6	20
1025	Effects of microRNA-135a on the epithelialâ€“mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3Î² through the Wnt/Î²-catenin signaling pathway. Experimental and Molecular Medicine, 2018, 50, e429-e429.	3.2	45
1026	LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 727-737.	1.4	36
1027	Dihydropyrimidine dehydrogenase predicts survival and response to interferon-Î± in hepatocellular carcinoma. Cell Death and Disease, 2018, 9, 69.	2.7	17

#	Article	IF	Citations
1028	HDACis (class I), cancer stem cell, and phytochemicals: Cancer therapy and prevention implications. Biomedicine and Pharmacotherapy, 2018, 97, 1445-1453.	2.5	35
1029	An update on the molecular pathology of urinary bladder tumors. Pathology Research and Practice, 2018, 214, 1-6.	1.0	33
1030	Overexpression of Nogo receptor 3 (NgR3) correlates with poor prognosis and contributes to the migration of epithelial cells of nasopharyngeal carcinoma patients. Journal of Molecular Medicine, 2018, 96, 265-279.	1.7	8
1031	Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells. Neoplasia, 2018, 20, 197-206.	2.3	34
1032	Galectin-3 and cancer stemness. Glycobiology, 2018, 28, 172-181.	1.3	100
1033	Localized delivery of chemokine for inÂvitro manipulation of hepatocellular carcinoma cell behaviors during the epithelialâ€“mesenchymal transition. Journal of Biomaterials Applications, 2018, 32, 945-956.	1.2	4
1034	Fâ€˜box proteins involved in cancerâ€˜associated drug resistance (Review). Oncology Letters, 2018, 15, 8891-8900.	0.8	20
1035	Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer. Molecular Cancer, 2018, 17, 42.	7.9	16
1036	A Forkhead Box Proteinâ€…C2 Inhibitor: Targeting Epithelialâ€“Mesenchymal Transition and Cancer Metastasis. ChemBioChem, 2018, 19, 1359-1364.	1.3	17
1037	Signalling mechanism(s) of epithelialâ€“mesenchymal transition and cancer stem cells in tumour therapeutic resistance. Clinica Chimica Acta, 2018, 483, 156-163.	0.5	63
1038	A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy. International Journal of Cancer, 2018, 143, 2133-2144.	2.3	119
1039	Development of Novel Therapeutic Response Biomarkers. , 2018, , 1273-1304.		0
1040	Different Chemosensitization Approaches in Gastric Cancer. , 2018, , 267-319.		4
1041	CAsubtype: An R Package to Identify Gene Sets Predictive of Cancer Subtypes and Clinical Outcomes. Interdisciplinary Sciences, Computational Life Sciences, 2018, 10, 169-175.	2.2	5
1042	Epithelialâ€“mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease. Developmental Dynamics, 2018, 247, 346-358.	0.8	190
1043	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. Clinical Cancer Research, 2018, 24, 197-208.	3.2	74
1044	Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. Cancer Discovery, 2018, 8, 59-73.	7.7	96
1045	Introduction to Cancer Stem Cells: Past, Present, and Future. Methods in Molecular Biology, 2018, 1692, 1-16.	0.4	16

#	Article	IF	Citations
1046	Self-Renewal and CSCs In Vitro Enrichment: Growth as Floating Spheres. Methods in Molecular Biology, 2018, 1692, 61-75.	0.4	29
1047	Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2018, 10, e1406.	6.6	70
1048	Suppression of TGF-Î²1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 1505-1512.	1.9	19
1049	Curcumin mediated downâ€regulation of Î±_VÎ²₃ integrin and upâ€regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells. Phytotherapy Research, 2018, 32, 355-364.	2.8	33
1050	Identification of a novel fusion gene HMGA2â€EGFR in glioblastoma. International Journal of Cancer, 2018, 142, 1627-1639.	2.3	12
1051	PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer. Breast Cancer Research and Treatment, 2018, 168, 531-542.	1.1	39
1052	A miRNA-200c/cathepsin L feedback loop determines paclitaxel resistance in human lung cancer A549 cells in vitro through regulating epithelialâ€“mesenchymal transition. Acta Pharmacologica Sinica, 2018, 39, 1034-1047.	2.8	34
1053	The combination of curcumin and 5-fluorouracil in cancer therapy. Archives of Pharmacal Research, 2018, 41, 1-13.	2.7	81
1054	SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer. Journal of Cell Biology, 2018, 217, 763-777.	2.3	34
1055	Smad3â€mediated recruitment of the methyltransferase SETDB1/ESET controls Snail1 expression and epithelialâ€“mesenchymal transition. EMBO Reports, 2018, 19, 135-155.	2.0	58
1056	Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-ÎºB mediated epithelialâ€“mesenchymal transition and stemness. Cancer Letters, 2018, 415, 73-85.	3.2	104
1057	Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma. Clinical and Experimental Medicine, 2018, 18, 177-190.	1.9	18
1058	Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device. Nature Protocols, 2018, 13, 34-58.	5.5	128
1059	Anti-PD-L1/TGFÎ²R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 93.e1-93.e11.	0.8	40
1060	CRTC2 promotes nonâ€small cell lung cancer A549 migration and invasion in vitro. Thoracic Cancer, 2018, 9, 136-141.	0.8	11
1061	TGFÎ² pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130.		85
1062	Resveratrol Induces Mitochondrial Apoptosis and Inhibits Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells. Nutrition and Cancer, 2018, 70, 125-135.	0.9	40
1063	The NOTCH4â€“HEY1 Pathway Induces Epithelialâ€“Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 619-633.	3.2	63

#	Article	IF	Citations
1064	Brucine suppresses breast cancer metastasis via inhibiting epithelial mesenchymal transition and matrix metalloproteinases expressions. Chinese Journal of Integrative Medicine, 2018, 24, 40-46.	0.7	30
1065	Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition. Anti-Cancer Drugs, 2018, 29, 871-879.	0.7	22
1066	Irradiated endothelial cells modulate the malignancy of liver cancer cells. Oncology Letters, 2019, 17, 2187-2196.	0.8	6
1067	Current research on head and neck cancer-associated long noncoding RNAs. Oncotarget, 2018, 9, 1403-1425.	0.8	16
1068	EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors. Cancer Research and Treatment, 2018, 50, 908-916.	1.3	32
1069	Effect of modulation of epithelialâ€'mesenchymal transition regulators Snail1 and Snail2 on cancer cell radiosensitivity by targeting of the cell cycle, cell apoptosis and cell migration/invasion (Review). Oncology Letters, 2018, 17, 23-30.	0.8	27
1070	MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World Journal of Gastroenterology, 2018, 24, 2949-2973.	1.4	159
1071	The SOX2OT/miRâ€'194â€'5p axis regulates cell proliferation and mobility of gastric cancer through suppressing epithelialâ€'mesenchymal transition. Oncology Letters, 2018, 16, 6361-6368.	0.8	15
1072	Structureâ€Guided Engineering of Cytotoxic Cabazitaxel for an Adaptive Nanoparticle Formulation: Enhancing the Drug Safety and Therapeutic Efficacy. Advanced Functional Materials, 2018, 28, 1804229.	7.8	43
1073	Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis. Journal of Experimental and Clinical Cancer Research, 2018, 37, 276.	3.5	46
1074	Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nature Communications, 2018, 9, 5005.	5.8	144
1075	Ivalin Inhibits Proliferation, Migration and Invasion by Suppressing Epithelial Mesenchymal Transition in Breast Cancer Cells. Nutrition and Cancer, 2018, 70, 1330-1338.	0.9	8
1077	Cellular Phenotype Plasticity in Cancer Dormancy and Metastasis. Frontiers in Oncology, 2018, 8, 505.	1.3	28
1078	Transfection of T-Box Transcription Factor BRACHYURY and SOX2 Synergistically Promote Self-Renewal and Invasive Phenotype in Oral Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 3620.	1.8	10
1079	Longitudinal single-cell RNA sequencing of patient-derived primary cells reveals drug-induced infidelity in stem cell hierarchy. Nature Communications, 2018, 9, 4931.	5.8	134
1080	Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways. Oncogenesis, 2018, 7, 85.	2.1	24
1081	miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/Î²-Catenin Axis. Theranostics, 2018, 8, 5801-5813.	4.6	54
1082	The great escape: How metastases of melanoma, and other carcinomas, avoid elimination. Experimental Biology and Medicine, 2018, 243, 1245-1255.	1.1	9

#	Article	IF	Citations
1083	The Role of Stem Cells in Dupuytrenâ€™s Disease. Plastic and Reconstructive Surgery - Global Open, 2018, 6, e1777.	0.3	8
1084	Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelialâ€Mesenchymal Transition Regulators and Stemness Genes. Hepatology Communications, 2018, 2, 1392-1407.	2.0	25
1085	Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis. Cancer Cell International, 2018, 18, 217.	1.8	9
1086	Long nonâ€‘coding RNA ENST00000547547 inhibits cell proliferation, invasion and migration in colorectal cancer cells. Oncology Reports, 2019, 41, 483-491.	1.2	9
1087	Î²-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2. Frontiers in Pharmacology, 2018, 9, 1413.	1.6	37
1088	Sphingomyelin synthase 1 regulates the epithelialâ€‘toâ€‘mesenchymal transition mediated by the TGFâ€Î²/Smad pathway in MDAâ€‘MBâ€‘231 cells. Molecular Medicine Reports, 2019, 19, 1159-1167.	1.1	12
1089	Nutritional stress reprograms dedifferention in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: a stochastic model of cancer stem cells. Cell Death Discovery, 2018, 4, 110.	2.0	35
1090	Moving Breast Cancer Therapy up a Notch. Frontiers in Oncology, 2018, 8, 518.	1.3	63
1091	An evaluation of TAZ and YAP crosstalk with TGFÎ² signalling in canine osteosarcoma suggests involvement of hippo signalling in disease progression. BMC Veterinary Research, 2018, 14, 365.	0.7	13
1092	Notch in Ovarian Cancer. , 2018, , 153-173.		0
1093	Notch Signaling in Estrogen-Dependent Cancers. , 2018, , 353-380.		0
1094	Single-Cell Imaging of Metastatic Potential of Cancer Cells. IScience, 2018, 10, 53-65.	1.9	20
1095	ALDH1 as a prognostic marker for lymph node metastasis in OSCC. Biomedical Reports, 2018, 9, 284-290.	0.9	6
1096	Seleniumâ€“lentinan inhibits tumor progression by regulating epithelialâ€“mesenchymal transition. Toxicology and Applied Pharmacology, 2018, 360, 1-8.	1.3	20
1097	Role of Tyrosine Kinases in Gastrointestinal Malignancies. , 2018, , .		1
1098	TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition. Scientific Reports, 2018, 8, 13231.	1.6	7
1099	Membrane associated collagen XIII promotes cancer metastasis and enhances anoikis resistance. Breast Cancer Research, 2018, 20, 116.	2.2	50
1100	Hypoxiaâ€inducible transgelin 2 selects epithelialâ€toâ€mesenchymal transition and Î³â€radiationâ€resistant subtypes by focal adhesion kinaseâ€associated insulinâ€like growth factor 1 receptor activation in nonâ€smallâ€cell lung cancer cells. Cancer Science, 2018, 109, 3519-3531.	1.7	26

#	Article	IF	Citations
1101	FOXC2 promotes epithelialâ€“mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology, 2018, 82, 1049-1059.	1.1	26
1102	Collagen prolyl 4-hydroxylase 1 is essential for HIF-1Î± stabilization and TNBC chemoresistance. Nature Communications, 2018, 9, 4456.	5.8	170
1103	Resistance of primary breast cancer cells with enhanced pluripotency and stem cell activity to sex hormonal stimulation and suppression. International Journal of Biochemistry and Cell Biology, 2018, 105, 84-93.	1.2	8
1104	Infiltrative and drugâ€resistant slowâ€cycling cells support metabolic heterogeneity in glioblastoma. EMBO Journal, 2018, 37, .	3.5	118
1105	Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Molecular Cancer, 2018, 17, 149.	7.9	103
1106	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. International Journal of Molecular Sciences, 2018, 19, 3164.	1.8	17
1107	The downregulation of WWOX induces epithelialâ€“mesenchymal transition and enhances stemness and chemoresistance in breast cancer. Experimental Biology and Medicine, 2018, 243, 1066-1073.	1.1	9
1108	Metastatic cancer cells compensate for low energy supplies in hostile microenvironments with bioenergetic adaptation and metabolic reprogramming. International Journal of Oncology, 2018, 53, 2590-2604.	1.4	9
1109	Increased Expression of Cullin 3 in Nasopharyngeal Carcinoma and Knockdown Inhibits Proliferation and Invasion. Oncology Research, 2018, 26, 111-122.	0.6	4
1110	Strigolactonesâ€”a novel class of phytohormones as anti-cancer agents. Journal of Pesticide Sciences, 2018, 43, 168-172.	0.8	7
1111	Inflammatory Role of Cancer-Associated Fibroblasts in Invasive Breast Tumors Revealed Using a Fibrous Polymer Scaffold. ACS Applied Materials & Interfaces, 2018, 10, 33814-33826.	4.0	38
1112	Exposure to nicotine-derived nitrosamine ketone and arecoline synergistically facilitates tumor aggressiveness via overexpression of epidermal growth factor receptor and its downstream signaling in head and neck squamous cell carcinoma. PLoS ONE, 2018, 13, e0201267.	1.1	9
1113	Micropillarâ€based culture platform induces epithelialâ€“mesenchymal transition in the alveolar epithelial cell line. Journal of Biomedical Materials Research - Part A, 2018, 106, 3165-3174.	2.1	12
1114	5-Fluorouracil may enrich cancer stem cells in canine mammary tumor cells inÃ¯Â¿Â½vitro. Oncology Letters, 2018, 15, 7987-7992.	0.8	10
1115	Rapid phenotyping of cancer stem cells using multichannel nanosensor arrays. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1931-1939.	1.7	22
1116	MEG3/miRâ€‘21 axis affects cell mobility by suppressing epithelialâ€‘mesenchymal transition in gastric cancer. Oncology Reports, 2018, 40, 39-48.	1.2	38
1117	Overexpression of Golgi Phosphoprotein 2 Is Associated With Poor Prognosis in Oral Squamous Cell Carcinoma. American Journal of Clinical Pathology, 2018, 150, 74-83.	0.4	10
1118	TGF-Î² plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochemical and Biophysical Research Communications, 2018, 502, 160-165.	1.0	119

#	Article	IF	Citations
1119	Dysregulation of the MiR-449b target TGFBI alters the TGFÎ² pathway to induce cisplatin resistance in nasopharyngeal carcinoma. Oncogenesis, 2018, 7, 40.	2.1	34
1120	miR-331-3p functions as an oncogene by targeting ST7L in pancreatic cancer. Carcinogenesis, 2018, 39, 1006-1015.	1.3	39
1121	Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator. Experimental and Therapeutic Medicine, 2018, 15, 3751-3758.	0.8	13
1123	Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. EBioMedicine, 2018, 31, 276-286.	2.7	24
1124	Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells. Cancer Letters, 2018, 433, 165-175.	3.2	51
1125	Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human nonâ€‘small lung cancer cells by regulating the YAP pathway. Oncology Reports, 2018, 40, 609-620.	1.2	21
1126	Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis. Seminars in Cancer Biology, 2018, 53, 90-109.	4.3	62
1127	Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice. Analytical Cellular Pathology, 2018, 2018, 1-12.	0.7	22
1128	Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment. Stem Cells International, 2018, 2018, 1-16.	1.2	593
1129	The Tumorgenicity of Glioblastoma Cell Line U87MG Decreased During Serial In Vitro Passage. Cellular and Molecular Neurobiology, 2018, 38, 1245-1252.	1.7	7
1130	MicroRNA-30b targets Snail to impede epithelial-mesenchymal transition in pancreatic cancer stem cells. Journal of Cancer, 2018, 9, 2147-2159.	1.2	32
1131	Impact of semaphorin expression on prognostic characteristics in breast cancer. Breast Cancer: Targets and Therapy, 2018, Volume 10, 79-88.	1.0	20
1132	How Tumor Cells Choose Between Epithelial-Mesenchymal Transition and Autophagy to Resist Stressâ€”Therapeutic Implications. Frontiers in Pharmacology, 2018, 9, 714.	1.6	13
1133	Strategies to Tackle Radiation Resistance by Penetrating Cancer Stem Cell Line of Scrimmage. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 18-39.	0.8	4
1134	Glutathione reductase-mediated thiol oxidative stress suppresses metastasis of murine melanoma cells. Free Radical Biology and Medicine, 2018, 129, 256-267.	1.3	20
1135	Transcription factor AP-4 promotes tumorigenic capability and activates the Wnt/Î²-catenin pathway in hepatocellular carcinoma. Theranostics, 2018, 8, 3571-3583.	4.6	70
1136	The human papillomavirus (HPV)-related cancer biology: An overview. Biomedicine and Pharmacotherapy, 2018, 106, 1537-1556.	2.5	96
1137	Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1Î±. Experimental Cell Research, 2018, 371, 63-71.	1.2	63

#	Article	IF	Citations
1138	Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells. Oncology Reports, 2018, 40, 877-886.	1.2	12
1139	Roles of genetic and microenvironmental factors in cancer epithelial-to-mesenchymal transition and therapeutic implication. Experimental Cell Research, 2018, 370, 190-197.	1.2	6
1140	Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics. Cancers, 2018, 10, 14.	1.7	26
1141	Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms. Cancers, 2018, 10, 124.	1.7	35
1142	Remedy of Targeting Cancer and Cancer Stem Cells with Botanicals. , 2018, , 289-320.		0
1143	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10Âyears and future perspectives. Wiener Klinische Wochenschrift, 2018, 130, 517-529.	1.0	3
1144	The regulatory effects of metformin on the [SNAIL/miR-34]:[ZEB/miR-200] system in the epithelial-mesenchymal transition(EMT) for colorectal cancer(CRC). European Journal of Pharmacology, 2018, 834, 45-53.	1.7	38
1145	Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. Frontiers in Endocrinology, 2018, 9, 277.	1.5	48
1146	Perspective: bidirectional exosomal transport between cancer stem cells and their fibroblast-rich microenvironment during metastasis formation. Npj Breast Cancer, 2018, 4, 18.	2.3	23
1147	Anticancer drug discovery from Chinese medicinal herbs. Chinese Medicine, 2018, 13, 35.	1.6	73
1148	Synergistic antitumor activity of aspirin and erlotinib: Inhibition of p38 enhanced aspirin plus erlotinibâ€'induced suppression of metastasis and promoted cancer cell apoptosis. Oncology Letters, 2018, 16, 2715-2724.	0.8	8
1149	Novel tripleâ€'positive markers identified in human nonâ€'small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics. Oncology Reports, 2018, 40, 669-681.	1.2	24
1150	Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. Nature Communications, 2018, 9, 2682.	5.8	62
1151	Role of Akt Isoforms Controlling Cancer Stem Cell Survival, Phenotype and Self-Renewal. Biomedicines, 2018, 6, 29.	1.4	38
1152	Liposomal delivery of a Pin1 inhibitor complexed with cyclodextrins as new therapy for high-grade serous ovarian cancer. Journal of Controlled Release, 2018, 281, 1-10.	4.8	29
1153	STAT3, stem cells, cancer stem cells and p63. Cellular and Molecular Biology Letters, 2018, 23, 12.	2.7	188
1154	MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer. BMC Cancer, 2018, 18, 74.	1.1	48
1155	RXRÎ± provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells. Cell Death and Disease, 2018, 9, 532.	2.7	23

#	Article	IF	Citations
1156	CARF enrichment promotes epithelialâ€“mesenchymal transition via Wnt/Î²-catenin signaling: its clinical relevance and potential as a therapeutic target. Oncogenesis, 2018, 7, 39.	2.1	30
1157	Cadherin Expression Shift Could Well Distinguish Esophageal Squamous Cell Carcinoma from Non-Cancerous Esophageal Tissues. Oncology Research and Treatment, 2018, 41, 380-385.	0.8	2
1158	miR-126 suppresses epithelial-to-mesenchymal transition and metastasis by targeting PI3K/AKT/Snail signaling of lung cancer cells. Oncology Letters, 2018, 15, 7369-7375.	0.8	26
1159	Telocinobufagin inhibits the epithelialâ€‘mesenchymal transition of breast cancer cells through the phosphoinositide 3â€‘kinase/protein kinase B/extracellular signalâ€‘regulated kinase/Snail signaling pathway. Oncology Letters, 2018, 15, 7837-7845.	0.8	3
1160	Survivin Inhibitors Mitigate Chemotherapeutic Resistance in Breast Cancer Cells by Suppressing Genotoxic Nuclear Factor-ÎºB Activation. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 184-193.	1.3	37
1161	Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil. Cancer Management and Research, 2018, Volume 10, 2729-2742.	0.9	15
1162	Antitumor effect of triptolide in T-cell lymphoblastic lymphoma by inhibiting cell viability, invasion, and epithelial–mesenchymal transition via regulating the PI3K/AKT/mTOR pathway. OncoTargets and Therapy, 2018, Volume 11, 769-779.	1.0	23
1163	Suppression of Breast Cancer Stem Cells and Tumor Growth by the RUNX1 Transcription Factor. Molecular Cancer Research, 2018, 16, 1952-1964.	1.5	48
1164	lncRNA H19 predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration and epithelial–mesenchymal transition in melanoma cells. OncoTargets and Therapy, 2018, Volume 11, 3583-3595.	1.0	33
1165	A comprehensive look at the role of hyperlipidemia in promoting colorectal cancer liver metastasis. Journal of Cancer, 2018, 9, 2981-2986.	1.2	15
1166	The lncRNA MIR4435-2HG promotes lung cancer progression by activating Î²-catenin signalling. Journal of Molecular Medicine, 2018, 96, 753-764.	1.7	72
1167	Ratiometric delivery of two therapeutic candidates with inherently dissimilar physicochemical property through pH-sensitive coreâ€“shell nanoparticles targeting the heterogeneous tumor cells of glioma. Drug Delivery, 2018, 25, 1302-1318.	2.5	19
1168	Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2â€type macrophage polarization. American Journal of Reproductive Immunology, 2018, 80, e12996.	1.2	13
1169	Modulation of the colon cancer cell phenotype by pro-inflammatory macrophages: A preclinical model of surgery-associated inflammation and tumor recurrence. PLoS ONE, 2018, 13, e0192958.	1.1	15
1170	HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma. Cancer Letters, 2018, 432, 121-131.	3.2	13
1171	The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. Cell Death and Disease, 2018, 9, 687.	2.7	34
1172	Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells. Molecular Pharmacology, 2018, 94, 907-916.	1.0	11
1173	Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow. Nature Reviews Cancer, 2018, 18, 576-585.	12.8	106

#	Article	IF	Citations
1174	Negative regulation of TGF-β by AMPK and implications in the treatment of associated disorders. Acta Biochimica Et Biophysica Sinica, 2018, 50, 523-531.	0.9	18
1175	Roles for AXL and MERTK in Resistance to Cytotoxic and Targeted Therapies. , 2019, , 61-85.		1
1176	Pien Tze Huang (ç‰‡ä»”ç™€) Overcomes Doxorubicin Resistance and Inhibits Epithelial-Mesenchymal Transition in MCF-7/ADR Cells. Chinese Journal of Integrative Medicine, 2019, 25, 598-603.	0.7	8
1177	Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI. Oncogene, 2019, 38, 455-468.	2.6	165
1178	Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancer. Briefings in Bioinformatics, 2019, 20, 717-731.	3.2	20
1179	Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers. Breast Cancer Research, 2019, 21, 87.	2.2	26
1180	Special Issue on Molecular Research Efforts in Urothelial Carcinoma: Summary of Included Topics. International Journal of Molecular Sciences, 2019, 20, 3790.	1.8	1
1181	Deciphering Hydrodynamic and Drug-Resistant Behaviors of Metastatic EMT Breast Cancer Cells Moving in a Constricted Microcapillary. Journal of Clinical Medicine, 2019, 8, 1194.	1.0	11
1182	Application of Nanotechnology in Targeting of Cancer Stem Cells: A Review. International Journal of Stem Cells, 2019, 12, 227-239.	0.8	38
1183	Sulforaphane inhibits epithelialâ€“mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells. Journal of Nutritional Biochemistry, 2019, 72, 108219.	1.9	19
1184	Reductive responsive micelle overcoming multidrug resistance of breast cancer by co-delivery of DOX and specific antibiotic. Journal of Materials Chemistry B, 2019, 7, 6075-6086.	2.9	24
1185	Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. Scientific Reports, 2019, 9, 10845.	1.6	18
1186	Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells. Cancers, 2019, 11, 972.	1.7	4
1187	Long noncoding RNA HAGLR acts as a microRNAâ€143â€5p sponge to regulate epithelialâ€mesenchymal transition and metastatic potential in esophageal cancer by regulating LAMP3. FASEB Journal, 2019, 33, 10490-10504.	0.2	46
1188	Epithelial-mesenchymal transition markers screened in a cell-based model and validated in lung adenocarcinoma. BMC Cancer, 2019, 19, 680.	1.1	31
1189	Asymmetric Division Gene Neurl2 Mediates Twist2 Regulation of Self-Renewal of Mouse Lewis Lung Cancer Stem Cells. Journal of Cancer, 2019, 10, 3381-3388.	1.2	6
1190	Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. Cancers, 2019, 11, 934.	1.7	45
1191	Adenosine interaction with adenosine receptor A2a promotes gastric cancer metastasis by enhancing PI3Kâ€“AKTâ€“mTOR signaling. Molecular Biology of the Cell, 2019, 30, 2527-2534.	0.9	49

#	Article	IF	Citations
1192	Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition. Journal of Biological Chemistry, 2019, 294, 13681-13696.	1.6	25
1193	Circular RNAs in drug resistant tumors. Biomedicine and Pharmacotherapy, 2019, 118, 109233.	2.5	63
1194	CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Research, 2019, 79, 4439-4452.	0.4	44
1195	Selenoprotein M stimulates the proliferative and metastatic capacities of renal cell carcinoma through activating the PI3K/AKT/mTOR pathway. Cancer Medicine, 2019, 8, 4836-4844.	1.3	21
1196	Tenascin-C increases lung metastasis by impacting blood vessel invasions. Matrix Biology, 2019, 83, 26-47.	1.5	41
1198	An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma . OncoTargets and Therapy, 2019, Volume 12, 7005-7014.	1.0	27
1199	Stem Cells in Pituitary Tumors: Experimental Evidence Supporting Their Existence and Their Role in Tumor Clinical Behavior. Frontiers in Endocrinology, 2019, 10, 745.	1.5	9
1200	Six2 is negatively correlated with prognosis and facilitates epithelial-mesenchymal transition via TGF-Î²/Smad signal pathway in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2019, 18, 525-531.	0.6	10
1201	Redox-Mediated Mechanism of Chemoresistance in Cancer Cells. Antioxidants, 2019, 8, 471.	2.2	100
1202	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. Frontiers in Oncology, 2019, 9, 1049.	1.3	24
1203	Balancing STAT Activity as a Therapeutic Strategy. Cancers, 2019, 11, 1716.	1.7	18
1204	The paracrine induction of prostate cancer progression by caveolin-1. Cell Death and Disease, 2019, 10, 834.	2.7	41
1205	Study on TCP/AQM network congestion with adaptive neural network and barrier Lyapunov function. Neurocomputing, 2019, 363, 27-34.	3.5	17
1206	Investigation of anti-cancer and migrastatic properties of novel curcumin derivatives on breast and ovarian cancer cell lines. BMC Complementary and Alternative Medicine, 2019, 19, 273.	3.7	39
1207	Metastatic Breast Carcinomaâ€“Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression. Clinical Cancer Research, 2019, 25, 7229-7242.	3.2	26
1208	Transforming Growth Factor-Beta (TGFÎ²) Signaling Pathway in Cholangiocarcinoma. Cells, 2019, 8, 960.	1.8	25
1209	Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer. Experimental and Therapeutic Medicine, 2019, 18, 3014-3024.	0.8	6
1210	Tumor Dormancy and Interplay with Hypoxic Tumor Microenvironment. International Journal of Molecular Sciences, 2019, 20, 4305.	1.8	74

#	Article	IF	Citations
1211	A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Scientific Reports, 2019, 9, 12511.	1.6	13
1212	Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Breast Cancer Research, 2019, 21, 104.	2.2	45
1213	Sorcin: a novel potential target in therapies of cancers . Cancer Management and Research, 2019, Volume 11, 7327-7336.	0.9	7
1214	N-Acetyltransferase 1 Knockout Elevates Acetyl Coenzyme A Levels and Reduces Anchorage-Independent Growth in Human Breast Cancer Cell Lines. Journal of Oncology, 2019, 2019, 1-11.	0.6	20
1216	Next-generation nanotheranostics targeting cancer stem cells. Nanomedicine, 2019, 14, 2487-2514.	1.7	19
1217	High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition . OncoTargets and Therapy, 2019, Volume 12, 7405-7413.	1.0	26
1218	The Emerging Roles of Cancer Stem Cells and Wnt/Beta-Catenin Signaling in Hepatoblastoma. Cancers, 2019, 11, 1406.	1.7	34
1219	Decoupling of Nrf2 Expression Promotes Mesenchymal State Maintenance in Non-Small Cell Lung Cancer. Cancers, 2019, 11, 1488.	1.7	7
1220	Dynamics of Phenotypic Heterogeneity Associated with EMT and Stemness during Cancer Progression. Journal of Clinical Medicine, 2019, 8, 1542.	1.0	109
1221	High-Efficiency Isolation and Rapid Identification of Heterogeneous Circulating Tumor Cells (CTCs) Using Dual-Antibody-Modified Fluorescent-Magnetic Nanoparticles. ACS Applied Materials & Interfaces, 2019, 11, 39586-39593.	4.0	68
1222	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes and Development, 2019, 33, 1295-1318.	2.7	203
1223	Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC. Cell Death and Disease, 2019, 10, 703.	2.7	25
1224	Investigating epithelial-to-mesenchymal transition with integrated computational and experimental approaches. Physical Biology, 2019, 16, 031001.	0.8	26
1225	Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma. Laboratory Investigation, 2019, 99, 659-670.	1.7	23
1226	CD44 splice isoform switching determines breast cancer stem cell state. Genes and Development, 2019, 33, 166-179.	2.7	146
1228	Profiling of Invasive Breast Carcinoma Circulating Tumour Cellsâ€"Are We Ready for the â€˜Liquidâ€™ Revolution?. Cancers, 2019, 11, 143.	1.7	8
1229	Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine, 2019, 25, 185-197.	3.5	118
1230	Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 761-772.	1.9	7

#	Article	IF	Citations
1231	<scp>TARBP</scp>2â€mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma. Molecular Oncology, 2019, 13, 928-945.	2.1	24
1232	LncRNA MIR210HG promotes proliferation and invasion of non-small cell lung cancer by upregulating methylation of CACNA2D2 promoter via binding to DNMT1 . OncoTargets and Therapy, 2019, Volume 12, 3779-3790.	1.0	53
1233	CD133 receptor mediated delivery of STAT3 inhibitor for simultaneous elimination of cancer cells and cancer stem cells in oral squamous cell carcinoma. Medical Hypotheses, 2019, 129, 109241.	0.8	15
1234	Cancer Stem Cells in Lung Cancer: Roots of Drug Resistance and Targets for Novel Therapeutic Strategies. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 51-92.	0.1	1
1235	mPGES-1 as a new target to overcome acquired resistance to gefitinib in non-small cell lung cancer cell lines. Prostaglandins and Other Lipid Mediators, 2019, 143, 106344.	1.0	5
1236	Epithelial-mesenchymal transition of cancer cells using bioengineered hybrid scaffold composed of hydrogel/3D-fibrous framework. Scientific Reports, 2019, 9, 8997.	1.6	30
1237	Systems-level Analysis Reveals Multiple Modulators of Epithelial-mesenchymal Transition and Identifies DNAJB4 and CD81 as Novel Metastasis Inducers in Breast Cancer. Molecular and Cellular Proteomics, 2019, 18, 1756-1771.	2.5	29
1238	Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma. International Journal of Molecular Sciences, 2019, 20, 2746.	1.8	138
1239	Microfluidic co-culture of liver tumor spheroids with stellate cells for the investigation of drug resistance and intercellular interactions. Analyst, The, 2019, 144, 4233-4240.	1.7	39
1240	Tracking tumor evolution one-cell-at-a-time. Molecular and Cellular Oncology, 2019, 6, 1590089.	0.3	6
1241	Targeting Cancer Stem Cells: A Strategy for Effective Eradication of Cancer. Cancers, 2019, 11, 732.	1.7	134
1242	Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT . Cancer Management and Research, 2019, Volume 11, 5133-5146.	0.9	20
1244	miR-205-5p regulates epithelial-mesenchymal transition by targeting PTEN via PI3K/AKT signaling pathway in cisplatin-resistant nasopharyngeal carcinoma cells. Gene, 2019, 710, 103-113.	1.0	37
1245	p53-Mediated PI3K/AKT/mTOR Pathway Played a Role in Ptox^{Dpt}-Induced EMT Inhibition in Liver Cancer Cell Lines. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-15.	1.9	23
1246	Cancer Stem Cell Challenges in Melanoma Characterization and Treatment. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 115-135.	0.1	1
1247	Investigation of specific binding of designed oligodeoxynucleotide decoys to transcription factors in HT29 cell line undergoing epithelialâ€“mesenchymal transition (EMT). Journal of Cellular Physiology, 2019, 234, 22765-22774.	2.0	11
1248	INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma . OncoTargets and Therapy, 2019, Volume 12, 3491-3507.	1.0	13
1249	Mechanics and Actomyosin-Dependent Survival/Chemoresistance of Suspended Tumor Cells in Shear Flow. Biophysical Journal, 2019, 116, 1803-1814.	0.2	53

#	Article	IF	Citations
1250	Contribution of Epithelial Plasticity to Therapy Resistance. Journal of Clinical Medicine, 2019, 8, 676.	1.0	42
1251	Enrichment of cancer stemâ€like cells by the induction of epithelialâ€mesenchymal transition using lentiviral vector carrying Eâ€cadherin shRNA in HT29 cell line. Journal of Cellular Physiology, 2019, 234, 22935-22946.	2.0	9
1252	The Role Played by SLUG, an Epithelialâ€“Mesenchymal Transition Factor, in Invasion and Therapeutic Resistance of Malignant Glioma. Cellular and Molecular Neurobiology, 2019, 39, 769-782.	1.7	12
1253	Ovarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology. Case Reports in Oncology, 2019, 12, 241-247.	0.3	5
1254	Modularized Perturbation of Alternative Splicing Across Human Cancers. Frontiers in Genetics, 2019, 10, 246.	1.1	1
1255	Effect of asiatic acid on epithelialâ€‘mesenchymal transition of human alveolar epithelium A549 cells induced by TGFâ€Î²1. Oncology Letters, 2019, 17, 4285-4292.	0.8	14
1256	A spermine-conjugated lipophilic Pt(<scp>iv</scp>) prodrug designed to eliminate cancer stem cells in ovarian cancer. Chemical Communications, 2019, 55, 6106-6109.	2.2	20
1257	TGFÎ²-induced SMAD4-dependent Apoptosis Proceeded by EMT in CRC. Molecular Cancer Therapeutics, 2019, 18, 1312-1322.	1.9	20
1258	Drug development using pancreatic and lung organoid models. , 2019, , 323-342.		0
1259	Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy. Digestive Diseases and Sciences, 2019, 64, 3215-3227.	1.1	23
1260	Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience. Journal of Oncology, 2019, 2019, 1-31.	0.6	83
1261	Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature, 2019, 569, 131-135.	13.7	287
1262	Lulling the Cancer Cell into an Eternal Sleep. Cancer Research, 2019, 79, 1756-1757.	0.4	0
1263	Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 166.	3.5	181
1264	MDM2 promotes epithelial–mesenchymal transition through activation of Smad2/3 signaling pathway in lung adenocarcinoma . OncoTargets and Therapy, 2019, Volume 12, 2247-2258.	1.0	20
1265	Pan-cancer genomic amplifications underlie a WNT hyperactivation phenotype associated with stem cell-like features leading to poor prognosis. Translational Research, 2019, 208, 47-62.	2.2	9
1266	Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFÎ²/BMP signaling in triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 134.	3.5	31
1267	Cancer Pathology. , 2019, , 19-32.		0

#	Article	IF	Citations
1268	CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner . OncoTargets and Therapy, 2019, Volume 12, 1075-1084.	1.0	11
1269	Meeting the Challenge of Targeting Cancer Stem Cells. Frontiers in Cell and Developmental Biology, 2019, 7, 16.	1.8	109
1270	ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells. Cells, 2019, 8, 210.	1.8	10
1271	Dietary Phytochemicals Targeting Cancer Stem Cells. Molecules, 2019, 24, 899.	1.7	72
1272	Programming of macrophages by UV-irradiated apoptotic cancer cells inhibits cancer progression and lung metastasis. Cellular and Molecular Immunology, 2019, 16, 851-867.	4.8	31
1273	MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells. Cancer Research, 2019, 79, 2031-2041.	0.4	28
1274	Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells. Pharmaceuticals, 2019, 12, 33.	1.7	9
1275	HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. Journal of Experimental and Clinical Cancer Research, 2019, 38, 110.	3.5	89
1276	Plastin 3 down-regulation augments the sensitivity of MDA-MB-231 cells to paclitaxel via the p38 MAPK signalling pathway. Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 684-694.	1.9	15
1277	MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene, 2019, 700, 110-119.	1.0	55
1278	Novel K6-K14 keratin fusion enhances cancer stemness and aggressiveness in oral squamous cell carcinoma. Oncogene, 2019, 38, 5113-5126.	2.6	13
1279	Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme. Theranostics, 2019, 9, 1453-1473.	4.6	32
1280	Glutathione <i>S</i>â€transferase omega 1 inhibition activates <scp>JNK</scp>â€mediated apoptotic response in breast cancer stem cells. FEBS Journal, 2019, 286, 2167-2192.	2.2	34
1281	Protein arginine methyltransferase 5: A novel therapeutic target for tripleâ€negative breast cancers. Cancer Medicine, 2019, 8, 2414-2428.	1.3	49
1282	Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. Cellular Oncology (Dordrecht), 2019, 42, 405-421.	2.1	52
1283	Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT. Nature Communications, 2019, 10, 1637.	5.8	86
1284	URG11 promotes proliferation and induced apoptosis of LNCaP cells. International Journal of Molecular Medicine, 2019, 43, 2075-2085.	1.8	4
1285	Immobilized Transforming Growth Factor-Beta 1 in a Stiffness-Tunable Artificial Extracellular Matrix Enhances Mechanotransduction in the Epithelial Mesenchymal Transition of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces, 2019, 11, 14660-14671.	4.0	17

#	Article	IF	Citations
1287	Cancer Stem Cellâ€Platelet Hybrid Membraneâ€Coated Magnetic Nanoparticles for Enhanced Photothermal Therapy of Head and Neck Squamous Cell Carcinoma. Advanced Functional Materials, 2019, 29, 1807733.	7.8	137
1288	Synergistic effect of phototherapy and chemotherapy on bladder cancer cells. Journal of Photochemistry and Photobiology B: Biology, 2019, 193, 148-154.	1.7	5
1289	Demethylzeylasteral (T-96) inhibits triple-negative breast cancer invasion by blocking the canonical and non-canonical TGF-Î² signaling pathways. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 593-603.	1.4	20
1290	Spleen Tyrosine Kinaseâ€“Mediated Autophagy Is Required for Epithelialâ€“Mesenchymal Plasticity and Metastasis in Breast Cancer. Cancer Research, 2019, 79, 1831-1843.	0.4	95
1291	Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation. BMC Cancer, 2019, 19, 148.	1.1	27
1292	Nanotechnology in metastatic cancer treatment: Current Achievements and Future Research Trends. Journal of Cancer, 2019, 10, 1358-1369.	1.2	23
1293	Autophagy inhibition with chloroquine reverts paclitaxel resistance and attenuates metastatic potential in human nonsmall lung adenocarcinoma A549 cells via ROS mediated modulation of Î²-catenin pathway. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 414-433.	2.2	61
1294	Long non-coding RNA DNM3OS promotes tumor progression and EMT in gastric cancer by associating with Snail. Biochemical and Biophysical Research Communications, 2019, 511, 57-62.	1.0	20
1295	Low-dose anti-inflammatory combinatorial therapy reduced cancer stem cell formation in patient-derived preclinical models for tumour relapse prevention. British Journal of Cancer, 2019, 120, 407-423.	2.9	28
1296	EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemoâ^'/radioresistance in nasopharyngeal carcinoma. Journal of Experimental and Clinical Cancer Research, 2019, 38, 82.	3.5	28
1297	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine, 2019, 8, 205.	1.0	17
1298	Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. Advances in Biological Regulation, 2019, 72, 63-77.	1.4	19
1299	The Role of ACKR3 in Breast, Lung, and Brain Cancer. Molecular Pharmacology, 2019, 96, 819-825.	1.0	25
1300	Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer. Future Oncology, 2019, 15, 727-737.	1.1	11
1301	Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs. International Journal of Molecular Sciences, 2019, 20, 800.	1.8	34
1302	Yifei Tongluo, a Chinese Herbal Formula, Suppresses Tumor Growth and Metastasis and Exerts Immunomodulatory Effect in Lewis Lung Carcinoma Mice. Molecules, 2019, 24, 731.	1.7	6
1303	Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer. BMC Cancer, 2019, 19, 159.	1.1	7
1304	Genotoxic activity of l-asparaginase produced by Streptomyces ansochromogenes UFPEDA 3420. World Journal of Microbiology and Biotechnology, 2019, 35, 41.	1.7	5

#	Article	IF	Citations
1305	Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acidâ€induced epithelialâ€mesenchymal transition and stemness in HeLa, 5637 and SCCâ€15 cells. Oncology Reports, 2019, 41, 3545-3554.	1.2	9
1306	Expression and significance of c-kit and epithelial-mesenchymal transition (EMT) molecules in thymic epithelial tumors (TETs). Journal of Thoracic Disease, 2019, 11, 4602-4612.	0.6	10
1307	Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy. Molecular Cancer Research, 2019, 17, 2331-2340.	1.5	21
1308	Precautionary Principle: Cancer Prevention Efforts During Critical Periods of Growth and Development. Clinical Journal of Oncology Nursing, 2019, 23, 659-663.	0.3	0
1309	Exposing the Underlying Relationship of Cancer Metastasis to Metabolism and Epithelial-Mesenchymal Transitions. IScience, 2019, 21, 754-772.	1.9	33
1310	2. Stem cells and lung cancer: between advanced diagnostics and new therapeutics. , 2019, , 14-33.		0
1311	Characterization and printability of Sodium alginate -Gelatin hydrogel for bioprinting NSCLC co-culture. Scientific Reports, 2019, 9, 19914.	1.6	106
1312	Mechanism of miR-210 involved in epithelialâ€“mesenchymal transition of pancreatic cancer cells under hypoxia. Journal of Receptor and Signal Transduction Research, 2019, 39, 399-406.	1.3	25
1313	Radiogenomics of Oncology. Advances in Clinical Radiology, 2019, 1, 71-82.	0.1	0
1314	Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer. Journal of Ovarian Research, 2019, 12, 125.	1.3	13
1315	Cancer Stem Cells: Root of the Evil. Critical Reviews in Oncogenesis, 2019, 24, 69-87.	0.2	7
1316	Exploring the Potential of MicroRNA Let-7c as a Therapeutic for Prostate Cancer. Molecular Therapy - Nucleic Acids, 2019, 18, 927-937.	2.3	16
1317	Anticancer Properties of Curcumin and Interactions With the Circadian Timing System. Integrative Cancer Therapies, 2019, 18, 153473541988915.	0.8	6
1318	Reverse Phase Protein Arrays. Advances in Experimental Medicine and Biology, 2019, , .	0.8	1
1319	The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway. EBioMedicine, 2019, 49, 55-71.	2.7	30
1320	Anticipating critical transitions in epithelialâ€“hybrid-mesenchymal cell-fate determination. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26343-26352.	3.3	32
1321	Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology and Oncology, 2019, 12, 134.	6.9	296
1322	Pannexin1 Is Associated with Enhanced Epithelial-To-Mesenchymal Transition in Human Patient Breast Cancer Tissues and in Breast Cancer Cell Lines. Cancers, 2019, 11, 1967.	1.7	27

#	Article	IF	Citations
1323	Transcriptional Reprogramming and Inhibition of Tumor-propagating Stem-like Cells by EC-8042 in ERG-positive Prostate Cancer. European Urology Oncology, 2019, 2, 415-424.	2.6	8
1324	Clinical Significance of KIAA1199 as a Novel Target for Gastric Cancer Drug Therapy. Anticancer Research, 2019, 39, 6567-6573.	0.5	10
1325	WNT Signaling in Tumors: The Way to Evade Drugs and Immunity. Frontiers in Immunology, 2019, 10, 2854.	2.2	161
1326	Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. International Journal of Cancer, 2019, 145, 10-19.	2.3	33
1327	Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 148-157.	3.3	238
1328	A New Patient-Derived Metastatic Glioblastoma Cell Line: Characterisation and Response to Sodium Selenite Anticancer Agent. Cancers, 2019, 11, 12.	1.7	22
1329	Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-Î²B pathway. Biomedicine and Pharmacotherapy, 2019, 109, 1994-2004.	2.5	35
1330	Resveratrol potentially increased the tumoricidal effect of doxorubicin on SKOV3 cancer stem cells in vitro. Journal of Cellular Biochemistry, 2019, 120, 8430-8437.	1.2	16
1331	Daurinoline suppressed the migration and invasion of chemo-resistant human non-small cell lung cancer cells by reversing EMT and Notch-1 and sensitized the cells to Taxol. Environmental Toxicology and Pharmacology, 2019, 66, 109-115.	2.0	11
1332	Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. International Journal of Cancer, 2019, 145, 1179-1188.	2.3	199
1333	Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2019, 28, 7-18.	1.9	18
1334	Fractionated radiotherapy might induce epithelialâ€mesenchymal transition and radioresistance in a cellular context manner. Journal of Cellular Biochemistry, 2019, 120, 8601-8610.	1.2	19
1335	Interleukin-23 receptor signaling mediates cancer dormancy and radioresistance in human esophageal squamous carcinoma cells via the Wnt/Notch pathway. Journal of Molecular Medicine, 2019, 97, 177-188.	1.7	14
1336	Resistance to EGFR Targeting Treatments in Colorectal Cancer. , 2019, , 257-269.		1
1337	Correlation between SALL4 stemness marker and bone morphogenetic protein signaling genes in esophageal squamous cell carcinoma. Journal of Biochemical and Molecular Toxicology, 2019, 33, e22262.	1.4	7
1338	Knockdown GREM1 suppresses cell growth, angiogenesis, and epithelialâ€mesenchymal transition in colon cancer. Journal of Cellular Biochemistry, 2019, 120, 5583-5596.	1.2	24
1339	Single-Cell Mass Cytometry of Archived Human Epithelial Tissue for Decoding Cancer Signaling Pathways. Methods in Molecular Biology, 2019, 1884, 215-229.	0.4	7
1340	Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer Biology and Therapy, 2019, 20, 617-632.	1.5	21

#	Article	IF	Citations
1341	Dietary phytochemicals in the regulation of epithelial to mesenchymal transition and associated enzymes: A promising anticancer therapeutic approach. Seminars in Cancer Biology, 2019, 56, 196-218.	4.3	23
1342	New insights into the mechanisms of epithelialâ€“mesenchymal transition and implications for cancer. Nature Reviews Molecular Cell Biology, 2019, 20, 69-84.	16.1	2,319
1344	<scp>DLG</scp>5 suppresses breast cancer stem cellâ€like characteristics to restore tamoxifen sensitivity by inhibiting <scp>TAZ</scp> expression. Journal of Cellular and Molecular Medicine, 2019, 23, 512-521.	1.6	25
1345	Carcinogenesis: the cancer cellâ€“mast cell connection. Inflammation Research, 2019, 68, 103-116.	1.6	16
1346	Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer. Frontiers in Oncology, 2019, 9, 21.	1.3	37
1347	UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells. Journal of Oncology, 2019, 2019, 1-15.	0.6	38
1348	Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior. Breast Cancer Research and Treatment, 2019, 174, 649-659.	1.1	37
1349	Epigenetics and the Microbiome. , 2019, , 79-103.		0
1350	Blockade of integrin Î²3 signals to reverse the stem-like phenotype and drug resistance in melanoma. Cancer Chemotherapy and Pharmacology, 2019, 83, 615-624.	1.1	13
1351	TGF-Î²-induced alternative splicing of TAK1 promotes EMT and drug resistance. Oncogene, 2019, 38, 3185-3200.	2.6	64
1353	Bioengineered models to study tumor dormancy. Journal of Biological Engineering, 2019, 13, 3.	2.0	27
1354	MiRâ€30â€5p suppresses cell chemoresistance and stemness in colorectal cancer through <scp>USP</scp>22/Wnt/Î²â€catenin signaling axis. Journal of Cellular and Molecular Medicine, 2019, 23, 630-640.	1.6	62
1355	3D bioprinted glioma cellâ€laden scaffolds enriching glioma stem cells via epithelialâ€“mesenchymal transition. Journal of Biomedical Materials Research - Part A, 2019, 107, 383-391.	2.1	46
1356	Glypicanâ€3â€Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology, 2019, 70, 563-576.	3.6	65
1357	Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance. Journal of Cellular Physiology, 2019, 234, 3238-3253.	2.0	43
1358	CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPTâ€11â€resistant LoVo colon cancer cells via Gî±iâ€2 and Gî±q/11. Journal of Cellular Physiology, 2019, 234, 11822-11834.	2.0	59
1359	Three-Dimensional Organoids Reveal Therapy Resistance of Esophageal and Oropharyngeal Squamous Cell Carcinoma Cells. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 73-91.	2.3	102
1360	Phenotypic Plasticity and the Origins and Progression of Ovarian Cancer. , 2019, , 529-545.		2

#	Article	IF	Citations
1361	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. , 2019, 194, 161-184.		244
1362	Association between Morphological Patterns of Myometrial Invasion and Cancer Stem Cell Markers in Endometrial Endometrioid Carcinoma. Pathology and Oncology Research, 2019, 25, 123-130.	0.9	17
1363	Updates in pancreatic cancer: Modest gains and hopeful targets. Journal of Oncology Pharmacy Practice, 2019, 25, 101-109.	0.5	4
1364	Interactive functions of microRNAs in the miRâ€23aâ€27aâ€24â€2 cluster and the potential for targeted therapy in cancer. Journal of Cellular Physiology, 2020, 235, 6-16.	2.0	26
1365	Metformin in breast cancer: preclinical and clinical evidence. Current Problems in Cancer, 2020, 44, 100488.	1.0	81
1366	Effects and mechanisms of tea for the prevention and management of cancers: An updated review. Critical Reviews in Food Science and Nutrition, 2020, 60, 1693-1705.	5.4	89
1367	Î±-Actinin-4 regulates cancer stem cell properties and chemoresistance in cervical cancer. Carcinogenesis, 2020, 41, 940-949.	1.3	21
1368	ECM-Mimetic Multiresponsive Nanobullets Targeted Against Metastasizing Circulating Tumor Clusters in Breast Cancer. Annals of Biomedical Engineering, 2020, 48, 568-581.	1.3	3
1369	Truncation of MYH8 tail in AML: a novel prognostic marker with increase cell migration and epithelialâ€“mesenchymal transition utilizing RAF/MAPK pathway. Carcinogenesis, 2020, 41, 817-827.	1.3	10
1370	Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelialâ€mesenchymal transition in Pancâ€1 and MiaPaCaâ€2 pancreatic cancer cells. Journal of Cellular Biochemistry, 2020, 121, 508-523.	1.2	16
1371	Activated Wnt/Î²-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer. Life Sciences, 2020, 254, 116816.	2.0	10
1372	Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Seminars in Cancer Biology, 2020, 60, 351-361.	4.3	122
1373	An EMTâ€related gene signature for the prognosis of human bladder cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 605-617.	1.6	132
1374	Nuclear Factor Erythroid-Derived 2-Like 2-Induced Reductive Stress Favors Self-Renewal of Breast Cancer Stem-Like Cellsviathe FoxO3a-Bmi-1 Axis. Antioxidants and Redox Signaling, 2020, 32, 1313-1329.	2.5	41
1375	Repurposing Antibacterial AM404 As a Potential Anticancer Drug for Targeting Colorectal Cancer Stem-Like Cells. Cancers, 2020, 12, 106.	1.7	15
1376	GATA1-regulated JAG1 promotes ovarian cancer progression by activating Notch signal pathway. Protoplasma, 2020, 257, 901-910.	1.0	23
1377	Hydrogen sulfide modulates epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via HIF-1Î± activation. Biochemical Pharmacology, 2020, 172, 113775.	2.0	53
1378	KrÃ¼ppel-like factors in breast cancer: Function, regulation and clinical relevance. Biomedicine and Pharmacotherapy, 2020, 123, 109778.	2.5	22

#	Article	IF	Citations
1379	A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 391-397.	2.5	19
1380	Fluorescent Polysaccharide Nanogels for the Detection of Tumor Heterogeneity in Drugâ€Surviving Cancer Cells. Advanced Biology, 2020, 4, 1900213.	3.0	8
1381	Modulation of Extracellular Matrix Rigidity Via Riboflavinâ€mediated Photocrosslinking Regulates Invasive Motility and Treatment Response in a 3D Pancreatic Tumor Model. Photochemistry and Photobiology, 2020, 96, 365-372.	1.3	15
1382	MicroRNAs, a Promising Target for Breast Cancer Stem Cells. Molecular Diagnosis and Therapy, 2020, 24, 69-83.	1.6	22
1383	Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102124.	1.7	43
1384	Disruption of Cancer Metabolic SREBP1/miR-142-5p Suppresses Epithelialâ€“Mesenchymal Transition and Stemness in Esophageal Carcinoma. Cells, 2020, 9, 7.	1.8	31
1385	microRNA: The Impact on Cancer Stemness and Therapeutic Resistance. Cells, 2020, 9, 8.	1.8	46
1386	DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer. Frontiers in Pharmacology, 2020, 11, 1250.	1.6	17
1387	A Marine Collagen-Based Biomimetic Hydrogel Recapitulates Cancer Stem Cell Niche and Enhances Progression and Chemoresistance in Human Ovarian Cancer. Marine Drugs, 2020, 18, 498.	2.2	9
1388	Non-genetic mechanisms of therapeutic resistance in cancer. Nature Reviews Cancer, 2020, 20, 743-756.	12.8	290
1389	Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor. PLoS ONE, 2020, 15, e0226464.	1.1	13
1390	IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells . OncoTargets and Therapy, 2020, Volume 13, 9721-9730.	1.0	36
1391	Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy. Biomedicines, 2020, 8, 371.	1.4	11
1392	SOX2 and squamous cancers. Seminars in Cancer Biology, 2020, 67, 154-167.	4.3	16
1393	The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. Cancers, 2020, 12, 2973.	1.7	39
1394	Engineering Three-Dimensional Tumor Models to Study Glioma Cancer Stem Cells and Tumor Microenvironment. Frontiers in Cellular Neuroscience, 2020, 14, 558381.	1.8	38
1395	Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells. Gastroenterology Report, 2020, 8, 390-398.	0.6	25
1396	TGF-Î² causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 2020, 10, 7656-7670.	4.6	34

#	Article	IF	Citations
1397	Dynamic Malignant Wave of Ribosome-Insulted Gut Niche via the Wnt-CTGF/CCN2 Circuit. IScience, 2020, 23, 101076.	1.9	7
1398	LY75 Suppression in Mesenchymal Epithelial Ovarian Cancer Cells Generates a Stable Hybrid EOC Cellular Phenotype, Associated with Enhanced Tumor Initiation, Spreading and Resistance to Treatment in Orthotopic Xenograft Mouse Model. International Journal of Molecular Sciences, 2020, 21, 4992.	1.8	2
1399	Systematic analysis reveals a functional role for STAMBPL1 in the epithelialâ€“mesenchymal transition process across multiple carcinomas. British Journal of Cancer, 2020, 123, 1164-1177.	2.9	10
1400	The Roles of H19 in Regulating Inflammation and Aging. Frontiers in Immunology, 2020, 11, 579687.	2.2	34
1401	Environmental chemicals, breast cancer progression and drug resistance. Environmental Health, 2020, 19, 117.	1.7	91
1402	The Inhibitory Role of miR-486-5p on CSC Phenotype Has Diagnostic and Prognostic Potential in Colorectal Cancer. Cancers, 2020, 12, 3432.	1.7	14
1403	Astaxanthin Reduces Stemness Markers in BT20 and T47D Breast Cancer Stem Cells by Inhibiting Expression of Pontin and Mutant p53. Marine Drugs, 2020, 18, 577.	2.2	13
1404	Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance. Cells, 2020, 9, 2598.	1.8	62
1405	ABL1-dependent OTULIN phosphorylation promotes genotoxic Wnt/Î²-catenin activation to enhance drug resistance in breast cancers. Nature Communications, 2020, 11, 3965.	5.8	32
1406	Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer. Pathology Research and Practice, 2020, 216, 153158.	1.0	8
1407	High expression of miR-135b predicts malignant transformation and poor prognosis of gastric cancer. Life Sciences, 2020, 257, 118133.	2.0	18
1408	Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2020, 529, 760-765.	1.0	5
1409	Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer. World Journal of Surgical Oncology, 2020, 18, 181.	0.8	34
1410	The Expressions and Mechanisms of Sarcomeric Proteins in Cancers. Disease Markers, 2020, 2020, 1-16.	0.6	4
1411	DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression. Theranostics, 2020, 10, 8903-8923.	4.6	16
1412	Current Trends in ATRA Delivery for Cancer Therapy. Pharmaceutics, 2020, 12, 707.	2.0	37
1413	Saffron Crudes and Compounds Restrict MACC1-Dependent Cell Proliferation and Migration of Colorectal Cancer Cells. Cells, 2020, 9, 1829.	1.8	12
1414	MTA3 gene expression as potential gene biomarker for epithelial mesenchymal transition (EMT) study in colorectal cancer (CRC) cases. AIP Conference Proceedings, 2020, , .	0.3	0

#	Article	IF	Citations
1415	Embryonal tumors with multi-layered rosettes: a disease of dysregulated miRNAs. Journal of Neuro-Oncology, 2020, 150, 63-73.	1.4	9
1416	OTULIN couples WNT signaling to resistance in triple-negative breast cancer. Molecular and Cellular Oncology, 2020, 7, 1825904.	0.3	4
1417	Cancer stemness of CD10â€positive cells regulated by Hedgehog pathway promotes the resistance to cisplatin in oral squamous cell carcinoma. Oral Diseases, 2021, 27, 1403-1411.	1.5	11
1418	Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression. ACS Omega, 2020, 5, 28273-28284.	1.6	1
1419	Low expression of Talin1 is associated with advanced pathological features in colorectal cancer patients. Scientific Reports, 2020, 10, 17786.	1.6	18
1420	An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells. Molecular Cancer Therapeutics, 2020, 19, 2267-2277.	1.9	29
1421	Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells. Molecular Biology Reports, 2020, 47, 7017-7027.	1.0	6
1422	Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer. Oncologist, 2020, 25, e1968-e1979.	1.9	17
1423	miR-149 contributes to resistance of 5-FU in gastric cancer via targeting TREM2 and regulating Î²-catenin pathway. Biochemical and Biophysical Research Communications, 2020, 532, 329-335.	1.0	14
1424	Neferine sensitized Taxol-resistant nasopharygeal carcinoma to Taxol by inhibiting EMT via downregulating miR-130b-5p. Biochemical and Biophysical Research Communications, 2020, 531, 573-580.	1.0	11
1425	EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway. Cancer Research, 2020, 80, 5035-5050.	0.4	39
1426	Cancer stem cell generation during epithelial-mesenchymal transition is temporally gated by intrinsic circadian clocks. Clinical and Experimental Metastasis, 2020, 37, 617-635.	1.7	19
1427	Back to the Future: Rethinking the Great Potential of lncRNAS for Optimizing Chemotherapeutic Response in Ovarian Cancer. Cancers, 2020, 12, 2406.	1.7	17
1428	Branched Î±-helical peptides enhanced antitumor efficacy and selectivity. Biomaterials Science, 2020, 8, 6387-6394.	2.6	4
1429	Obg-like ATPase 1 inhibited oral carcinoma cell metastasis through TGFÎ²/SMAD2 axis in vitro. BMC Molecular and Cell Biology, 2020, 21, 65.	1.0	3
1430	YAP-Mediated Repression of HRK Regulates Tumor Growth, Therapy Response, and Survival Under Tumor Environmental Stress in Neuroblastoma. Cancer Research, 2020, 80, 4741-4753.	0.4	12
1431	DNER promotes epithelialâ€“mesenchymal transition and prevents chemosensitivity through the Wnt/Î²-catenin pathway in breast cancer. Cell Death and Disease, 2020, 11, 642.	2.7	29
1432	The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer. Cancers, 2020, 12, 2249.	1.7	13

#	Article	IF	Citations
1433	Extracellular Vesicle-Based Communication May Contribute to the Co-Evolution of Cancer Stem Cells and Cancer-Associated Fibroblasts in Anti-Cancer Therapy. Cancers, 2020, 12, 2324.	1.7	9
1434	Human Papillomavirus 16 (HPV16) E2 Repression of TWIST1 Transcription Is a Potential Mediator of HPV16 Cancer Outcomes. MSphere, 2020, 5, .	1.3	12
1435	Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization. Cell Death and Disease, 2020, 11, 1073.	2.7	11
1436	Epigenetics in Breast Cancer Therapyâ€"New Strategies and Future Nanomedicine Perspectives. Cancers, 2020, 12, 3622.	1.7	36
1437	Expression pattern of ALDH1, E-cadherin, Vimentin and Twist in early and late onset sporadic colorectal cancer. Biomarkers in Medicine, 2020, 14, 1371-1382.	0.6	7
1438	Analysis of Melanoma Secretome for Factors That Directly Disrupt the Barrier Integrity of Brain Endothelial Cells. International Journal of Molecular Sciences, 2020, 21, 8193.	1.8	7
1439	LncRNA AC010789.1 Promotes Colorectal Cancer Progression by Targeting MicroRNA-432-3p/ZEB1 Axis and the Wnt/Î²-Catenin Signaling Pathway. Frontiers in Cell and Developmental Biology, 2020, 8, 565355.	1.8	16
1440	NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence via the induction of ASCT2. International Journal of Biological Sciences, 2020, 16, 3100-3115.	2.6	13
1441	The role of epithelial-mesenchymal transition in regulating radioresistance. Critical Reviews in Oncology/Hematology, 2020, 150, 102961.	2.0	45
1442	Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines. British Journal of Cancer, 2020, 123, 101-113.	2.9	38
1443	Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody. Scientific Reports, 2020, 10, 6810.	1.6	14
1444	Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer. Clinical Breast Cancer, 2020, 20, 275-282.	1.1	4
1445	MiR-153 reduces stem cell-like phenotype and tumor growth of lung adenocarcinoma by targeting Jagged1. Stem Cell Research and Therapy, 2020, 11, 170.	2.4	17
1446	Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G₀/G₁ Cell Cycle Arrest and Intrinsic Apoptosis. Anticancer Research, 2020, 40, 3209-3220.	0.5	31
1447	Mitochondrial DNA alterations may influence the cisplatin responsiveness of oral squamous cell carcinoma. Scientific Reports, 2020, 10, 7885.	1.6	37
1448	Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity. Frontiers in Molecular Biosciences, 2020, 7, 63.	1.6	38
1449	Exosomes in hypoxia-induced remodeling of the tumor microenvironment. Cancer Letters, 2020, 488, 1-8.	3.2	55
1450	Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT. Oncogene, 2020, 39, 5152-5164.	2.6	33

#	Article	IF	Citations
1451	Circulating tumour cells in head and neck cancers: Biological insights. Journal of Oral Pathology and Medicine, 2020, 49, 842-848.	1.4	3
1452	Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models. Materials Science and Engineering C, 2020, 116, 111229.	3.8	30
1453	Advanced High-Content-Screening Applications of Clonogenicity in Cancer. SLAS Discovery, 2020, 25, 734-743.	1.4	13
1454	Cancer Biology and Prevention in Diabetes. Cells, 2020, 9, 1380.	1.8	39
1455	Role of CC Chemokines Subfamily in the Platinum Drugs Resistance Promotion in Cancer. Frontiers in Immunology, 2020, 11, 901.	2.2	24
1456	The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness. Cancers, 2020, 12, 1582.	1.7	26
1457	Extracellular BMP Antagonists, Multifaceted Orchestrators in the Tumor and Its Microenvironment. International Journal of Molecular Sciences, 2020, 21, 3888.	1.8	16
1458	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	1.8	46
1459	RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. Journal of Cellular Physiology, 2020, 235, 7261-7272.	2.0	34
1460	Tumor Cell Invasion in Glioblastoma. International Journal of Molecular Sciences, 2020, 21, 1932.	1.8	154
1461	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. Nature Reviews Urology, 2020, 17, 292-307.	1.9	59
1462	Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression. Medical Oncology, 2020, 37, 24.	1.2	68
1463	TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ. Oncogene, 2020, 39, 3710-3725.	2.6	19
1464	A novel miR-200c/c-myc negative regulatory feedback loop is essential to the EMT process, CSC biology and drug sensitivity in nasopharyngeal cancer. Experimental Cell Research, 2020, 391, 111817.	1.2	21
1465	ZEB1: A Critical Regulator of Cell Plasticity, DNA Damage Response, and Therapy Resistance. Frontiers in Molecular Biosciences, 2020, 7, 36.	1.6	112
1466	CBX7 binds the E-box to inhibit TWIST-1 function and inhibit tumorigenicity and metastatic potential. Oncogene, 2020, 39, 3965-3979.	2.6	27
1467	TGF-beta: a master immune regulator. Expert Opinion on Therapeutic Targets, 2020, 24, 427-438.	1.5	101
1468	Upregulation of Fucosyltransferase 3, 8 and protein O-Fucosyltransferase 1, 2 genes in esophageal cancer stem-like cells (CSLCs). Glycoconjugate Journal, 2020, 37, 319-327.	1.4	11

#	Article	IF	Citations
1469	Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rbâ€E2F signaling and epithelialâ€mesenchymal transition. Cancer Science, 2020, 111, 1422-1434.	1.7	19
1470	LncRNA SNHG3 promotes bladder cancer proliferation and metastasis through miRâ€515â€5p/GINS2 axis. Journal of Cellular and Molecular Medicine, 2020, 24, 9231-9243.	1.6	49
1471	TGF-Î² induced EMT and stemness characteristics are associated with epigenetic regulation in lung cancer. Scientific Reports, 2020, 10, 10597.	1.6	93
1472	p70S6K Promotes Acquired Resistance of Erlotinib Through Induction of Epithelial-Mesenchymal Transition in Non-Small Cell Lung Carcinoma . OncoTargets and Therapy, 2020, Volume 13, 5257-5270.	1.0	4
1473	The Role of Glypicans in Cancer Progression and Therapy. Journal of Histochemistry and Cytochemistry, 2020, 68, 841-862.	1.3	42
1474	Nanotechnology-Based Cisplatin Intracellular Delivery to Enhance Chemo-Sensitivity of Ovarian Cancer . International Journal of Nanomedicine, 2020, Volume 15, 4793-4810.	3.3	18
1475	Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resistance Updates, 2020, 53, 100715.	6.5	275
1476	Protein Tyrosine Phosphatases in Tumor Progression and Metastasis: Promoter or Protection?. , 0, , .		6
1477	3D culture technologies of cancer stem cells: promising ex vivo tumor models. Journal of Tissue Engineering, 2020, 11, 204173142093340.	2.3	47
1478	MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma. BMC Cancer, 2020, 20, 597.	1.1	21
1479	<scp>CEACAM6</scp> promotes cisplatin resistance in lung adenocarcinoma and is regulated by <scp>microRNA</scp>â€146a and <scp>microRNA</scp>â€26a. Thoracic Cancer, 2020, 11, 2473-2482.	0.8	11
1480	Phenyl boronic acid-modified lipid nanocarriers of niclosamide for targeting triple-negative breast cancer. Nanomedicine, 2020, 15, 1551-1565.	1.7	18
1481	Impact of Age-Related Genetic Differences on the Therapeutic Outcome of Papillary Thyroid Cancer. Cancers, 2020, 12, 448.	1.7	8
1482	Multistability in the epithelial-mesenchymal transition network. BMC Bioinformatics, 2020, 21, 71.	1.2	31
1483	The malignancy of liver cancer cells is increased by IL-4/ERK/AKT signaling axis activity triggered by irradiated endothelial cells. Journal of Radiation Research, 2020, 61, 376-387.	0.8	14
1484	Spindle cell renal cell carcinoma diagnosed after sunitinib treatment for chromophobe renal cell carcinoma. IJU Case Reports, 2020, 3, 36-39.	0.1	0
1485	Transglutaminase-2 facilitates extracellular vesicle-mediated establishment of the metastatic niche. Oncogenesis, 2020, 9, 16.	2.1	89
1486	Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy. Frontiers in Molecular Biosciences, 2019, 6, 160.	1.6	596

#	Article	IF	Citations
1487	Gain-of-Function Mutations in p53 in Cancer Invasiveness and Metastasis. International Journal of Molecular Sciences, 2020, 21, 1334.	1.8	20
1488	Dual targeting of TGF-Î² and PD-L1 via a bifunctional anti-PD-L1/TGF-Î²RII agent: status of preclinical and clinical advances. , 2020, 8, e000433.		166
1489	Hepatocellular Carcinoma Cells with Downregulated ZEB2 Become Resistant to Resveratrol by Concomitant Induction of ABCG2 Expression. Molecular Biology, 2020, 54, 75-81.	0.4	4
1490	The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells. Cancer Cell, 2020, 37, 226-242.e7.	7.7	117
1491	Hepatic stellate cells promote the progression of hepatocellular carcinoma through microRNA-1246-RORÎ±-Wnt/Î²-Catenin axis. Cancer Letters, 2020, 476, 140-151.	3.2	34
1492	Human Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype. Cancers, 2020, 12, 226.	1.7	24
1493	Silencing of FOXA2 decreases Eâ€cadherin expression and is associated with lymph node metastasis in oral cancer. Oral Diseases, 2020, 26, 756-765.	1.5	15
1494	Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFÎ² Signaling Pathway in Breast Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 805.	1.8	18
1495	ATP-responsive mitochondrial probes for monitoring metabolic processes of glioma stem cells in a 3D model. Chemical Science, 2020, 11, 2744-2749.	3.7	20
1496	Angiocrine endothelium: from physiology to cancer. Journal of Translational Medicine, 2020, 18, 52.	1.8	53
1497	Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines. Cancers, 2020, 12, 1117.	1.7	9
1498	Suppression of cancer stem cells. , 2020, , 365-398.		0
1499	Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. Cancer Cell, 2020, 37, 471-484.	7.7	485
1500	Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 27, 102195.	1.7	30
1501	Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State. Molecular and Cellular Proteomics, 2020, 19, 375-389.	2.5	26
1502	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. JCO Precision Oncology, 2020, 4, 319-334.	1.5	67
1503	Medicinal Plants Used in Traditional Management of Cancer in Uganda: A Review of Ethnobotanical Surveys, Phytochemistry, and Anticancer Studies. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-26.	0.5	60
1504	Role of Wnt/Î²-Catenin Signaling in the Chemoresistance Modulation of Colorectal Cancer. BioMed Research International, 2020, 2020, 1-9.	0.9	69

#	Article	IF	Citations
1505	A Feedback Loop Comprising EGF/TGFÎ± Sustains TFCP2-Mediated Breast Cancer Progression. Cancer Research, 2020, 80, 2217-2229.	0.4	18
1506	Revisiting Cancer Stem Cells as the Origin of Cancer-Associated Cells in the Tumor Microenvironment: A Hypothetical View from the Potential of iPSCs. Cancers, 2020, 12, 879.	1.7	44
1507	The Emerging Roles of Exosomes as EMT Regulators in Cancer. Cells, 2020, 9, 861.	1.8	70
1508	Genetic characteristics of gastric-type mucinous carcinoma of the uterine cervix. Modern Pathology, 2021, 34, 637-646.	2.9	32
1509	Turning liabilities into opportunities: Off-target based drug repurposing in cancer. Seminars in Cancer Biology, 2021, 68, 209-229.	4.3	39
1511	TGFÎ² biology in cancer progression and immunotherapy. Nature Reviews Clinical Oncology, 2021, 18, 9-34.	12.5	420
1512	The oncogenic potential of NANOG: An important cancer induction mediator. Journal of Cellular Physiology, 2021, 236, 2443-2458.	2.0	35
1513	Combined inhibition of CD73 and ZEB1 by Arg-Gly-Asp (RGD)-targeted nanoparticles inhibits tumor growth. Colloids and Surfaces B: Biointerfaces, 2021, 197, 111421.	2.5	18
1514	OSR1 phosphorylates the Smad2/3 linker region and induces TGF-Î²1 autocrine to promote EMT and metastasis in breast cancer. Oncogene, 2021, 40, 68-84.	2.6	20
1515	AXL Inhibition Induces DNA Damage and Replication Stress in Nonâ€“Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research, 2021, 19, 485-497.	1.5	32
1516	Deep tumorâ€penetrated nanosystem eliminates cancer stem cell for highly efficient liver cancer therapy. Chemical Engineering Journal, 2021, 421, 127874.	6.6	7
1517	EMT, cancer stem cells and autophagy; The three main axes of metastasis. Biomedicine and Pharmacotherapy, 2021, 133, 110909.	2.5	238
1518	Applications of Surface Modification Technologies in Nanomedicine for Deep Tumor Penetration. Advanced Science, 2021, 8, 2002589.	5.6	124
1519	Direct and Indirect Regulators of Epithelialâ€“Mesenchymal Transitionâ€“Mediated Immunosuppression in Breast Carcinomas. Cancer Discovery, 2021, 11, 1286-1305.	7.7	76
1520	Glioma stem cells and their roles within the hypoxic tumor microenvironment. Theranostics, 2021, 11, 665-683.	4.6	89
1521	Astragaloside IV enhanced carboplatin sensitivity in prostate cancer by suppressing AKT/NF-ÎºB signaling pathway. Biochemistry and Cell Biology, 2021, 99, 214-222.	0.9	10
1522	Molecular subtypes of colorectal cancer: AnÂemerging therapeutic opportunity for personalized medicine. Genes and Diseases, 2021, 8, 133-145.	1.5	71
1523	Ovalitenone Inhibits the Migration of Lung Cancer Cells via the Suppression of AKT/mTOR and Epithelial-to-Mesenchymal Transition. Molecules, 2021, 26, 638.	1.7	6

#	Article	IF	Citations
1524	Anoikis and the Human Gut Epithelium in Health and Disease. , 2021, , 95-126.		3
1525	Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. Journal of Experimental and Clinical Cancer Research, 2021, 40, 28.	3.5	72
1526	Mechanisms of chemoresistance and approaches to overcome its impact in gynecologic cancers. , 2021, , 77-126.		1
1527	Phenotypic plasticity: The emergence of cancer stem cells, collective cell migration, and the impact on immune surveillance. , 2021, , 183-190.		0
1528	Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer. , 2021, 4, 684-709.		9
1529	Engineered Fe₃O₄-based nanomaterials for diagnosis and therapy of cancer. New Journal of Chemistry, 2021, 45, 7918-7941.	1.4	13
1530	Hypoxia-induced Nur77 activates PI3K/Akt signaling via suppression of Dicer/let-7i-5p to induce epithelial-to-mesenchymal transition. Theranostics, 2021, 11, 3376-3391.	4.6	17
1531	The Role of ZEB2 Expression in Pediatric and Adult Glioblastomas. Anticancer Research, 2021, 41, 175-185.	0.5	3
1532	MEDAG enhances breast cancer progression and reduces epirubicin sensitivity through the AKT/AMPK/mTOR pathway. Cell Death and Disease, 2021, 12, 97.	2.7	17
1533	Research progress of EMT in Cancer Metastasis. E3S Web of Conferences, 2021, 245, 03049.	0.2	1
1534	Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer. Theranostics, 2021, 11, 6592-6606.	4.6	9
1535	miR-30a/SOX4 Double Negative Feedback Loop is modulated by Disulfiram and regulates EMT and Stem Cell-like properties in Breast Cancer. Journal of Cancer, 2021, 12, 5053-5065.	1.2	8
1536	PGC7 promotes tumor oncogenic dedifferentiation through remodeling DNA methylation pattern for key developmental transcription factors. Cell Death and Differentiation, 2021, 28, 1955-1970.	5.0	21
1537	Therapeutic approaches to overcome temozolomide resistance in glioblastoma. , 2021, , 507-545.		1
1538	Opuntia spp. Benefits in Chronic Diseases. , 2021, , 423-455.		0
1539	Cancer recurrence and lethality are enabled by enhanced survival and reversible cell cycle arrest of polyaneuploid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	61
1540	GTW inhibits the Epithelial to Mesenchymal Transition of Epithelial Ovarian Cancer via ILK/AKT/GSK3Î²/Slug Signalling Pathway. Journal of Cancer, 2021, 12, 1386-1397.	1.2	6
1541	Apolipoprotein C1 stimulates the malignant process of renal cell carcinoma via the Wnt3a signaling. Cancer Cell International, 2021, 21, 41.	1.8	8

#	Article	IF	Citations
1542	Signaling and Drug Resistance. Current Human Cell Research and Applications, 2021, , 79-94.	0.1	0
1543	HIF-Prolyl Hydroxylase Domain Proteins (PHDs) in Cancerâ€"Potential Targets for Anti-Tumor Therapy?. Cancers, 2021, 13, 988.	1.7	16
1544	Paper-supported co-culture system for dynamic investigations of the lung-tropic migration of breast cancer cells. Biomedical Materials (Bristol), 2021, 16, 025028.	1.7	4
1545	Epigenetic targeting of cancer stem cells by polyphenols (cancer stem cells targeting). Phytotherapy Research, 2021, 35, 3649-3664.	2.8	12
1546	A microfluidic platform for dissociating clinical scale tissue samples into single cells. Biomedical Microdevices, 2021, 23, 10.	1.4	5
1547	Small extracellular vesicles deliver TGFâ€Î²1 and promote adriamycin resistance in breast cancer cells. Molecular Oncology, 2021, 15, 1528-1542.	2.1	2
1548	Linking EMT programmes to normal and neoplastic epithelial stem cells. Nature Reviews Cancer, 2021, 21, 325-338.	12.8	273
1549	The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 600373.	1.6	3
1550	Roles of the H19/microRNAâ€'675 axis in the proliferation and epithelialâ€'mesenchymal transition of human cutaneous squamous cell carcinoma cells. Oncology Reports, 2021, 45, .	1.2	16
1551	Mitotic kinases as drivers of the epithelial-to-mesenchymal transition and as therapeutic targets against breast cancers. Experimental Biology and Medicine, 2021, 246, 1036-1044.	1.1	5
1552	MiR-21 Is Required for the Epithelialâ€"Mesenchymal Transition in MDA-MB-231 Breast Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 1557.	1.8	29
1553	The emerging role of estrogen related receptorÎ± in complications of nonâ€'small cell lung cancers (Review). Oncology Letters, 2021, 21, 258.	0.8	11
1554	Evaluating the Epithelial-Mesenchymal Program in Human Breast Epithelial Cells Cultured in Soft Agar Using a Novel Macromolecule Extraction Protocol. Cancers, 2021, 13, 807.	1.7	7
1555	Clinico-Pathological Importance of miR-146a in Lung Cancer. Diagnostics, 2021, 11, 274.	1.3	19
1556	MRPL13 Promotes Tumor Cell Proliferation, Migration and EMT Process in Breast Cancer Through the PI3K-AKT-mTOR Pathway. Cancer Management and Research, 2021, Volume 13, 2009-2024.	0.9	23
1557	Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition. Translational Lung Cancer Research, 2021, 10, 1424-1443.	1.3	19
1558	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 2021, 13, 1538.	1.7	37
1559	Expanding Roles of De Novo Lipogenesis in Breast Cancer. International Journal of Environmental Research and Public Health, 2021, 18, 3575.	1.2	24

#	Article	IF	Citations
1560	Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types. Journal of Translational Medicine, 2021, 19, 124.	1.8	7
1561	The critical role of peroxiredoxin-2 in colon cancer stem cells. Aging, 2021, 13, 11170-11187.	1.4	10
1562	Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome. Cancer Letters, 2021, 501, 114-123.	3.2	7
1563	Thinking Differently about Cancer Treatment Regimens. Cancer Discovery, 2021, 11, 1016-1023.	7.7	29
1564	Shc3 promotes hepatocellular carcinoma stemness and drug resistance by interacting with Î²-catenin to inhibit its ubiquitin degradation pathway. Cell Death and Disease, 2021, 12, 278.	2.7	18
1565	Targeting Genome Stability in Melanomaâ€"A New Approach to an Old Field. International Journal of Molecular Sciences, 2021, 22, 3485.	1.8	4
1566	Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC). Journal of Thoracic Disease, 2021, 13, 1370-1379.	0.6	7
1567	Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer. Cancers, 2021, 13, 1316.	1.7	5
1568	Olig2 regulates p53-mediated apoptosis, migration and invasion of melanoma cells. Scientific Reports, 2021, 11, 7778.	1.6	7
1569	Cancer Stem Cells and Neovascularization. Cells, 2021, 10, 1070.	1.8	23
1570	PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers, 2021, 13, 2168.	1.7	28
1571	Post-transcriptional repression of circadian component CLOCK regulates cancer-stemness in murine breast cancer cells. ELife, 2021, 10, .	2.8	12
1572	Exosomal microRNAs in colorectal cancer: Overcoming barriers of the metastatic cascade (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	16
1573	CASB: a concanavalin Aâ€based sample barcoding strategy for singleâ€cell sequencing. Molecular Systems Biology, 2021, 17, e10060.	3.2	14
1574	Isolation and Characterization of Human Colon Adenocarcinoma Stem-Like Cells Based on the Endogenous Expression of the Stem Markers. International Journal of Molecular Sciences, 2021, 22, 4682.	1.8	6
1575	Circular RNA hsa_circ_0003288 induces EMT and invasion by regulating hsa_circ_0003288/miR-145/PD-L1 axis in hepatocellular carcinoma. Cancer Cell International, 2021, 21, 212.	1.8	41
1576	MicroRNA Expression Profile Distinguishes Glioblastoma Stem Cells from Differentiated Tumor Cells. Journal of Personalized Medicine, 2021, 11, 264.	1.1	12
1577	Induction of the epithelial-mesenchymal transition in the endometrium by chronic endometritis in infertile patients. PLoS ONE, 2021, 16, e0249775.	1.1	12

#	Article	IF	Citations
1578	Targeted PD-L1 PLGA/liposomes-mediated luteolin therapy for effective liver cancer cell treatment. Journal of Biomaterials Applications, 2021, 36, 843-850.	1.2	16
1579	Inhibition of the Notch signaling pathway attenuates progression of cell motility, metastasis, and epithelial-to-mesenchymal transition-like phenomena induced by low concentrations of cisplatin in osteosarcoma. European Journal of Pharmacology, 2021, 899, 174058.	1.7	11
1580	CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5. Cell Death and Disease, 2021, 12, 464.	2.7	19
1581	Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors. Cells, 2021, 10, 1142.	1.8	12
1582	Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells. International Journal of Molecular Sciences, 2021, 22, 5059.	1.8	18
1583	Regulatory effect of microRNAâ€‘223â€‘3p on breast cancer cell processes via the Hippo/Yap signaling pathway. Oncology Letters, 2021, 22, 516.	0.8	11
1584	Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. Cancers, 2021, 13, 2666.	1.7	79
1585	Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy. Biomedicines, 2021, 9, 500.	1.4	33
1586	Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice. Cancers, 2021, 13, 2189.	1.7	8
1587	Our Journey Beyond Sunset Boulevard: Evidence-Based Analysis of Tumor-Targeted Cancer Gene Therapy Shines a Critical Spotlight on Long-Term Cancer-Free Survival. , 0, , .		0
1588	Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines. Biology, 2021, 10, 467.	1.3	7
1589	The ZEB2â€dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer. Molecular Oncology, 2021, 15, 2065-2083.	2.1	18
1590	Jorunnamycin A Suppresses Stem-Like Phenotypes and Sensitizes Cisplatin-Induced Apoptosis in Cancer Stem-Like Cell-Enriched Spheroids of Human Lung Cancer Cells. Marine Drugs, 2021, 19, 261.	2.2	6
1591	SMAD4 Expression in Renal Cell Carcinomas Correlates With a Stem-Cell Phenotype and Poor Clinical Outcomes. Frontiers in Oncology, 2021, 11, 581172.	1.3	5
1592	Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A. Scientific Reports, 2021, 11, 10652.	1.6	9
1593	Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy. Cancers, 2021, 13, 2491.	1.7	9
1594	Molecular and Metabolic Reprogramming: Pulling the Strings Toward Tumor Metastasis. Frontiers in Oncology, 2021, 11, 656851.	1.3	9
1595	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. Cancers, 2021, 13, 2907.	1.7	3

#	Article	IF	Citations
1596	Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 194.	3.5	17
1597	Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells. Current Oncology, 2021, 28, 2150-2172.	0.9	9
1598	MCRS1 EXPRESSION MORE IN TUMOR PART AND SERVES AS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA. , 2021, , 72-75.		0
1599	Nannocystin Ax, a natural elongation factor 1Î± inhibitor from Nannocystis sp., suppresses epithelial-mesenchymal transition, adhesion and migration in lung cancer cells. Toxicology and Applied Pharmacology, 2021, 420, 115535.	1.3	5
1600	Repurposing of Antimicrobial Agents for Cancer Therapy: What Do We Know?. Cancers, 2021, 13, 3193.	1.7	31
1601	Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. Cancers, 2021, 13, 2980.	1.7	8
1602	Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-Î²-treated epithelial cancer cells. Scientific Reports, 2021, 11, 12763.	1.6	8
1603	Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Pancreatology, 2021, 21, 771-778.	0.5	4
1604	FHL3 Contributes to EMT and Chemotherapy Resistance Through Up-Regulation of Slug and Activation of TGFÎ²/Smad-Independent Pathways in Gastric Cancer. Frontiers in Oncology, 2021, 11, 649029.	1.3	15
1605	Small interferingâ€‘high mobility group A2 attenuates epithelialâ€‘mesenchymal transition in thymic cancer cells via the Wnt/Î²â€‘catenin pathway. Oncology Letters, 2021, 22, 586.	0.8	5
1606	Repurposing of Anticancer Stem Cell Drugs in Brain Tumors. Journal of Histochemistry and Cytochemistry, 2021, 69, 002215542110254.	1.3	5
1607	Activity of trastuzumab emtansine (T-DM1) in 3D cell culture. Breast Cancer Research and Treatment, 2021, 188, 65-75.	1.1	7
1608	Understanding the Central Role of Citrate in the Metabolism of Cancer Cells and Tumors: An Update. International Journal of Molecular Sciences, 2021, 22, 6587.	1.8	51
1609	The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. Npj Precision Oncology, 2021, 5, 56.	2.3	44
1610	Pro-Health and Anti-Cancer Activity of Fungal Fractions Isolated from Milk-Supplemented Cultures of Lentinus (Pleurotus) Sajor-caju. Biomolecules, 2021, 11, 1089.	1.8	6
1611	Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma. Frontiers in Oncology, 2021, 11, 641522.	1.3	19
1612	Ethnobotanical Study of Medicinal Plants Used for Management of Cancer in Karonga District, Northern Malawi. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 1622-1631.	0.9	5
1613	Abnormal function of telomere protein TRF2 induces cell mutation and the effects of environmental tumorâ€‘promoting factors (Review). Oncology Reports, 2021, 46, .	1.2	11

#	Article	IF	Citations
1614	Is Curcumin the Answer to Future Chemotherapy Cocktail?. Molecules, 2021, 26, 4329.	1.7	19
1615	Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications. Frontiers in Molecular Biosciences, 2021, 8, 689139.	1.6	21
1616	Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs. Cancers, 2021, 13, 3697.	1.7	41
1617	Prognostic role and biologic features of Musashi-2 expression in colon polyps and during colorectal cancer progression. PLoS ONE, 2021, 16, e0252132.	1.1	5
1618	TRIB2 Stimulates Cancer Stem-Like Properties through Activating the AKT-GSK3Î²-Î²-Catenin Signaling Axis. Molecules and Cells, 2021, 44, 481-492.	1.0	3
1619	FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Molecular Therapy, 2021, 29, 2583-2600.	3.7	39
1620	Norcycloartocarpin targets Akt and suppresses Akt-dependent survival and epithelial-mesenchymal transition in lung cancer cells. PLoS ONE, 2021, 16, e0254929.	1.1	4
1621	Dynamic EMT: a multiâ€tool for tumor progression. EMBO Journal, 2021, 40, e108647.	3.5	291
1622	Challenges for Better Diagnosis and Management of Pancreatic and Biliary Tract Cancers Focusing on Blood Biomarkers: A Systematic Review. Cancers, 2021, 13, 4220.	1.7	1
1623	The Role of the IL-6 Cytokine Family in Epithelialâ€“Mesenchymal Plasticity in Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 8334.	1.8	46
1624	Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway. World Journal of Surgical Oncology, 2021, 19, 232.	0.8	12
1625	The Function of the Mutant p53-R175H in Cancer. Cancers, 2021, 13, 4088.	1.7	36
1626	The plasticity of mRNA translation during cancer progression and therapy resistance. Nature Reviews Cancer, 2021, 21, 558-577.	12.8	100
1627	The Role of Curcumin in Cancer Treatment. Biomedicines, 2021, 9, 1086.	1.4	59
1628	Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188568.	3.3	75
1629	ARTEMIN Promotes Oncogenicity and Resistance to 5-Fluorouracil in Colorectal Carcinoma by p44/42 MAPK Dependent Expression of CDH2. Frontiers in Oncology, 2021, 11, 712348.	1.3	3
1630	Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. Cell Chemical Biology, 2021, 28, 1206-1220.e6.	2.5	19
1631	Identification and Elucidation of the Protective isomiRs in Lung Cancer Patient Prognosis. Frontiers in Genetics, 2021, 12, 702695.	1.1	1

#	Article	IF	Citations
1632	Comprehensive Proteomic Analysis of Colon Cancer Tissue Revealed the Reason for the Worse Prognosis of Right-Sided Colon Cancer and Mucinous Colon Cancer at the Protein Level. Current Oncology, 2021, 28, 3554-3572.	0.9	6
1633	The Role of Cellular Prion Protein in Cancer Biology: A Potential Therapeutic Target. Frontiers in Oncology, 2021, 11, 742949.	1.3	13
1634	Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. Acta Biomaterialia, 2021, 132, 401-420.	4.1	9
1635	Novel miR-5088-5p promotes malignancy of breast cancer by inhibiting DBC2. Molecular Therapy - Nucleic Acids, 2021, 25, 127-142.	2.3	9
1636	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. Cancers, 2021, 13, 4778.	1.7	27
1637	Defining the Role of GLI/Hedgehog Signaling in Chemoresistance: Implications in Therapeutic Approaches. Cancers, 2021, 13, 4746.	1.7	11
1638	Sporadic cell death in macroscale 3D tumor grafts with high drug resistance by activating cell-ECM interactions. Biofabrication, 2021, 13, 045022.	3.7	4
1639	Poly (ADP-ribose) polymerase (PARP) inhibition in cancer: Potential impact in cancer stem cells and therapeutic implications. European Journal of Pharmacology, 2021, 911, 174546.	1.7	5
1640	A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers, 2021, 13, 4650.	1.7	5
1641	Stationed or Relocating: The Seesawing EMT/MET Determinants from Embryonic Development to Cancer Metastasis. Biomedicines, 2021, 9, 1265.	1.4	10
1642	The transcription factor BACH1 at the crossroads of cancer biology: From epithelialâ€“mesenchymal transition to ferroptosis. Journal of Biological Chemistry, 2021, 297, 101032.	1.6	44
1643	MicroRNA-495/TGF-Î²/FOXC1 axis regulates multidrug resistance in metaplastic breast cancer cells. Biochemical Pharmacology, 2021, 192, 114692.	2.0	12
1644	Cancer cell states and emergent properties of the dynamic tumor system. Genome Research, 2021, 31, 1719-1727.	2.4	12
1645	Accelerating AXL targeting for TNBC therapy. International Journal of Biochemistry and Cell Biology, 2021, 139, 106057.	1.2	5
1646	Butein induces intrinsic pathway of apoptosis, vimentin proteolysis, and inhibition of cancer stem cell population in a human papillary thyroid cancer cell line. Toxicology in Vitro, 2021, 77, 105244.	1.1	5
1647	Epithelial to Mesenchymal Transition. , 2021, , .		1
1648	Examining heterogeneity of stromal cells in tumor microenvironment based on pan-cancer single-cell RNA sequencing data. Cancer Biology and Medicine, 2021, 18, 0-0.	1.4	1
1649	A positive feedback loop between TAZ and miR-942-3p modulates proliferation, angiogenesis, epithelial-mesenchymal transition process, glycometabolism and ROS homeostasis in human bladder cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 44.	3.5	17

#	Article	IF	Citations
1650	Tweaking EMT and MDR dynamics to constrain triple-negative breast cancer invasiveness by EGFR and Wnt/Î²-catenin signaling regulation. Cellular Oncology (Dordrecht), 2021, 44, 405-422.	2.1	22
1651	Up-regulation of L Antigen Family Member 3 Associates With Aggressive Progression of Breast Cancer. Frontiers in Oncology, 2020, 10, 553628.	1.3	3
1652	Sevoflurane promotes the apoptosis of laryngeal squamous cell carcinoma in-vitro and inhibits its malignant progression via miR-26a/FOXO1 axis. Bioengineered, 2021, 12, 6364-6376.	1.4	5
1653	Targeting epigenetic regulatory machinery to overcome cancer therapy resistance. Seminars in Cancer Biology, 2022, 83, 487-502.	4.3	32
1654	YY1-modulated long non-coding RNA SNHG12 promotes gastric cancer metastasis by activating the miR-218-5p/YWHAZ axis. International Journal of Biological Sciences, 2021, 17, 1629-1643.	2.6	20
1655	Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Target. Cells Tissues Organs, 2022, 211, 157-182.	1.3	70
1656	Dual-targeting SERS-encoded graphene oxide nanocarrier for intracellular co-delivery of doxorubicin and 9-aminoacridine with enhanced combination therapy. Analyst, The, 2021, 146, 6893-6901.	1.7	11
1657	Prominin-1 (CD133) and Metastatic Melanoma: Current Knowledge and Therapeutic Perspectives. Advances in Experimental Medicine and Biology, 2013, 777, 197-211.	0.8	8
1658	Inflammation and Lung Cancer: The Role of Epithelialâ€“Mesenchymal Transition. , 2015, , 23-68.		3
1659	Resistance to Anti-Cancer Therapeutics. , 2019, , 65-82.		1
1660	Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC. Recent Results in Cancer Research, 2020, 215, 3-24.	1.8	2
1661	Mucins and Tumor Biology. , 2016, , 43-61.		3
1662	Epigenetics and the Microbiome. , 2017, , 1-25.		1
1663	Antibody-Targeted Nanoparticles for Cancer Treatment. , 2020, , 35-65.		3
1664	Thymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1581-1598.	1.4	30
1665	MicroRNAs in regulation of triple-negative breast cancer progression. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1401-1411.	1.2	121
1666	Identification of chemosensitizers by drug repurposing to enhance the efficacy of cancer therapy. , 2020, , 295-310.		3
1667	3D porous chitosan-chondroitin sulfate scaffolds promote epithelial to mesenchymal transition in prostate cancer cells. Biomaterials, 2020, 254, 120126.	5.7	38

#	Article	IF	Citations
1668	Impaired p65 degradation by decreased chaperone-mediated autophagy activity facilitates epithelial-to-mesenchymal transition. Oncogenesis, 2017, 6, e387-e387.	2.1	23
1669	Oxytocin inhibits head and neck squamous cell carcinoma cell migration by early growth response-1 upregulation. Anti-Cancer Drugs, 2017, 28, 613-622.	0.7	10
1675	Aldolase A promotes epithelialâ€mesenchymal transition to increase malignant potentials of cervical adenocarcinoma. Cancer Science, 2020, 111, 3071-3081.	1.7	32
1676	Epithelial-Mesenchymal Transitionâ€"A Hallmark of Breast Cancer Metastasis. Cancer Hallmarks, 2013, 1, 38-49.	0.9	135
1677	Cancer stem cellâ€"associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight, 2019, 4, .	2.3	23
1678	Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. Journal of Clinical Investigation, 2020, 130, 1782-1792.	3.9	44
1679	ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. Journal of Clinical Investigation, 2014, 124, 2696-2708.	3.9	101
1680	Epigenetic silencing of tumor suppressor Par-4 promotes chemoresistance in recurrent breast cancer. Journal of Clinical Investigation, 2018, 128, 4413-4428.	3.9	44
1681	S100A16 Regulates HeLa Cell through the Phosphatidylinositol 3 Kinase (PI3K)/AKT Signaling Pathway. Medical Science Monitor, 2020, 26, e919757.	0.5	5
1682	Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3Î²/Snail Signaling in Non-Small Cell Lung Cancer. Medical Science Monitor, 2020, 26, e925298.	0.5	2
1683	Up-Regulation of Sonic Hedgehog Contributes to TGF-Î²1-Induced Epithelial to Mesenchymal Transition in NSCLC Cells. PLoS ONE, 2011, 6, e16068.	1.1	119
1684	GLI1 Confers Profound Phenotypic Changes upon LNCaP Prostate Cancer Cells That Include the Acquisition of a Hormone Independent State. PLoS ONE, 2011, 6, e20271.	1.1	11
1685	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e21369.	1.1	56
1686	A Cell-Based Small Molecule Screening Method for Identifying Inhibitors of Epithelial-Mesenchymal Transition in Carcinoma. PLoS ONE, 2012, 7, e33183.	1.1	75
1687	Extract of Pleurotus pulmonarius Suppresses Liver Cancer Development and Progression through Inhibition of VEGF-Induced PI3K/AKT Signaling Pathway. PLoS ONE, 2012, 7, e34406.	1.1	53
1688	A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma. PLoS ONE, 2012, 7, e34705.	1.1	106
1689	Derivation of Myoepithelial Progenitor Cells from Bipotent Mammary Stem/Progenitor Cells. PLoS ONE, 2012, 7, e35338.	1.1	13
1690	Histone Deacetylase Inhibitors Induce Epithelial-to-Mesenchymal Transition in Prostate Cancer Cells. PLoS ONE, 2012, 7, e45045.	1.1	89

#	Article	IF	Citations
1691	Hypoxia Induces EMT in Low and Highly Aggressive Pancreatic Tumor Cells but Only Cells with Cancer Stem Cell Characteristics Acquire Pronounced Migratory Potential. PLoS ONE, 2012, 7, e46391.	1.1	114
1692	Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade. PLoS ONE, 2013, 8, e54659.	1.1	26
1693	A miRNA Signature of Chemoresistant Mesenchymal Phenotype Identifies Novel Molecular Targets Associated with Advanced Pancreatic Cancer. PLoS ONE, 2014, 9, e106343.	1.1	52
1694	Mesenchymal Phenotype Predisposes Lung Cancer Cells to Impaired Proliferation and Redox Stress in Response to Glutaminase Inhibition. PLoS ONE, 2014, 9, e115144.	1.1	38
1695	Epigenetic Regulation of Elf5 Is Associated with Epithelial-Mesenchymal Transition in Urothelial Cancer. PLoS ONE, 2015, 10, e0117510.	1.1	18
1696	ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold. PLoS ONE, 2016, 11, e0159677.	1.1	16
1697	Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous Carcinoma. PLoS ONE, 2016, 11, e0162088.	1.1	11
1698	A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516. PLoS ONE, 2016, 11, e0162394.	1.1	57
1699	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS ONE, 2016, 11, e0164811.	1.1	17
1700	SLC12A8 plays a key role in bladder cancer progression and EMT. Open Medicine (Poland), 2020, 16, 058-067.	0.6	6
1701	Targeting the TGFÎ² pathway in uterine carcinosarcoma. Cell Stress, 2020, 4, 252-260.	1.4	7
1702	RKIP-Mediated Chemo-Immunosensitization of Resistant Cancer Cells via Disruption of the NF-ÎºB/Snail/YY1/RKIP Resistance-Driver Loop. Critical Reviews in Oncogenesis, 2014, 19, 431-445.	0.2	31
1703	Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?. Critical Reviews in Oncogenesis, 2015, 20, 155-171.	0.2	88
1704	Inhibition of Epithelial-to-Mesenchymal Transition (EMT) in Cancer by Nitric Oxide: Pivotal Roles of Nitrosylation of NF-ÎºB, YY1 and Snail. Forum on Immunopathological Diseases and Therapeutics, 2012, 3, 125-133.	0.1	24
1706	Poly-lactic-co-glycolic acid Nanoformulation of Small Molecule Antagonist GANT61 for Cancer Annihilation by Modulating Hedgehog Pathway. NanoWorld Journal, 2017, 03, .	0.8	13
1708	The lncRNA ENSG00000254041.1 promotes cell invasiveness and associates with poor prognosis of pancreatic ductal adenocarcinoma. Aging, 2020, 12, 3647-3661.	1.4	6
1709	Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes and Cancer, 2016, 7, 169-181.	0.6	15
1710	Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells. Genes and Cancer, 2017, 8, 673-681.	0.6	10

#	Article	IF	Citations
1711	Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget, 2016, 7, 51965-51980.	0.8	35
1712	EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway. Oncotarget, 2016, 7, 47938-47953.	0.8	24
1713	Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings. Oncotarget, 2016, 7, 60395-60406.	0.8	32
1714	AKT-ions with a TWIST between EMT and MET. Oncotarget, 2016, 7, 62767-62777.	0.8	71
1715	Comparative profiling between primary colorectal carcinomas and metastases identifies heterogeneity on drug resistance. Oncotarget, 2016, 7, 63937-63949.	0.8	10
1716	PARP3 controls TGFÎ² and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget, 2016, 7, 64109-64123.	0.8	71
1717	Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells. Oncotarget, 2016, 7, 73414-73431.	0.8	26
1718	Lung cancer tumorigenicity and drug resistance are maintained through ALDHhiCD44hi tumor initiating cells. Oncotarget, 2013, 4, 1698-1711.	0.8	90
1719	FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition. Oncotarget, 2016, 7, 83424-83436.	0.8	48
1720	Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells. Oncotarget, 2016, 7, 81123-81143.	0.8	23
1721	Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFÎ²2-bioenergetics-mitochondrial priming. Oncotarget, 2016, 7, 82013-82027.	0.8	23
1722	Curcumin increases exosomal TCF21 thus suppressing exosome-induced lung cancer. Oncotarget, 2016, 7, 87081-87090.	0.8	49
1723	The role of tumor microenvironment in therapeutic resistance. Oncotarget, 2017, 8, 3933-3945.	0.8	189
1724	ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells. Oncotarget, 2014, 5, 351-362.	0.8	30
1725	Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer. Oncotarget, 2013, 4, 2512-2522.	0.8	131
1726	Aminopeptidase A initiates tumorigenesis and enhances tumor cell stemness via TWIST1 upregulation in colorectal cancer. Oncotarget, 2017, 8, 21266-21280.	0.8	18
1727	Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget, 2017, 8, 20961-20973.	0.8	41
1728	Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget, 2013, 4, 2326-2338.	0.8	33

#	Article	IF	Citations
1729	Hypoxia-induced PLOD2 promotes proliferation, migration and invasion via PI3K/Akt signaling in glioma. Oncotarget, 2017, 8, 41947-41962.	0.8	76
1730	U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. Oncotarget, 2017, 8, 44533-44549.	0.8	11
1731	Increased CCL19 expression is associated with progression in cervical cancer. Oncotarget, 2017, 8, 73817-73825.	0.8	44
1732	EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells. Oncotarget, 2017, 8, 47998-48011.	0.8	16
1733	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	0.8	21
1734	Targeting the MUC1-C oncoprotein inhibits self-renewal capacity of breast cancer cells. Oncotarget, 2014, 5, 2622-2634.	0.8	59
1735	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget, 2014, 5, 10368-10381.	0.8	18
1736	CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1Î±-induced twist expression. Oncotarget, 2017, 8, 74506-74518.	0.8	20
1737	Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer. Oncotarget, 2017, 8, 95392-95400.	0.8	10
1738	Telomere DNA damage signaling regulates cancer stem cell evolution, epithelial mesenchymal transition, and metastasis. Oncotarget, 2017, 8, 80139-80155.	0.8	11
1739	Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-ÎºB pathway in EGFR-mutant NSCLC. Oncotarget, 2017, 8, 92240-92253.	0.8	41
1740	DUSP4 promotes doxorubicin resistance in gastric cancer through epithelial-mesenchymal transition. Oncotarget, 2017, 8, 94028-94039.	0.8	37
1741	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget, 2014, 5, 6049-6062.	0.8	140
1742	Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget, 2014, 5, 5782-5797.	0.8	109
1743	Loss of p53-inducible long non-coding RNA LINC01021 increases chemosensitivity. Oncotarget, 2017, 8, 102783-102800.	0.8	13
1744	Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas. Oncotarget, 2018, 9, 607-621.	0.8	26
1745	Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines. Oncotarget, 2018, 9, 16185-16196.	0.8	26
1746	A drug combination targeting hypoxia induced chemoresistance and stemness in glioma cells. Oncotarget, 2018, 9, 18351-18366.	0.8	13

#	Article	IF	Citations
1747	Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget, 2014, 5, 10763-10777.	0.8	17
1748	Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition. Oncotarget, 2018, 9, 22986-23002.	0.8	12
1749	CDKL2 promotes epithelial-mesenchymal transition and breast cancer progression. Oncotarget, 2014, 5, 10840-10853.	0.8	32
1750	Synergistic antitumor effect of a Î³-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma. Oncotarget, 2018, 9, 34996-35007.	0.8	22
1751	Cell type specific gene expression analysis of prostate needle biopsies resolves tumor tissue heterogeneity. Oncotarget, 2015, 6, 1302-1314.	0.8	20
1752	CD44+/EPCAM+ cells detect a subpopulation of ALDHhigh cells in human non-small cell lung cancer: A chance for targeting cancer stem cells?. Oncotarget, 2020, 11, 1545-1555.	0.8	22
1753	Irinotecan treatment and senescence failure promote the emergence of more transformed and invasive cells that depend on anti-apoptotic Mcl-1. Oncotarget, 2015, 6, 409-426.	0.8	42
1754	Intrinsic TGF-Î²2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Oncotarget, 2015, 6, 1008-1019.	0.8	27
1755	Morphine promotes cancer stem cell properties, contributing to chemoresistance in breast cancer. Oncotarget, 2015, 6, 3963-3976.	0.8	67
1756	KITENIN promotes glioma invasiveness and progression, associated with the induction of EMT and stemness markers. Oncotarget, 2015, 6, 3240-3253.	0.8	46
1757	CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget, 2015, 6, 8313-8322.	0.8	96
1758	FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. Oncotarget, 2015, 6, 6310-6325.	0.8	66
1759	Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition. Oncotarget, 2015, 6, 8807-8821.	0.8	54
1760	Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. Oncotarget, 2015, 6, 15578-15593.	0.8	134
1761	ERÎ± inhibits epithelial-mesenchymal transition by suppressing Bmi1 in breast cancer. Oncotarget, 2015, 6, 21704-21717.	0.8	21
1762	P73 tumor suppressor and its targets, p21 and PUMA, are required for madin-darby canine kidney cell morphogenesis by maintaining an appropriate level of epithelial to mesenchymal transition. Oncotarget, 2015, 6, 13994-14004.	0.8	12
1763	Inhibition of ERRÎ± suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Oncotarget, 2015, 6, 25588-25601.	0.8	50
1764	Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. Oncotarget, 2015, 6, 25074-25092.	0.8	53

#	Article	IF	Citations
1765	Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget, 2015, 6, 19968-19975.	0.8	23
1766	The metastasis suppressor, NDRG1, inhibits â€œstemnessâ€•of colorectal cancer via down-regulation of nuclear Î²-catenin and CD44. Oncotarget, 2015, 6, 33893-33911.	0.8	40
1767	MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget, 2015, 6, 39661-39675.	0.8	41
1768	A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget, 2015, 6, 40005-40025.	0.8	61
1769	STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell. Oncotarget, 2015, 6, 41944-41958.	0.8	36
1770	Combinatorial TGF-Î² attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget, 2015, 6, 37526-37543.	0.8	59
1771	Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibition. Oncotarget, 2015, 6, 44306-44322.	0.8	35
1772	Targeting Notch to overcome radiation resistance. Oncotarget, 2016, 7, 7610-7628.	0.8	50
1773	Leukemia inhibitory factor promotes EMT through STAT3-dependent miR-21 induction. Oncotarget, 2016, 7, 3777-3790.	0.8	65
1774	The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Oncotarget, 2016, 7, 14279-14290.	0.8	30
1775	Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling. Oncotarget, 2016, 7, 11708-11723.	0.8	58
1776	Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget, 2016, 7, 13984-14001.	0.8	30
1777	Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transitionviadown-regulating LOXL2 expression. Oncotarget, 2016, 7, 23684-23699.	0.8	23
1778	Expression of epithelial-mesenchymal transition-related genes increases with copy number in multiple cancer types. Oncotarget, 2016, 7, 24688-24699.	0.8	17
1779	Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells. Oncotarget, 2016, 7, 32221-32231.	0.8	81
1780	Visfatin is involved in promotion of colorectal carcinoma malignancy through an inducing EMT mechanism. Oncotarget, 2016, 7, 32306-32317.	0.8	27
1781	miR186 suppresses prostate cancer progression by targeting Twist1. Oncotarget, 2016, 7, 33136-33151.	0.8	36
1782	Spheroid cancer stem cells display reprogrammed metabolism and obtain energy by actively running the tricarboxylic acid (TCA) cycle. Oncotarget, 2016, 7, 33297-33305.	0.8	52

#	Article	IF	Citations
1783	IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib. Oncotarget, 0, 7, 42031-42044.	0.8	48
1784	ATG4A promotes tumor metastasis by inducing the epithelial-mesenchymal transition and stem-like properties in gastric cells. Oncotarget, 2016, 7, 39279-39292.	0.8	27
1785	Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget, 0, 7, 42447-42460.	0.8	30
1786	Motility and stem cell properties induced by the epithelial-mesenchymal transition require destabilization of lipid rafts. Oncotarget, 2016, 7, 51553-51568.	0.8	32
1787	Regulation of ABCB1 activity by microRNA-200c and microRNA-203a in breast cancer cells: the quest for microRNAsâ€™ involvement in cancer drug resistance. , 2019, 2, 897-911.		3
1788	The effects of growth hormone on therapy resistance in cancer. , 2019, 2, 827-846.		16
1789	Harnessing protein kinase A activation to induce mesenchymal-epithelial programs to eliminate chemoresistant, tumor-initiating breast cancer cells. Translational Cancer Research, 2016, 5, S226-S232.	0.4	5
1790	The role of tumor-derived exosomes in epithelial mesenchymal transition (EMT). Translational Cancer Research, 2017, 6, S90-S92.	0.4	22
1791	Obesity as an oncological risk factor. Literature review. Meditsinskiy Sovet, 2019, , 94-102.	0.1	6
1792	Gene Silencing Strategies in Cancer Therapy: An Update for Drug Resistance. Current Medicinal Chemistry, 2019, 26, 6282-6303.	1.2	14
1793	Cancer Stem Cells and Combination Therapies to Eradicate Them. Current Pharmaceutical Design, 2020, 26, 1994-2008.	0.9	6
1794	Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities. Current Drug Metabolism, 2020, 20, 1114-1131.	0.7	20
1795	Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells. Current Molecular Medicine, 2013, 13, 459-463.	0.6	13
1796	Emerging Role of Mucins in Epithelial to Mesenchymal Transition. Current Cancer Drug Targets, 2013, 13, 945-956.	0.8	45
1797	Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics. Current Cancer Drug Targets, 2019, 19, 82-100.	0.8	18
1798	Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT. Current Cancer Drug Targets, 2020, 20, 654-665.	0.8	11
1799	Natural Compounds Targeting Cancer Stem Cells: A Promising Resource for Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2019, 19, 1796-1808.	0.9	20
1800	Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. Anticancer Research, 2017, 37, 35-46.	0.5	162

#	Article	IF	Citations
1801	Chemical Proteomic Approaches Targeting Cancer Stem Cells: A Review of Current Literature. Cancer Genomics and Proteomics, 2017, 14, 315-327.	1.0	7
1802	ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance. Cancer Genomics and Proteomics, 2018, 15, 127-141.	1.0	52
1803	MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B. Yonsei Medical Journal, 2019, 60, 1146.	0.9	30
1804	Calcium Signaling in Brain Cancers: Roles and Therapeutic Targeting. Cancers, 2019, 11, 145.	1.7	44
1805	Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells. International Journal of Molecular Sciences, 2021, 22, 224.	1.8	22
1806	How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression. International Journal of Molecular Sciences, 2021, 22, 387.	1.8	54
1807	SIX1 ve Kanser KÃ¶k HÃ¼cre BelirteÃ§lerinin Hepatoselluler Karsinomada KapsamlÄ± Analizi. Celal Bayar Ãœniversitesi SaÄŸlÄ±k Bilimleri EnstitÃ¼sÃ¼ Dergisi, 0, , .	0.1	1
1808	DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment. Advanced Pharmaceutical Bulletin, 2020, 11, 618-623.	0.6	9
1809	Twist2 is a valuable prognostic biomarker for colorectal cancer. World Journal of Gastroenterology, 2013, 19, 2404.	1.4	27
1810	miR-132 inhibits colorectal cancer invasion and metastasisviadirectly targeting ZEB2. World Journal of Gastroenterology, 2014, 20, 6515.	1.4	99
1811	Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes. World Journal of Gastroenterology, 2015, 21, 3876.	1.4	44
1812	miRâ€‘593 inhibits proliferation and invasion and promotes apoptosis in nonâ€‘small cell lung cancer cells by targeting SLUGâ€‘associated signaling pathways. Molecular Medicine Reports, 2019, 20, 5172-5182.	1.1	14
1813	Baicalein suppresses the proliferation and invasiveness of colorectal cancer cells by inhibiting Snailâ€‘induced epithelialâ€‘mesenchymal transition. Molecular Medicine Reports, 2020, 21, 2544-2552.	1.1	18
1814	Wnt/Î²â€‘catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review). Molecular Medicine Reports, 2020, 23, .	1.1	23
1815	Markers of epithelial-mesenchymal transition in an experimental breast cancer model induced by organophosphorous pesticides and estrogen (Review). Oncology Letters, 2020, 20, 1-1.	0.8	10
1816	Long nonâ€‘coding RNA MEG3 suppresses epithelialâ€‘toâ€‘mesenchymal transition by inhibiting the PSAT1â€‘dependent GSKâ€‘3Î²/Snail signaling pathway in esophageal squamous cell carcinoma. Oncology Reports, 2020, 44, 2130-2142.	1.2	14
1817	The role of epithelial-mesenchymal transition in pancreatic cancer. Journal of Gastrointestinal Oncology, 2011, 2, 151-6.	0.6	27
1818	Heparan sulfate D-glucosamine 3-O-sulfotransferase 3B1 is a novel regulator of transforming growth factor-beta-mediated epithelial-to-mesenchymal transition and regulated by miR-218 in nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics, 2018, 14, 24-29.	0.3	15

#	Article	IF	Citations
1819	Identification and characterization of glycine decarboxylase as a direct target of snail in the epithelialâ€“mesenchymal transition of cancer cells. Tumor & Microenvironment, 2018, 1, 55.	0.7	2
1820	Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer. Cancer Research and Treatment, 2012, 44, 151-156.	1.3	151
1821	CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer. Cancer Research and Treatment, 2020, 52, 622-633.	1.3	32
1822	Modulation of cell death pathways in cancer stem cells: Targeting histone demethylases. Advances in Bioscience and Biotechnology (Print), 2012, 03, 720-730.	0.3	1
1823	PGRMC1 Elevation in Multiple Cancers and Essential Role in Stem Cell Survival. Advances in Lung Cancer (Irvine), 2015, 04, 37-51.	0.2	32
1824	Reduction of Intracellular-Reactive Oxygen Species and Diminished Mitogen-Activated Protein Kinases (MAPKs) Activation are Associated with Oral Squamous Cell Carcinoma Cell Aggressiveness. Walailak Journal of Science and Technology, 2018, 15, 131-141.	0.5	1
1825	Clinical Application of Circulating Tumor Cells in Gastric Cancer. Gut and Liver, 2019, 13, 394-401.	1.4	24
1826	Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer. Journal of Gastric Cancer, 2020, 20, 408.	0.9	14
1827	Bone metastases: When and how lung cancer interacts with bone. World Journal of Clinical Oncology, 2014, 5, 149.	0.9	39
1828	Cancer stem cells and early stage basal-like breast cancer. World Journal of Obstetrics and Gynecology, 2016, 5, 150.	0.5	5
1829	Epithelial-mesenchymal Transition is Associated with Acquired Resistance to 5-Fluorocuracil in HT-29 Colon Cancer Cells. Toxicological Research, 2015, 31, 151-156.	1.1	61
1830	Matrix metalloproteinase 3 polymorphisms as a potential marker of enhanced susceptibility to lung cancer in chronic obstructive pulmonary disease subjects. Annals of Agricultural and Environmental Medicine, 2014, 21, 546-551.	0.5	10
1831	Current Opinions on Chemoresistance: An Overview. Bioinformation, 2018, 14, 80-85.	0.2	44
1832	Complexities of TGF-Î² Targeted Cancer Therapy. International Journal of Biological Sciences, 2012, 8, 964-978.	2.6	293
1833	Hydrogen Peroxide Promotes Epithelial to Mesenchymal Transition and Stemness in Human Malignant Mesothelioma Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3625-3630.	0.5	64
1834	An Epigenetic Mechanism Underlying Doxorubicin Induced EMT in the Human BGC-823 Gastric Cancer Cell. Asian Pacific Journal of Cancer Prevention, 2014, 15, 4271-4274.	0.5	21
1835	LARP7 suppresses P-TEFb activity to inhibit breast cancer progression and metastasis. ELife, 2014, 3, e02907.	2.8	64
1836	Axon-like protrusions promote small cell lung cancer migration and metastasis. ELife, 2019, 8, .	2.8	37

#	Article	IF	Citations
1837	NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process. International Journal of Medical Sciences, 2021, 18, 3768-3779.	1.1	10
1838	Akt isoforms differentially provide for chemoresistance in prostate cancer. Cancer Biology and Medicine, 2021, 19, 635-650.	1.4	7
1839	Functional roles of exosomal miRNAs in multi-drug resistance in cancer chemotherapeutics. Experimental and Molecular Pathology, 2021, 118, 104592.	0.9	7
1840	Alternative RNA splicing in stem cells and cancer stem cells: Importance of transcript-based expression analysis. World Journal of Stem Cells, 2021, 13, 1394-1416.	1.3	4
1841	Characterisation of Levonorgestrel-Resistant Endometrial Cancer Cells. Cancer Management and Research, 2021, Volume 13, 7871-7884.	0.9	2
1842	The emerging roles of GÎ±12/13 proteins on the hallmarks of cancer in solid tumors. Oncogene, 2022, 41, 147-158.	2.6	15
1844	Seeding metastases: The role and clinical utility of circulating tumour cells. Tumor Biology, 2021, 43, 285-306.	0.8	1
1845	Impact of Metabolic and Therapeutic Stresses on Glioma Progression and Therapy. , 0, , .		0
1846	Bone Marrow-Derived Cells Support Malignant Transformation of Low-Grade Glioma. , 0, , .		0
1847	Global OMICs Profiling and Functional Analysis of CD44+/CD24â^' Stem-Like Cells in Normal Human Breast Tissue and Breast Cancer. , 2012, , 607-626.		0
1849	Midkine/P63 Axis in Regulation of Epithelial-Mesenchymal Transition. , 2012, , 41-52.		0
1850	Multidrug Resistence and Breast Cancer. , 0, , .		0
1851	Targeting Cancer Stem Cell Efficient DNA Repair Pathways: Screening for New Therapeutics. , 2013, , 157-172.		0
1852	MicroRNAs in Cancer Stem Cells. , 2013, , 29-41.		0
1853	Mechanisms of Resistance to Radiation. , 2013, , 49-57.		1
1854	Chemotherapy Increases Aggressiveness of Prostate Cancer via Epithelial Mesenchymal Transition. Cell Biology: Research & Therapy, 2013, 02, .	0.2	2
1855	The Multifunctional Roles of TGF-Î² in Navigating the Metastatic Cascade. , 2013, , 169-187.		0
1856	Genomic-Epigenomic Signaling Pathways Changes in Cellular Differentiation Process. American Journal of Biomedical Research, 2013, 1, 35-42.	0.2	1

#	Article	IF	Citations
1858	Tumour Stem Cell Enrichment by Anticancer Drugs: A Potential Mechanism of Tumour Recurrence. , 2014, , 9-19.		0
1859	Investigating the Role of the Embryonic Stem Cell Self-Renewal Gene NANOG in Neoplastic Processes. Stem Cells and Cancer Stem Cells, 2014, , 15-27.	0.1	0
1861	Microfluidic Devices as In-Vitro Microenvironments for Stem Cell Culture. , 2014, , .		0
1865	Cytokine Networks and Cancer Stem Cells. , 2015, , 67-87.		1
1866	Breast Cancer Stem Cells. , 2015, , 177-197.		0
1867	Colorectal Cancer Stem Cells. , 2015, , 227-245.		0
1869	A Novel Approach to Peritoneal Dissemination of Mucin-Expressing Malignancies of Gastrointestinal Origin. , 2016, , 99-158.		0
1870	Hostâ€"Tumor Interactions in Brain Cancer Metastasis Leading to Drug Resistance. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 237-253.	0.1	0
1872	E-CADHERIN EXPRESSION DOWNREGULATION ELEVATES TUMOROGENIC POTENTIAL OF HUMAN COLON CANCER CELL LINE HCT116 VIA INCREASE IN CANCER STEM CELLS AMOUNT. , 2016, 15, 6-14.	0.3	1
1873	Development of Novel Therapeutic Response Biomarkers. , 2017, , 1-32.		0
1874	Refractory Mechanisms. , 2017, , 351-367.		0
1875	Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative. Anticancer Research, 2017, 37, 2785-2807.	0.5	8
1877	Molecularly Targeted Therapies in Pancreatic Cancer. , 2018, , 219-233.		0
1880	First Evidences of Epithelial-Mesenchymal Transition and Cancer Stem-Cell Phenotype Acquisition in Dermo-Epidermal Junction of BPV-Infected Neoplasms. Journal of Biotechnology and Biomedical Science, 2017, 1, 10-30.	0.6	1
1881	Urothelial Tumors: Moving from Morphology to Biology. Journal of Medical & Surgical Pathology, 2018, 03, .	0.2	0
1882	Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies. , 2018, , 191-224.		0
1883	Precision Medicine Approaches to Cancer Diagnosis and Treatment: Focus on Cancer Stem Cell Biomarkers. Open Biomarkers Journal, 2018, 8, 9-16.	0.1	0
1885	Luteolin Induces Apoptosis via Mitochondrial Pathway and Inhibits Invasion and Migration of Oral Squamous Cell Carcinoma by Suppressing Epithelial-Mesenchymal Transition Induced Transcription Factors. International Journal of Oral Biology: Official Journal of the Korean Academy of Oral Biology and the UCLA Dental Research Institute, 2018, 43, 69-76.	0.1	1

#	Article	IF	Citations
1887	EMT-mechanizm induces the leukemic stemness phenotype in myeloid leukemias. Faktori Eksperimental Noi Evolucii Organizmiv, 0, 23, 256-260.	0.0	0
1889	Immunotherapeutic approaches in pediatric osteosarcoma. Minerva Pediatrica, 2018, 70, 635-636.	2.6	0
1890	RPPAs for Cell Subpopulation Analysis. Advances in Experimental Medicine and Biology, 2019, 1188, 227-237.	0.8	0
1891	Overexpression of YY1 Regulates the Resistance of Cancer Stem Cells: Targeting YY1. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 93-113.	0.1	0
1892	Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction. , 2019, 2, 365-380.		3
1893	Ferroptosis in Cancer Disease. , 2019, , 285-301.		0
1894	NUMB knockdown enhanced the anti-tumor role of cisplatin on ovarian cancer cells by inhibiting cell proliferation and epithelial-mesenchymal transition. Translational Cancer Research, 2019, 8, 379-388.	0.4	2
1900	Nanomedicine in Cancer Stem Cell Therapy. , 2020, , 67-105.		2
1901	LncRNA ASAP1-IT1 enhances cancer cell stemness via regulating miR-509-3p/YAP1 axis in NSCLC. Cancer Cell International, 2021, 21, 572.	1.8	5
1902	Integrins regulate stemness in solid tumor: an emerging therapeutic target. Journal of Hematology and Oncology, 2021, 14, 177.	6.9	41
1903	Expression of Selected Epithelial-Mesenchymal Transition Transcription Factors in Endometrial Cancer. BioMed Research International, 2020, 2020, 1-13.	0.9	5
1904	Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine. Genes and Diseases, 2022, 9, 668-681.	1.5	12
1906	Correlation of Muscle Invasion in Bladder Cancer with Cell Adhesion Properties and Oncoprotein Overexpression Using E-Cadherin and HER2/neu Immunohistochemical Markers.. Open Access Macedonian Journal of Medical Sciences, 2020, 8, 43-48.	0.1	0
1910	The interplay of autophagy and epithelial-to-mesenchymal transition in cancer progression. Uspehi Molekularnoj Onkologii, 2020, 7, 8-19.	0.1	0
1912	Introducing, OncoTarget. Oncotarget, 2010, 1, 2-2.	0.8	0
1913	In vitro Studies of Transendothelial Migration for Biological and Drug Discovery. Frontiers in Medical Technology, 2020, 2, 600616.	1.3	19
1914	Expanding roles of ZEB factors in tumorigenesis and tumor progression. American Journal of Cancer Research, 2011, 1, 897-912.	1.4	90
1916	Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine. Anticancer Research, 2012, 32, 799-806.	0.5	14

#	Article	IF	Citations
1917	Cancer stem cells and tumor transdifferentiation: implications for novel therapeutic strategies. American Journal of Stem Cells, 2013, 2, 52-61.	0.4	30
1919	Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma. International Journal of Clinical and Experimental Pathology, 2014, 7, 2976-86.	0.5	15
1921	Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma. International Journal of Clinical and Experimental Pathology, 2015, 8, 560-8.	0.5	31
1922	Neovibsanin B inhibits human malignant brain tumor cell line proliferation and induces apoptosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 6456-62.	1.3	0
1923	KDM6B induces epithelial-mesenchymal transition and enhances clear cell renal cell carcinoma metastasis through the activation of SLUG. International Journal of Clinical and Experimental Pathology, 2015, 8, 6334-44.	0.5	23
1924	Imaging Reporters for Proteasome Activity Identify Tumor- and Metastasis-Initiating Cells. Molecular Imaging, 2015, 14, 414-28.	0.7	8
1927	Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung Cancer. The Malaysian Journal of Medical Sciences, 2016, 23, 9-21.	0.3	19
1928	Vasohibin 2 as a potential predictor of aggressive behavior of triple-negative breast cancer. American Journal of Translational Research (discontinued), 2017, 9, 2911-2919.	0.0	4
1929	USP51 promotes deubiquitination and stabilization of ZEB1. American Journal of Cancer Research, 2017, 7, 2020-2031.	1.4	27
1932	Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer. American Journal of Translational Research (discontinued), 2019, 11, 1145-1153.	0.0	13
1933	Tannic acid attenuates the formation of cancer stem cells by inhibiting NF-Î¹B-mediated phenotype transition of breast cancer cells. American Journal of Cancer Research, 2019, 9, 1664-1681.	1.4	6
1934	Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271. Cancer Biology and Medicine, 2019, 16, 498-513.	1.4	6
1936	High expression of long non-coding RNA NNT-AS1 facilitates progression of cholangiocarcinoma through promoting epithelial-mesenchymal transition. American Journal of Translational Research (discontinued), 2019, 11, 5438-5456.	0.0	6
1937	Yes-associated protein 1 promotes bladder cancer invasion by regulating epithelial-mesenchymal transition. International Journal of Clinical and Experimental Pathology, 2019, 12, 1070-1077.	0.5	2
1938	Evaluation of the correlativity of gender determining region Y-box 4, N-cadherin, CD44 and E-cadherin expression in the prognosis of esophageal squamous cell carcinoma. International Journal of Clinical and Experimental Pathology, 2019, 12, 1745-1756.	0.5	1
1939	Prognostic value of epithelial-mesenchymal transition related genes: SLUG and QKI in breast cancer patients. International Journal of Clinical and Experimental Pathology, 2019, 12, 2009-2021.	0.5	3
1940	High expression of is associated with EMAST and poor prognosis in CRC patients. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, S30-S36.	0.6	0
1941	targeting as a therapeutic approach for treatment of metastatic breast cancer. American Journal of Cancer Research, 2020, 10, 211-223.	1.4	16

#	Article	IF	Citations
1942	lncRNA VIMâ€˜AS1 promotes cell proliferation, metastasis and epithelialâ€˜mesenchymal transition by activating the Wnt/Î²â€˜catenin pathway in gastric cancer. Molecular Medicine Reports, 2020, 22, 4567-4578.	1.1	3
1943	Decursin inhibits cell growth and autophagic flux in gastric cancer via suppression of cathepsin C. American Journal of Cancer Research, 2021, 11, 1304-1320.	1.4	1
1944	Effect of Menadione and Combination of Gemcitabine and CisplatinÂon Cancer Stem Cells in Human Non-small Cell Lung Cancer (NSCLC) Cell Line A549. Iranian Journal of Pharmaceutical Research, 2021, 20, 105-117.	0.3	3
1945	Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. Cancers, 2021, 13, 6029.	1.7	2
1946	Advances in Immunotherapy and the TGF-Î² Resistance Pathway in Metastatic Bladder Cancer. Cancers, 2021, 13, 5724.	1.7	13
1947	Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation. Frontiers in Oncology, 2021, 11, 775418.	1.3	22
1948	Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelialâ€“Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells. Journal of Agricultural and Food Chemistry, 2021, 69, 14557-14567.	2.4	6
1949	Regulatory role of the transforming growth factor-Î² signaling pathway in the drug resistance of gastrointestinal cancers. World Journal of Gastrointestinal Oncology, 2021, 13, 1648-1667.	0.8	4
1950	Nuclear accumulation of KPNA2 impacts radioresistance through positive regulation of the PLSCR1â€“STAT1 loop in lung adenocarcinoma. Cancer Science, 2022, 113, 205-220.	1.7	10
1951	Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling. International Journal of Molecular Sciences, 2021, 22, 12438.	1.8	15
1952	Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma. Cancers, 2021, 13, 5895.	1.7	6
1953	Chloroquine Induces ROS-mediated Macrophage Migration Inhibitory Factor Secretion and Epithelial to Mesenchymal Transition in ER-positive Breast Cancer Cell Lines. Journal of Mammary Gland Biology and Neoplasia, 2021, , 1.	1.0	4
1954	Effects of Anti-Cancer Drug Sensitivity-Related Genetic Differences on Therapeutic Approaches in Refractory Papillary Thyroid Cancer. International Journal of Molecular Sciences, 2022, 23, 699.	1.8	5
1955	Spontaneous formation and spatial self-organization of mechanically induced mesenchymal-like cells within geometrically confined cancer cell monolayers. Biomaterials, 2022, 281, 121337.	5.7	6
1956	Current insights on extracellular vesicle-mediated glioblastoma progression: Implications in drug resistance and epithelial-mesenchymal transition. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130065.	1.1	12
1958	lncRNA VIMâ€˜AS1 promotes cell proliferation, metastasis and epithelialâ€˜mesenchymal transition by activating the Wnt/Î²â€˜catenin pathway in gastric cancer. Molecular Medicine Reports, 2020, 22, 4567-4578.	1.1	14
1959	TGFÎ² Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFÎ² Induced EMT in PDAC. Cancers, 2021, 13, 6204.	1.7	8
1960	Inhibition of the proliferation, invasion, migration, and epithelial-mesenchymal transition of prostate cancer cells through the action of ATP1A2 on the TGF-Î²/Smad pathway. Translational Andrology and Urology, 2022, 11, 53-66.	0.6	2

#	Article	IF	Citations
1961	Selection of Cancer Stem Cellâ€“Targeting Agents Using Bacteriophage Display. Methods in Molecular Biology, 2022, 2394, 787-810.	0.4	1
1962	Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells. Biomolecules, 2022, 12, 190.	1.8	14
1963	CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. , 2022, 10, e003289.		31
1964	TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer. Aging, 2022, 14, 297-315.	1.4	8
1965	Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression. Biomedicines, 2022, 10, 301.	1.4	5
1966	Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma. Disease Markers, 2022, 2022, 1-17.	0.6	2
1967	Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer. International Journal of Molecular Sciences, 2022, 23, 1152.	1.8	13
1968	An Individualized EMT-Related Gene Signature to Predict Recurrence-Free Survival in Stage II/III Colorectal Cancer Patients. Digestive Diseases and Sciences, 2022, , 1.	1.1	1
1969	Computational Methods for the Analysis and Prediction of EGFR-mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, PP, 1-1.	1.9	14
1970	O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells. Frontiers in Immunology, 2021, 12, 791551.	2.2	9
1971	Identification of a Four-Gene-Based SERM Signature for Prognostic and Drug Sensitivity Prediction in Gastric Cancer. Frontiers in Oncology, 2021, 11, 799223.	1.3	7
1972	Single-cell analysis of gastric pre-cancerous and cancer lesions reveals cell lineage diversity and intratumoral heterogeneity. Npj Precision Oncology, 2022, 6, 9.	2.3	48
1973	Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities. Cells, 2022, 11, 511.	1.8	6
1974	A natural selenium polysaccharide from Pleurotus ostreatus: Structural elucidation, anti-gastric cancer and anti-colon cancer activity in vitro. International Journal of Biological Macromolecules, 2022, 201, 630-640.	3.6	18
1975	PTPN6-EGFR Protein Complex: A Novel Target for Colon Cancer Metastasis. Journal of Oncology, 2022, 2022, 1-11.	0.6	2
1976	TGF-Î²1 induced deficiency of linc00261 promotes epithelialâ€“mesenchymal-transition and stemness of hepatocellular carcinoma via modulating SMAD3. Journal of Translational Medicine, 2022, 20, 75.	1.8	7
1977	FAK in Cancer: From Mechanisms to Therapeutic Strategies. International Journal of Molecular Sciences, 2022, 23, 1726.	1.8	61
1978	Downregulation of KCTD12 contributes to melanoma stemness by modulating CD271. Cancer Biology and Medicine, 2019, 16, 498-513.	1.4	11

#	Article	IF	Citations
1979	Mechanism of resistance to toxic xenobiotics in humans. , 2022, , 245-259.		0
1980	Molecular Docking as a Therapeutic Approach for Targeting Cancer Stem Cell Metabolic Processes. Frontiers in Pharmacology, 2022, 13, 768556.	1.6	13
1981	Association of ALDH1 with Response to Radiotherapy and Its Impact on Survival in Patients with Advanced Stage of Head and Neck Squamous Cell Carcinoma (HNSCC). Asian Pacific Journal of Cancer Prevention, 2022, 23, 419-427.	0.5	2
1982	Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 99-112.	1.8	12
1983	Clinical application of gelatin sponge microparticles-transcatheter arterial chemoembolization combined with synchronous antigen-presenting dendritic cell sequential reinfusion for treatment of advanced large liver cancer. Medicine (United States), 2022, 101, e28803.	0.4	2
1984	The Role of Tumor Stem Cell Exosomes in Cancer Invasion and Metastasis. Frontiers in Oncology, 2022, 12, 836548.	1.3	17
1985	Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance. Frontiers in Oncology, 2022, 12, 856974.	1.3	35
1986	COL11A1-Driven Epithelialâ€“Mesenchymal Transition and Stemness of Pancreatic Cancer Cells Induce Cell Migration and Invasion by Modulating the AKT/GSK-3Î²/Snail Pathway. Biomolecules, 2022, 12, 391.	1.8	12
1987	Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment. Seminars in Cancer Biology, 2022, 86, 709-719.	4.3	12
1988	Targeting circDGKD Intercepts TKIâ€™s Effects on Up-Regulation of Estrogen Receptor Î² and Vasculogenic Mimicry in Renal Cell Carcinoma. Cancers, 2022, 14, 1639.	1.7	5
1989	Fibrous stroma: Driver and passenger in cancer development. Science Signaling, 2022, 15, eabg3449.	1.6	15
1990	Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine. Particle and Particle Systems Characterization, 0, , 2100276.	1.2	0
1991	Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism. Frontiers in Genetics, 2022, 13, 849040.	1.1	34
1992	Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma. Disease Markers, 2022, 2022, 1-18.	0.6	6
1993	Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer. Radiology and Oncology, 2022, 56, 185-197.	0.6	9
1994	GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. Journal of Oncology, 2022, 2022, 1-11.	0.6	0
1995	Gambogic acid inhibits epithelialâ€“mesenchymal transition in breast cancer cells through upregulation of <scp>SIRT1</scp> expression in vitro. Precision Medical Sciences, 2022, 11, 14-22.	0.1	2
1996	In vitro anticancer efficacy of a polyphenolic combination of Quercetin, Curcumin, and Berberine in triple negative breast cancer (TNBC) cells. Phytomedicine Plus, 2022, 2, 100265.	0.9	9

#	Article	IF	Citations
1997	Understanding the Complex Milieu of Epithelial-Mesenchymal Transition in Cancer Metastasis: New Insight Into the Roles of Transcription Factors. Frontiers in Oncology, 2021, 11, 762817.	1.3	20
1998	Role of Tâ€box genes in cancer, epithelialâ€mesenchymal transition, and cancer stem cells. Journal of Cellular Biochemistry, 2022, 123, 215-230.	1.2	7
1999	DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells. Cells, 2022, 11, 97.	1.8	8
2000	Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape. Cancers, 2022, 14, 44.	1.7	16
2001	Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-ÎºB-Snail Signaling Pathway in Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2021, 22, 4017-4029.	0.5	4
2002	LncRNA PNKY is upregulated in breast cancer and promotes cell proliferation and EMT in breast cancer cells. , 2021, , .		0
2003	Chemoresistance Mechanisms in Colon Cancer: Focus on Conventional Chemotherapy. Clinical Cancer Drugs, 2021, 8, 67-105.	0.3	0
2004	Preparation and Anti-tumor Study of Dextran 70,000-Selenium Nanoparticles and Poloxamer 188-Selenium Nanoparticles. AAPS PharmSciTech, 2022, 23, 29.	1.5	6
2005	Role of microRNAs in response to cadmium chloride in pancreatic ductal adenocarcinoma. Archives of Toxicology, 2022, 96, 467-485.	1.9	6
2006	Moderate Static Magnet Fields Suppress Ovarian Cancer Metastasis via ROS-Mediated Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	9
2007	The Use of Nanomedicine to Target Signaling by the PAK Kinases for Disease Treatment. Cells, 2021, 10, 3565.	1.8	1
2008	Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?. Drug Resistance Updates, 2021, 59, 100790.	6.5	19
2009	Lactobacillus fermentum ZS09 Mediates Epithelialâ€“Mesenchymal Transition (EMT) by Regulating the Transcriptional Activity of the Wnt/Î²-Catenin Signalling Pathway to Inhibit Colon Cancer Activity. Journal of Inflammation Research, 2021, Volume 14, 7281-7293.	1.6	6
2010	Pathophysiology of miR-146a in lung cancer. Prospects of rising of efficiency of targeted therapy. Reviews on Clinical Pharmacology and Drug Therapy, 2021, 19, 359-381.	0.2	2
2011	OUP accepted manuscript. Journal of Radiation Research, 2022, , .	0.8	3
2012	Understanding Drug Sensitivity and Tackling Resistance in Cancer. Cancer Research, 2022, 82, 1448-1460.	0.4	24
2013	MicroRNA-642b-3p functions as an oncomiR in gastric cancer by down-regulating the CUB and sushi multiple domains protein 1/smad axis. Bioengineered, 2022, 13, 9614-9628.	1.4	3
2014	Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis. Frontiers in Oncology, 2022, 12, 828112.	1.3	15

#	Article	IF	Citations
2015	Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nature Cell Biology, 2022, 24, 554-564.	4.6	53
2016	The paradigm of drug resistance in cancer: an epigenetic perspective. Bioscience Reports, 2022, 42, .	1.1	21
2017	Deregulated signaling networks in lung cancer. , 0, , 421-442.		0
2035	Diagnostic and therapeutic biomarkers in colorectal cancer: a review.. American Journal of Cancer Research, 2022, 12, 661-680.	1.4	0
2036	Pharmacogenomics and outcomes for hepatocellular cancer treatment. , 2022, , 401-414.		0
2037	Signaling Pathways Regulating the Expression of the Glioblastoma Invasion Factor TENM1. Biomedicines, 2022, 10, 1104.	1.4	1
2038	Utilizing Carbon Ions to Treat Medulloblastomas that Exhibit Chromothripsis. Current Stem Cell Reports, 0, , 1.	0.7	0
2039	Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nature Reviews Clinical Oncology, 2022, 19, 499-514.	12.5	140
2040	Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition. Annals of Diagnostic Pathology, 2022, 59, 151973.	0.6	1
2041	Identification of a cytisine-based EED-EZH2 protein-protein interaction inhibitor preventing metastasis in triple-negative breast cancer cells. , 2022, 1, .		10
2042	Identification of mutant p53-specific proteins interaction network using TurboID-based proximity labeling. Biochemical and Biophysical Research Communications, 2022, 615, 163-171.	1.0	5
2043	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. Cold Spring Harbor Molecular Case Studies, 2022, 8, .	0.7	6
2044	LncRNA SSTR5-AS1 as a Prognostic Marker Promotes Cell Proliferation and Epithelial-to-Mesenchymal Transition in Prostate Cancer. Critical Reviews in Eukaryotic Gene Expression, 2023, 33, 1-12.	0.4	3
2045	PHF13 epigenetically activates TGFÎ² driven epithelial to mesenchymal transition. Cell Death and Disease, 2022, 13, .	2.7	2
2046	Sensitization of Non-Small Cell Lung Cancer Cells to Gefitinib and Reversal of Epithelialâ€“Mesenchymal Transition by Aloe-Emodin Via PI3K/Akt/TWIS1 Signal Blockage. Frontiers in Oncology, 0, 12, .	1.3	7
2047	Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Research and Therapy, 2022, 13, .	2.4	43
2048	miR-126-5p affects the chemosensitivity of colorectal cancer cells by regulating SPRED1, ERK1/2 pathway and apoptosis. Genes and Diseases, 2022, , .	1.5	0
2049	Interaction of crown ethers with the ABCG2 transporter and their implication for multidrug resistance reversal. Histochemistry and Cell Biology, 0, , .	0.8	3

#	Article	IF	Citations
2050	D-tryptophan triggered epithelial-mesenchymal transition by activating TGF-Î² signaling pathway. Food Science and Human Wellness, 2022, 11, 1215-1221.	2.2	2
2052	Microenvironmental regulation of tumor initiation and development. Scientia Sinica Vitae, 2022, 52, 1377-1390.	0.1	1
2053	Breast cancer awareness package on knowledge, attitude and practice towards breast self examination to prevent breast cancer among women in adopted communities â€“ a pilot analysis. , 2022, , 471-483.		0
2054	The Expression Profile of miRNA in Glioma and the Role of miR-339-5p in Glioma. BioMed Research International, 2022, 2022, 1-8.	0.9	4
2055	STAT3-EMT axis in tumors: Modulation of cancer metastasis, stemness and therapy response. Pharmacological Research, 2022, 182, 106311.	3.1	51
2057	MicroRNA-485-5p targets keratin 17 to regulate oral cancer stemness and chemoresistance via the integrin/FAK/Src/ERK/Î²-catenin pathway. Journal of Biomedical Science, 2022, 29, .	2.6	25
2058	Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer. Molecular Biomedicine, 2022, 3, .	1.7	3
2059	All-in-One Nanowire Assay System for Extracellular Vesicle Capture and Analysis from Ex Vivo Brain Tumor Model. SSRN Electronic Journal, 0, , .	0.4	0
2060	Insight into the molecular mechanisms of gastric cancer stem cell in drug resistance of gastric cancer. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 794-813.	0.9	2
2062	Formoxanthone C Inhibits Malignant Tumor Phenotypes of Human A549 Multidrug Resistant-cancer Cells through Signal Transducer and Activator of Transcription 1-Histone Deacetylase 4 Signaling. Journal of Cancer Prevention, 2022, 27, 112-121.	0.8	1
2063	AMPKâ€™s double-faced role in advanced stages of prostate cancer. Clinical and Translational Oncology, 2022, 24, 2064-2073.	1.2	5
2064	Assessment of a Size-Based Method for Enriching Circulating Tumour Cells in Colorectal Cancer. Cancers, 2022, 14, 3446.	1.7	3
2065	Could inhibition of metalloproteinases be used to block the process of metastasis?. Cell Biochemistry and Function, 2022, 40, 600-607.	1.4	11
2066	Greatly Enhanced CTC Culture Enabled by Capturing CTC Heterogeneity Using a PEGylated PDMSâ€“Titaniumâ€“Gold Electromicrofluidic Device with Glutathione-Controlled Gentle Cell Release. ACS Nano, 2022, 16, 11374-11391.	7.3	20
2067	Asymmetric Cell Division and Tumor Heterogeneity. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	5
2068	Stanniocalcin 2 drives malignant transformation of human glioblastoma cells by targeting SNAI2 and Matrix Metalloproteinases. Cell Death Discovery, 2022, 8, .	2.0	3
2069	Recent advances in the molecular basis of chemotherapy resistance and potential application of epigenetic therapeutics in chemorefractory renal cell carcinoma. WIREs Mechanisms of Disease, 2022, 14, .	1.5	1
2070	The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus. Scientific Reports, 2022, 12, .	1.6	12

#	Article	IF	Citations
2071	MiR-21/Sonic Hedgehog (SHH)/PI3K/AKT Pathway is Associated with NSCLC of Primary EGFR-TKI Resistance. Oncologie, 2022, 24, 579-590.	0.2	3
2072	MEDICINAL PLANTS FOR PREVENTION AND CURE OF BREAST CANCER: A REVIEW. , 2022, , 54-58.		0
2073	Special issue â€œThe advance of solid tumor research in Chinaâ€• Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating <scp>AKT</scp> signaling. International Journal of Cancer, 0, , .	2.3	0
2074	DYNLT3 overexpression induces apoptosis and inhibits cell growth and migration via inhibition of the Wnt pathway and EMT in cervical cancer. Frontiers in Oncology, 0, 12, .	1.3	4
2075	Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy. Acta Biomaterialia, 2022, 152, 380-392.	4.1	9
2076	Sodium selenite inhibits proliferation and metastasis through ROSâ€mediated NFâ€ºB signaling in renal cell carcinoma. BMC Cancer, 2022, 22, .	1.1	3
2077	Genome-Wide Super-Enhancer-Based Analysis: Identification of Prognostic Genes in Oral Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 9154.	1.8	2
2078	Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration. Breast Cancer: Targets and Therapy, 0, Volume 14, 211-227.	1.0	1
2079	Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Frontiers in Pharmacology, 0, 13, .	1.6	4
2081	Comprehensive and Integrated Analysis Identifies ZEB1 as a Key Novel Gene in Oral Squamous Cell Carcinoma. Contrast Media and Molecular Imaging, 2022, 2022, 1-14.	0.4	2
2082	Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond. Current Oncology, 2022, 29, 5489-5507.	0.9	19
2083	The aberrant cancer metabolic gene carbohydrate sulfotransferase 11 promotes non-small cell lung cancer cell metastasis via dysregulation of ceruloplasmin and intracellular iron balance. Translational Oncology, 2022, 25, 101508.	1.7	6
2084	The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. Journal of Hematology and Oncology, 2022, 15, .	6.9	160
2085	Silencing of RNA binding protein, ZFP36L1, promotes epithelial-mesenchymal transition in liver cancer cells by regulating transcription factor ZEB2. Cellular Signalling, 2022, 100, 110462.	1.7	4
2086	Drug and apoptosis resistance in cancer stem cells (CSCs): A puzzle with many pieces. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 850-72.	0.9	14
2087	"GDF-15 Signaling Leading to Epithelial-to-Mesenchymal Transition in Colorectal Cancer - a Literature Review". Journal of Medical & Radiation Oncology, 2022, 2, 1-7.	0.0	1
2088	DNMT3A/miR-129-2-5p/Rac1 Is an Effector Pathway for SNHG1 to Drive Stem-Cell-like and Invasive Behaviors of Advanced Bladder Cancer Cells. Cancers, 2022, 14, 4159.	1.7	4
2090	Metformin and histone deacetylase inhibitor based anti-inflammatory nanoplatform for epithelial-mesenchymal transition suppression and metastatic tumor treatment. Journal of Nanobiotechnology, 2022, 20, .	4.2	8

#	Article	IF	Citations
2091	Downregulation of SOX21-AS1 Alleviated Cisplatin Resistance in Cervical Cancer Through Epithelialâ€“Mesenchymal Transition Inhibition. Rejuvenation Research, 2022, 25, 243-252.	0.9	2
2093	Potential Therapeutic Agents against Paclitaxelâ€”And Sorafenib-Resistant Papillary Thyroid Carcinoma. International Journal of Molecular Sciences, 2022, 23, 10378.	1.8	3
2094	Nanoparticleâ€Based Follistatin Messenger RNA Therapy for Reprogramming Metastatic Ovarian Cancer and Ameliorating Cancerâ€Associated Cachexia. Small, 2022, 18, .	5.2	6
2095	Label-Free Isolation of Low-Adhesion Cells with Stem Properties for Cancer Stem Cell-Specific Drug Evaluation. Analytical Chemistry, 0, , .	3.2	0
2096	Evodiamine as an anticancer agent: a comprehensive review on its therapeutic application, pharmacokinetic, toxicity, and metabolism in various cancers. Cell Biology and Toxicology, 2023, 39, 1-31.	2.4	8
2097	SNCA inhibits epithelialâ€“mesenchymal transition and correlates to favorable prognosis of breast cancer. Carcinogenesis, 2022, 43, 1071-1082.	1.3	2
2098	NEDD9 scaffolding protein expression as a negative prediction marker in non-small cell lung cancer (NSCLC). Siberian Journal of Oncology, 2022, 21, 47-55.	0.1	0
2099	Evidence that cervical cancer cells cultured as tumorspheres maintain high CD73 expression and increase their protumor characteristics through TGFâ€Î²2 production. Cell Biochemistry and Function, 2022, 40, 760-772.	1.4	7
2100	Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT. Cancer Gene Therapy, 2023, 30, 74-84.	2.2	8
2101	Insights Into the Role of Matrix Metalloproteinases in Cancer and its Various Therapeutic Aspects: A Review. Frontiers in Molecular Biosciences, 0, 9, .	1.6	17
2102	Molecular mechanism of CD163+ tumor-associated macrophage (TAM)-derived exosome-induced cisplatin resistance in ovarian cancer ascites. Annals of Translational Medicine, 2022, 10, 1014-1014.	0.7	8
2103	LncRNA SNHG6 sponges miR-101 and induces tamoxifen resistance in breast cancer cells through induction of EMT. Frontiers in Oncology, 0, 12, .	1.3	7
2104	UBE2T regulates epithelialâ€“mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. Journal of Ovarian Research, 2022, 15, .	1.3	3
2105	Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	8
2106	Five EMT-Related Gene Signatures Predict Acute Myeloid Leukemia Patient Outcome. Disease Markers, 2022, 2022, 1-8.	0.6	5
2107	Bench to Bedside: New Therapeutic Approaches with Extracellular Vesicles and Engineered Biomaterials for Targeting Therapeutic Resistance of Cancer Stem Cells. ACS Biomaterials Science and Engineering, 2022, 8, 4673-4696.	2.6	1
2108	A systems biology investigation of curcumin potency against TGF-Î²-induced EMT signaling in lung cancer. 3 Biotech, 2022, 12, .	1.1	2
2109	Ethanolic extract of Origanum syriacum L. leaves exhibits potent anti-breast cancer potential and robust antioxidant properties. Frontiers in Pharmacology, 0, 13, .	1.6	3

#	Article	IF	Citations
2110	Matrine induces hepatocellular carcinoma apoptosis and represses EMT and stemness through microRNA-299-3p/PGAM1 axis. Growth Factors, 2022, 40, 200-211.	0.5	3
2111	New insights into cholesterolâ€mediated ERRÎ± activation in breast cancer progression and proâ€tumoral microenvironment orchestration. FEBS Journal, 2023, 290, 1481-1501.	2.2	6
2113	A Novel Detection Method of Breast Cancer through a Simple Panel of Biomarkers. International Journal of Molecular Sciences, 2022, 23, 11983.	1.8	0
2114	Heterochiral dipeptide <scp>d</scp>â€phenylalanylâ€<scp>l</scp>â€phenylalanine (Hâ€^DPheâ€^LPheâ€OH) as a potential inducer of metastatic suppressor NM23H1 in p53 wildâ€type and mutant cells. Molecular Carcinogenesis, 2022, 61, 1143-1160.	3.3	1
2115	TNS1: Emerging Insights into Its Domain Function, Biological Roles, and Tumors. Biology, 2022, 11, 1571.	1.3	6
2116	Crosstalk between HSF1 and STAT3 mediated by ILâ€8 autocrine signaling maintains the cancer stem cell phenotype in liver cancer. Journal of Gastroenterology and Hepatology (Australia), 0, , .	1.4	1
2117	Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma. Acta Neuropathologica Communications, 2022, 10, .	2.4	1
2118	The SUMO protease SENP1 promotes aggressive behaviors of high HIF2Î± expressing renal cell carcinoma cells. Oncogenesis, 2022, 11, .	2.1	4
2119	Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance. Gynecologic Oncology, 2022, 167, 502-512.	0.6	1
2120	Development of an adenosquamous carcinoma histo pathology-selective lung metastasis model. Biology Open, 0, , .	0.6	0
2121	Redox balance and autophagy regulation in cancer progression and their therapeutic perspective. , 2023, 40, .		12
2122	Old Dog, New Trick: A Tumor-Intrinsic Role for PD-1 in Chemoresistant Tumor Subclones. Clinical Cancer Research, 2023, 29, 505-507.	3.2	2
2123	Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer. Pharmaceutics, 2022, 14, 2432.	2.0	7
2124	Engineered upconversion nanocarriers for synergistic breast cancer imaging and therapy: Current state of art. Journal of Controlled Release, 2022, 352, 652-672.	4.8	6
2125	Breast carcinogenesis induced by organophosphorous pesticides. Advances in Pharmacology, 2022, , .	1.2	1
2126	A novel cell-based assay for the high-throughput screening of epithelialâ€“mesenchymal transition inhibitors: Identification of approved and investigational drugs that inhibit epithelialâ€“mesenchymal transition. Lung Cancer, 2023, 175, 36-46.	0.9	1
2127	Generation and Evaluation of Hydrogel-Facilitated 3D Tumor Microenvironments of Breast Cancer. Nano LIFE, 2022, 12, .	0.6	0
2128	USP22 Contributes to Chemoresistance, Stemness, and EMT Phenotype of Triple-Negative Breast Cancer Cells by egulating the Warburg Effect via c-Myc Deubiquitination. Clinical Breast Cancer, 2023, 23, 162-175.	1.1	2

#	Article	IF	Citations
2129	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFÎ² and PD-1/PD-L1. Expert Opinion on Investigational Drugs, 2022, 31, 1187-1202.	1.9	1
2130	Emerging Roles of the Unique Molecular Chaperone Cosmc in the Regulation of Health and Disease. Biomolecules, 2022, 12, 1732.	1.8	4
2131	c-Src inhibitor PP2 inhibits head and neck cancer progression through regulation of the epithelialâ€“mesenchymal transition. Experimental Biology and Medicine, 2023, 248, 492-500.	1.1	2
2132	The Role of miRNAs, circRNAs and Their Interactions in Development and Progression of Hepatocellular Carcinoma: An Insilico Approach. Genes, 2023, 14, 13.	1.0	3
2133	De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity. International Journal of Molecular Sciences, 2022, 23, 15594.	1.8	4
2134	TWIST1 Plays Role in Expression of Stemness State Markers in ESCC. Genes, 2022, 13, 2369.	1.0	1
2135	Cyanidin inhibits glioma stem cells proliferation through the Wnt signaling pathway. International Journal of Neuroscience, 0, , 1-8.	0.8	1
2136	Value of biomarkers in epithelialâ€“mesenchymal transition models of liver cancer under different interventions: a meta-analysis. Future Oncology, 0, , .	1.1	0
2137	Theranostics for Triple-Negative Breast Cancer. Diagnostics, 2023, 13, 272.	1.3	7
2138	Inhibition of WNT signaling by conjugated microRNA nano-carriers: A new therapeutic approach for treating triple-negative breast cancer a perspective review. Critical Reviews in Oncology/Hematology, 2023, 182, 103901.	2.0	4
2139	Optimized Method for Using Embryonic Microenvironment to Reprogram Cancer Stem Cells. Journal of Basic and Clinical Health Sciences, 0, , .	0.2	0
2140	Advances of Wnt Signalling Pathway in Colorectal Cancer. Cells, 2023, 12, 447.	1.8	12
2141	All-in-One Nanowire Assay System for Capture and Analysis of Extracellular Vesicles from an ex Vivo Brain Tumor Model. ACS Nano, 2023, 17, 2235-2244.	7.3	9
2142	Epithelial-mesenchymal transition and resistance to EGFR inhibitors. , 2023, , 105-124.		0
2143	Poor-prognosis molecular subtypes in adenocarcinomas of pancreato-biliary and gynecological origin: A systematic review. Critical Reviews in Oncology/Hematology, 2023, 185, 103982.	2.0	0
2144	Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. Critical Reviews in Oncology/Hematology, 2023, 182, 103920.	2.0	18
2145	The epigenome and the many facets of cancer drug tolerance. Advances in Cancer Research, 2023, , 1-39.	1.9	4
2146	Acetylated xylo-oligosaccharide from Hawthorn kernels inhibits colon cancer cells in vitro and in vivo. Journal of Functional Foods, 2023, 102, 105436.	1.6	1

#	Article	IF	Citations
2147	The hypoxia-inducible factor-1Î± in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	4
2148	Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells. International Journal of Molecular Sciences, 2023, 24, 3704.	1.8	7
2149	Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways. Biomedicine and Pharmacotherapy, 2023, 160, 114395.	2.5	8
2150	Luteolin directly binds to KDM4C and attenuates ovarian cancer stemness via epigenetic suppression of PPP2CA/YAP axis. Biomedicine and Pharmacotherapy, 2023, 160, 114350.	2.5	5
2151	Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer. Biochemical Pharmacology, 2023, 210, 115459.	2.0	7
2152	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. Scientific Reports, 2023, 13, .	1.6	1
2153	Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer. Cell Death and Disease, 2023, 14, .	2.7	2
2154	Photothermal Attenuation of Cancer Cell Stemness, Chemoresistance, and Migration Using CD44-Targeted MoS₂ Nanosheets. Nano Letters, 2023, 23, 1989-1999.	4.5	9
2155	Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers. Biology, 2023, 12, 488.	1.3	0
2156	miR-508-5p serves as an anti-oncogene by targeting S100A16 to regulate AKT signaling and epithelial-mesenchymal transition process in lung adenocarcinoma cells. American Journal of the Medical Sciences, 2023, , .	0.4	0
2158	Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer. European Medical Journal (Chelmsford, England), 0, , 50-56.	3.0	0
2159	LncRNA PNKY Is Upregulated in Breast Cancer and Promotes Cell Proliferation and EMT in Breast Cancer Cells. Non-coding RNA, 2023, 9, 25.	1.3	0
2160	A novel computational predictive biological approach distinguishes Integrin Î²1 as a salient biomarker for breast cancer chemoresistance. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166702.	1.8	0
2161	Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy. Cells, 2023, 12, 1156.	1.8	7
2162	Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer. Cancer Research Communications, 2023, 3, 659-671.	0.7	3
2198	Roles of Cancer Stem Cells in Therapy Resistance and Disease Recurrence. , 2023, , 149-165.		1
2225	Mechanisms of PARP Inhibitor Resistance. Cancer Treatment and Research, 2023, , 25-42.	0.2	0
2233	RNA Modifications in Cancer Stem Cell Biology. Cancer Treatment and Research, 2023, , 25-47.	0.2	0

#	Article	IF	Citations
2239	Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets. Signal Transduction and Targeted Therapy, 2024, 9, .	7.1	0
2243	Colorectal cancer: understanding of disease. , 2024, , 1-27.		0
2255	Three-Dimensional Tumor Models to Study Cancer Stemness-Mediated Drug Resistance. Cellular and Molecular Bioengineering, 0, , .	1.0	0